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Cardiac vulnerability to ischaemia/reperfusion (I/R) changes during development; 
14-day old rat heart being least vulnerable compared to adult or younger postnatal 
hearts. The underlying mechanisms are not known, thus design of age-specific 
optimal cardioprotective interventions is difficult. Recent work has shown activation 
of cAMP/PKA/Epac signalling pathway is cardioprotective in adult hearts. Whether 
this also mediate protection in postnatal hearts is unknown. This will be addressed 
in this thesis. 
 
Wistar rats of 7, 14, and 28 days postnatal & adults were used. Cardiac proteome was 
examined using TMT-MS/MS and bioinformatic analysis. Langendorff perfused 
hearts were exposed to I/R and injury assessed by measuring cardiac enzyme release 
and infarction by staining with tetrazolium chloride. Isolated cardiomyocytes were 
used in suspension to study simulated reperfusion injury (H2O2 & 3mM Ca2+) and 
viability measured by Trypan blue staining. Superfused field stimulated isolated 
cardiomyocytes were exposed to metabolic inhibition and contraction measured 
using edge tracking whilst Ca2+ transients measured using Fura-2-AM. Isolated 
mitochondria were used to study mitochondrial permeability transition pore (MPTP) 
sensitivity to Ca2+. Selective cAMP analogues were used to directly activate PKA, Epac 
or both. Isoproterenol a β-Adrenergic receptor (β-AR) agonist, was used to stimulate 
cAMP/PKA/Epac signalling pathways.  
 
Proteomics showed age-related variation in networks concerned with β-adrenergic 
signalling, Ca2+ homeostasis, mitochondrial regulation, and antioxidant activity. 
Simultaneous activation of PKA & Epac conferred cardioprotection in whole heart 
and in cardiomyocytes across the age ranges. In mitochondria from both adult and 
14-day hearts, perfusion with isoprenaline or activation of both PKA and Epac 
reduced MPTP sensitivity to Ca2+.  
 
Despite significant molecular and cellular developmental changes and vulnerability 
to I/R, direct or indirect β-AR signalling involving Epac and PKA activation protects 
against acute injury in both adult and immature hearts and cardiomyocytes and this 
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1 General Introduction 
This thesis examines “The Cardioprotective Role of the Exchange Protein Activated 
by cAMP (Epac) during Postnatal Development”. The introduction addresses this by 
first examining cardiac metabolism and physiology in the healthy adult heart, and 
then looking at how those processes become disordered in ischaemia and in 
subsequent reperfusion, with particular emphasis on the key role of the 
mitochondria in that process. It then moves on to look at different modes in which 
the heart has historically been protected from that injury before looking at how 
cAMP signalling through the β- adrenoreceptor, particularly through EPAC and its 
counterpart PKA interacts with those targets for protection. Finally, it provides an 
overview of some key differences between the adult and developing heart with 
relevance to cardioprotection.  
 
1.1 Overall View of Cardiac Physiology & Metabolism 
The heart produces and consumes the largest amount of energy of any organ, and if 
that production of energy were to fail, the organism as a whole dies. The heart 
requires a large flux of ATP in order to support its repeated cycles of excitation and 
contraction; these are energy-intense functions requiring movement of ions against 
electrochemical gradients and conformational changes of proteins to 
thermodynamically unfavourable states. To that end, a large proportion of the 
biomass in the heart is dedicated to energy production with multiply redundant 
pathways (  
Figure 1-1). The heart is able to utilise a range of metabolic substrates to feed this 
demand for energy (Bing, Siegel et al. 1953); under physiological conditions the 
majority (60-90% comes from utilisation by oxidation of fatty acids (Vusse, Glatz et 
al. 1992), with glucose, broken down through glycolysis, the remainder (10-40%) 





Figure 1-1 Cardiac metabolic pathways.The reducing equivalents are used by the electron transport chain to 
generate a proton gradient, which in turn is used for the production of ATP. ACC indicates acetyl-CoA carboxylase; 
CPT, carnitine palmitoyltransferase; FAT, fatty acid transporter; G6P, glucose 6-phosphate; GLUT, glucose 
transporter; IMS, mitochondrial intermembrane space; MCD, malonyl-CoA decarboxylase; MPC, mitochondrial 
pyruvate carrier; PDH, pyruvate dehydrogenase; and PDK, pyruvate dehydrogenase kinase (Doenst, Nguyen et al. 
2013). 
 
The tricarboxylic acid cycle (TCA) is the convergent point for metabolism of the 
majority of these substrates under physiological conditions (Doenst, Nguyen et al. 
2013). It refers to a series of enzymatic conversions of substrates to acetyl- CoA 
followed by stepwise decarboxylation producing NADH and FADH2 to supply 
mitochondrial oxidative phosphorylation, as well as GTP. NADH is an important 
electron donor in redox reactions in particular the generation of the mitochondrial 
proton gradient; the ready supply of it in the oxidised form is thus vital for 
physiological ATP production.  
 
The main product of the TCA cycle is NADH, which is then used in the mitochondrial 
electron transport chain to produce a proton gradient. This functions through the 
donation of electrons through a series of inner mitochondrial membrane bound 
multiprotein complexes ultimately to be accepted by oxygen. It is this proton- motive 




Roughly 90% of the ATP production in the heart comes from substrates funnelled 
through the tricarboxylic acid cycle. The main substrate, fatty acids, cannot be 
synthesised de novo in the heart, although there is a limited store of triglycerides. 
Consequently, the heart is exquisitely sensitive to disruptions to its supply of fatty 
acids through blood flow as it becomes dependent upon minority substrates for 
maintenance of ATP production.  
 
1.1.1 Excitation-Contraction (E-C) coupling & Ca2+ cycling 
Excitation- contraction coupling in the heart refers to the linkage between electrical 
excitation of tissues and their organised, rhythmic, contraction. The heart as a whole 
exhibits automaticity; this generates a wave of depolarisation starting in the 
sinoatrial node and spreading in a synchronised manner through the conducting 
system of the heart before exciting the cardiomyocytes directly which causes the 
release of Ca2+. This Ca2+ transient is key to the interaction between actin and myosin 
which produces contraction; it must be recycled back into storage for the heart to 
relax and so the movement of Ca2+ into and out of the sarcoplasm is driving the 
Figure 1-2 Cardiac Excitation-contraction coupling. A diagram showing processes in adult 
cardiomyocyte that are responsible of Ca2+ cycling and the associated contraction-relaxation 
cycles. The inset is a summary of timeline associated with the action potential, Ca2+ transient and 
contraction. NCX, Na+/Ca2+ exchange; RyR, Ryanodine receptor; SR, sarcoplasmic reticulum; ATP, 
ATPase; PLB, phospholamban. From Bers 2002. 
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mechanics of contraction (Bers 2002). A schematic overview of Ca2+ mobilisation 
during E-C coupling is shown in Figure 1-2.  
1.1.1.1 Excitation 
The influx of Ca2+ begins during the plateau phase of the cardiac action potential. In 
this phase, L-type Ca2+ channels open once the membrane potential is greater than -
40 mV (Beeler and Reuter 1970, Benitah, Alvarez et al. 2010) causing an influx and 
rapid rise in intracellular Ca2+.  This inward Ca2+ current is relatively small; however 
this triggers in the adult heart a much larger release of Ca2+ from intracellular stores 
(Ca2+-transient). This process is known as calcium- induced calcium release (CICR) 
(Fabiato 1985, Talo, Stern et al. 1990, Bers 2002), which is regulated through the 
action of the ryanodine receptor (RyR) family (Pessah, Waterhouse et al. 1985).  
1.1.1.2 Contraction 
Cardiac muscle is composed of thick and thin filaments. The thick filament is 
comprised of many molecules of myosin, with heads which may form crossbridges. 
The thin filaments however are made up of actin in helical form, with troponins and 
tropomyosin alongside these helices covering the myosin binding sites of actin when 
the muscle is relaxed. There are multiple forms of troponin; I, which inhibits the actin- 
myosin interaction; C, responsible for Ca2+ binding; and T which interacts with 
tropomyosin. Once troponin C binds to Ca2+, it initiates a cascade of conformational 
changes though troponin T and I through to tropomyosin, unveiling the previously 
occluded myosin binding site (Yasui, Fuchs et al. 1968, Eisenberg and Kielley 1974) 
allowing the myosin head and actin to bind, in an ATP- consuming interaction, 
causing a conformational change of the head and resulting in movement of the 
filaments with reference to one another and thus contraction (Coupland, Pinniger et 
al. 2005). Once the ADP disassociates, the contractile phase is completed.  
1.1.1.3 Relaxation 
Synchronous with the rise in sarcoplasmic Ca2+, SERCA, NCX and the mitochondrial 
uniporter as important determinants of Ca2+ homeostasis increase their action in 
response to the change (Hove-Madsen and Bers 1993). 
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The continued release of Ca2+ from intracellular stores triggered by CICR and 
regulated by the ryanodine receptor must cease in order for relaxation to occur.  The 
termination of this is controlled through interaction of the ryanodine receptor with 
calsequestrin, a calcium binding protein in the sarcoplasmic reticulum. Prior to 
excitation, when the SR Ca2+ content is high, calsequestrin is unbound to the RyR, and 
in this state, the RyR may be induced to cause CICR by a rise in sarcoplasmic Ca2+. This 
release of calcium reduces the concentration remaining in the SR, which then allows 
the calsequestrin to bind to the RyR inactivating the binding site for Ca2+ (Stevens, 
Terentyev et al. 2009), so stopping the Ca2+ release. 
A further complex network of systems exists to regulate the levels of Ca2+ that are 
permitted to occur during each phase of the cardiac cycle, balancing inflows from SR 
stores and the extracellular environment. When Ca2+ release is triggered from the SR, 
the amount which is released depends upon how much is stored in the SR; i.e. the 
higher then content, the greater the proportionate release (Bassani, Yuan et al. 
1995). Meanwhile, the LTCC in the t-tubules become inactivated during prolonged 
depolarisation in a Ca2+ dependent manner (Yue, Backx et al. 1990). By a combination 
of these effects, a negative feedback loop exists (Sham, Cleemann et al. 1995); the 
more Ca2+ released from the SR, the more rapid the inactivation of the LTCC, and so 
reducing the influx of Ca2+ into the cell, feeding back into the mechanism of CICR and 
so reducing the amount of Ca2+ released from the SR. Thus there is a homeostatic 
mechanism balancing release in a given state of the cell. However, it is not always 
physiologically appropriate for the Ca2+ level to be maintained at this set point. In 
situations where the cardiac output must be increased, there needs to be a positive 
inotropic response which is accomplished through activity at the β- adrenoreceptor. 
The end result of activity here is to increase Ca2+ transient amplitude and hence 
contractility, as well as increased Ca2+ cycling for the chronotropic response through 
the actions of cAMP as a second messenger from this receptor family. As is discussed 
later in Section 1.5, this signalling system is a vital link between the external 
physiological environ and control of the contractile apparatus of the cardiomyocyte. 
Shortly afterwards, in phase 3 delayed rectifier K+ channels open causing rapid 
repolarization; the L-type Ca2+ channels close as a consequence as the membrane 
25 
 
potential once again falls. In addition to stoppage of Ca2+ entry, the elevated cytosolic 
Ca2+ is removed mainly via SERCA & NCX resulting in a fall back to diastolic levels 





1.2 Cardiac Ischaemia & Reperfusion (I/R) Injury  
Ischaemia is the situation which occurs when the blood flow to a tissue is mismatched 
to the demand of that tissue and so is insufficient to meet the metabolic 
requirements. There are multiple components to this phenomenon; stagnant 
hypoxia, with a reduced oxygen delivery to the tissue is important, but the other 
components of reduced substrate delivery and impaired efflux are also significant. 
Reperfusion injury occurs when that blood flow is resumed; and is in itself 
independently associated with contractile dysfunction, intracellular hypercalcaemia, 
and necrotic cell death. Therefore ischaemia and reperfusion injury, as distinct 
phenomena, have linked but distinct mechanisms of harm.  
 
1.2.1 Pathophysiological Basis of I/R Injury 
Ischaemic events due to interruption or cessation of blood flow are a significant 
trigger for morbidity clinically, and affect every organ system, albeit some more 
commonly than others. Treatment for these events invariably involves restoration of 
normal flow- revascularisation, or reperfusion. This reperfusion, the reintroduction 
of oxygen and metabolic substrates alongside the removal of the products of 
metabolism is intended at normalising the situation within a tissue but triggers a 
series of events within the newly reperfused cells, some of which are significantly 
deleterious.  Indeed, some therapeutic modalities in themselves invariably result in 
both ischaemia and reperfusion- organ allograft transplantation is a key example.  
 
However, the more common scenario is cardiac ischaemia and reperfusion injury; 
within the heart this situation occurs for both pathophysiological and iatrogenic 
reasons. The most obvious and most frequent event in the adult is the occlusion of a 
coronary artery by a thrombus leading to reduced or absent flow distal to the 
occlusion, and subsequent insufficiency of flow to the tissues in the territory of that 
coronary artery.   
 
In the setting of open-heart surgery, cardiopulmonary bypass is used in order to 
facilitate operating upon the interior of an arrested heart. This necessarily involves 
clamping of the aorta at the root and so there is no physiological flow of blood 
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through any of the coronary arteries, resulting in global ischaemia. This may lead to 
an excess risk of postoperative complication, a prolonged stay in hospital, as well as 
a poorer cardiac and functional outcome from surgery if the risk of I/R injury is not 
mitigated (Buckberg 1995).  
 
Other situations can occur more rarely resulting in cardiac I/R injury from extra-
cardiac pathologies, such as an obstructing pulmonary embolus in the right sided 
circulation, or from hypoxaemic hypoxia from reduced oxygen uptake for any other 
reason, but these scenarios are very heterogenous and so outside the scope of this 
work. 
 
1.2.2 Cellular Consequences of Cardiac Ischaemia  
1.2.2.1 Inhibition of Oxidative Phosphorylation 
The primary mode by which ATP is produced to satisfy the energy needs of the 
cardiomyocyte is through oxidative phosphorylation in the mitochondria by the 
tricarboxylic acid cycle; this ultimately requires oxygen as an electron acceptor, so a 
lack of oxygen in ischaemia stops ATP production via this means. This leaves 
breakdown of glycogen via glycolysis as the sole means for ATP production during 
ischaemia; stoichiometrically this is inefficient and so ATP levels within the 
cardiomyocyte drop rapidly, to about 80% of the baseline 2 minutes after the onset 




Figure 1-3 Key cellular metabolic and ionic changes in rat heart exposed to 30 min ischaemia followed by 
reperfusion (Murphy and Steenbergen 2008). 
In this situation where oxygen and fatty acids are not readily available, glucose is 
broken down to form ATP and pyruvate (Taegtmeyer 1994, Taegtmeyer, Lam et al. 
2016);  
 
Glucose + 2 NAD+ + 2 ADP + 2 Pi → 2 pyruvate + 2 NADH + 2 H+ + 2 ATP + 2 H2O 
 
Under aerobic conditions, the NADH would normally be recycled to NAD+ through its 
action at complex 1. This is not possible if the electron transport chain is inhibited, 
and so in order to carry on with the process of ATP generation via glycolysis, NADH is 
instead recycled by formation of lactate; 
 
pyruvate + NADH + H+ → lactate + NAD+ 
 
- therefore further NAD+ is available for glycolysis to continue. However, this 
consumes the supply of pyruvate which is then not available for entry into the 
TCA cycle.  
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So rather than pyruvate, as the product of glycolysis, being converted to Acetyl- CoA 
for entry into the TCA cycle it is instead used to form lactate, by lactate 
dehydrogenase in a step converting NADH to NAD+. Lactate as the product of this 
final step readily becomes ionised and so the net effect of all energy production 
occurring via glycolysis is an accumulation of hydrogen ions and lactate. This results 
in an intracellular acidosis. The metabolic and ionic changes seen are summarised in 
Figure 1-3. 
 
1.2.2.2 Results of intracellular acidosis & ionic disruption 
An important mechanism for the maintenance of intracellular pH homeostasis is the 
sarcolemmal Na+/H+ exchanger. In response to the rise in H+ ions, this antiporter 
increases its flux; this leads to an increase in intracellular Na+ levels [Na+]i (Lazdunski, 
Frelin et al. 1985, Silverman and Stern 1994). What might then be expected would 
be an increase in Na+ extrusion through the Na+-K+ ATPase;  however in the ischaemic 
low-ATP state, this pump is inhibited. Rather the transmembrane Na+ gradient is 
reduced, and this has the effect of reversing the direction of the Na+/Ca2+ exchanger 
(NCX); in the ischaemic environment the acidosis limits NCX activity, limiting the rate 
of rise of intracellular [Ca2+]. Nonetheless, another reservoir into which Ca2+ is usually 
stored is the sarcoplasmic reticulum via SERCA; this is an ATP dependent process and 
so inhibition in the ischaemic state contributes to a rise in intracellular Ca2+ (Ferrari, 
Pedersini et al. 1993). 
 
Ca2+ loading causes disruptive changes to the heart during ischaemia. However, this 
depends on the extent of Ca2+-loading which is determined by the duration of 
ischaemia. Long periods of sustained ischaemia can result in sufficient Ca2+ loading 
to trigger mitochondrial permeability transition (usually more a feature during 
reperfusion, Section 1.2.3). Further, it can cause hypercontracture and rigor of the 





1.2.3 Reperfusion of the Ischaemic Heart 
Acidosis is beneficial during relatively short periods of ischaemia as it inhibits MPTP 
opening but it eventually becomes damaging as the ischaemic time becomes 
extended. Sustained low pH would trigger significant Na+ accumulation and 
eventually resulting in Ca2+ accumulation. However, this can also occur during 
reperfusion following relatively short periods of ischaemia (see Figure 1-3, above). 
Whilst intuitively restoring normal perfusion of tissue would seem a necessary step 
in limiting injury, reperfusion does paradoxically cause further injury in itself, made 
evident by an increase in infarct size, reduction in contractility and arrhythmia in the 
immediate aftermath of reperfusion. Several phenomena occur which each 
contribute to the additional injury incurred during reperfusion, governing ionic 
homeostasis, pH levels, and oxidative stress.  
 
A key early event when flow is restored is normalization of pH (Piper, Garcña-Dorado 
et al. 1998). The reintroduction of blood flow removes H+ ions from the extracellular 
spaces, and so creates a pH gradient between the intracellular space and the 
intersititium. In the reperfused state, the Na+/H+ antiporter becomes still more 
active, so intracellular Na+ levels rise whilst the pH normalizes, triggering a further 
rise in intracellular Ca2+ (Abdallah, Wolf et al. 2010) with rising ATP levels, through 
NCX. This excess in Ca2+ levels is handled by two main reserves; SR storage via SERCA, 
and mitochondrial Ca2+ uptake. This can become overwhelming and lead to 
mitochondrial swelling, and ultimately rupture (Allen and Orchard 1987, Griffiths, 
Ocampo et al. 2000) 
 
A further consequence of the removal of the acidosis is the loss of inhibition of the 
contractile machinery; this has the effect of increasing ATP consumption and causing 
hypercontracture, and so is in itself harmful as it uses energy reserves and postpones 
re-establishment of ionic and metabolic homeostasis (Ladilov, Siegmund et al. 1995).  
 
ATP production becomes re-established along with the reintroduction of oxygen and 
metabolic substrates, when TCA flux is again viable. It has been known for some time 
that some component of reperfusion injury results from the resumption of ATP 
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production, known as the ‘oxygen paradox’ (Hearse, Humphrey et al. 1973, Ganote 
1983). An important element of this is oxidative stress and the production of reactive 
oxygen species (ROS). This occurs from reintroduction of oxygen to the mitochondrial 
electron transport chain complexes, and activation of xanthine and NADPH oxidases.  
 
1.2.3.1 Reactive Oxygen Species 
ROS refers to a collection of oxidants containing oxygen; these may be radical or non-
radical species capable of freely oxidizing other molecules.  Biologically, some 
significant examples of these include the superoxide radical (O2-·), hydroxyl radical 
(·OH), and hydrogen peroxide (H2O2) forming peroxynitrite, ONOO− (Zorov, 
Juhaszova et al. 2014) (Figure 1-4). Consequences of the release of these species 
include damage to cell and organelle membranes, interruption of signalling cascades 
but most significantly they increase the opening likelihood of the mitochondrial 
permeability transition pore (detailed in section 1.3) which is the key event linking 
reperfusion to tissue damage.  
 
Figure 1-4 Formation and removal of reactive oxygen species (Turrens 2007)O2-·, superoxide radical; ·OH, 
superoxide radical; ONOO−, peroxynitrite. 
 
Under normal circumstances, ROS are produced at a relatively low rate through 
mitochondrial respiration and other processes, but are dealt with through a variety 
of enzymatic antioxidant systems to prevent any significant damage. However, 
whether in a physiological state of low production or a pathological state where 
production is higher, the likely source in eukaryotes is the electron transport chain. 
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Mechanistically, this is likely because under conditions of high membrane potential 
and low oxygen transport,  it becomes more energetically favourable for electrons to 
‘leak’ from the chain of complexes (Ohkohchi, Endoh et al. 1999). 
 
Thus, the term ‘oxidative stress’ is used to describe that situation, where the 
production of ROS cannot be sufficiently controlled. Many external influences on the 
heart can trigger this, but it is particularly marked in the forms of surgery involving 
ischaemia and reperfusion; that is especially in cardiac surgery requiring aortic 
clamping (Dhalla, Elmoselhi et al. 2000).   
 
Given that ROS are produced endogenously however, it is unsurprising that there are 
enzymatic systems in place to remove them. These are concentrated spatially in the 
areas in which ROS are most prevalent- at the mitochondria, in the case of 
glutathione peroxidase and superoxide dismutase. The spatial relationship minimises 
the time between ROS generation and detoxification.  
 
Superoxide dismutase, SOD, is a particularly important antioxidant (Turrens 2003). It 
catalyses the conversion of O2.- to hydrogen peroxide through-  
 
2O2.- + 2H+ → H2O2 + O2 
 
This oxygen radical converted to hydrogen peroxide by SOD is highly reactive. Were 
it not dismutased to H2O2, an alternative reaction with NO forms the extremely 
potent peroxynitrite radical. Such is the importance of this enzyme that in 
mitochondrial SOD KO mice, huge levels of oxidative stress are seen causing death 
within days post-natal  (Li, Huang et al. 1995). However, H2O2 is in itself a potentially 
damaging species. It is specifically removed by catalase;  
 
H2O2 → 2H2O + O2 
 
-so by two successive enzymatically catalysed reactions, a harmful species is 
rendered much less so. The removal of H2O2 is also not solely dependent upon the 
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action of catalase; glutathione peroxidase, present in both the cytoplasm and 
mitochondria, may also scavenge H2O2, as can peroxiredoxin. Glutathione peroxidase 
is particularly important in preventing lipid peroxidation in organelle membranes and 
in removing membrane bound lipid hydroperoxides (Meister and Anderson 1983, 
Szymonik-Lesiuk, Czechowska et al. 2003). A number of studies have shown a 
protective effect of supranormal levels of glutathione peroxidase or increased flux 
through the reaction it catalyses; for instance increased glutathione levels, the 
substrate for glutathione peroxidase, are correlated with greater levels of function 
and reduced infarct size in a porcine model of cardiac surgery (Singh, Lee et al. 1989); 
this helps to demonstrate the importance of these enzymatic defence mechanisms 
in cardiomyocytes. 
 
Non enzymatic mechanisms also exist which reduce the activity of ROS in the heart. 
These are particularly important for the detoxification of some of the very potent 
oxidising species such as the ONOO.- radical. Rather than being eliminated by 
enzymatic activity, simpler compounds exist to quench their action; these include 
ubiquinone, and Vitamin E (Turrens 2003). 
 
1.2.3.2 ROS and I/R injury 
A balance exists between variable production of ROS, increased in conditions of 
oxidative stress, and elimination, through enzymatic and non-enzymatic 
mechanisms. Whilst production of ROS can occur during ischaemia through such 
pathways as enhanced arachidonic acid metabolism the main involvement of ROS in 
I/R injury comes through excess Ca2+ and oxidative stress on reperfusion leading to 
significantly increased electron leak in the mitochondria (Dhalla, Elmoselhi et al. 
2000, Robin, Guzy et al. 2007). Once reperfusion has occurred, the mitochondria are 
in themselves impaired due to the events during ischaemia and so their ability to 
generate flux through the electron transport chain is reduced (Makazan, Saini et al. 
2007); this leads to an accumulation of less stable intermediates and then a 




These ROS are a potent trigger for opening of the MPTP on restoration of blood flow. 
This occurs in the context of a Ca2+ loaded cardiomyocyte; these conditions prime the 
MPTP to open at the onset of reperfusion. The role of ROS in regulating the opening 
of the MPTP is critical to determining the ultimate degree of injury as a consequence 
of reperfusion. The events leading to opening of the MPTP as a consequence of 
ischaemia & reperfusion are summarised in Figure 1-5. 
 
 
Figure 1-5 Schematic diagram showing the sequence of events thought to lead to cell death in the cardiomyocyte 
following ischaemia and subsequent restoration of perfusion.  
Initially, cessation of blood flow leads to accumulation of metabolic byproducts from the switch to anaerobic 
respiration, and a depletion of ATP. This leads to a disturbance in ionic homeostasis due to failure of energy- 
dependent mechanisms to maintain the physiological gradients, followed as a consequence by Ca2+ loading and 





1.3 The Mitochondrial Permeability Transition Pore (MPTP) 
Mitochondria provide the main source of ATP in mammalian cells and are particularly 
dense in tissues with high energy demands and so are a prominent ultrastructural 
feature in the cardiomyocyte. They have two surrounding membranes; an outer and 
an inner mitochondrial membrane The outer mitochondrial membrane (OMM) is 
relatively permeable to small solutes (<5 kDa) but the inner mitochondrial membrane 
(IMM) is highly impermeable and provides the functional barrier to solute movement 
(Seifert, Ligeti et al. 2015). 
 
In order for their energy- producing function to operate, the inner mitochondrial 
membrane must remain relatively impermeable. However, in certain conditions- high 
calcium, phosphate and especially under oxidative stress- this membrane becomes 
more permeable. This leads inevitably to swelling of the mitochondrion, uncoupling 
of respiration, reversal of the F1/F0 ATPase and eventually rupture (Halestrap and 
Richardson 2015). This phenomenon was originally known as the permeability 
transition; Haworth & Hunter in 1979 (Hunter and Haworth 1979) demonstrated that 
this was due to the formation of a non-selective channel in the inner mitochondrial 
membrane porous to substances < 1.5 kDa in mass. This permeability transition was 
inhibited by the addition of cyclosporin A, (Crompton, Ellinger et al. 1988), which 
provided the first direct evidence of cyclophilin-D as a structural component of the 
hypothetical pore.  
 
Under conditions where the pore opens, there is no barrier to equilibration between 
the mitochondrial matrix and the cytosol. Thus, a consequence of pore opening is the 
movement of small molecules which have a collective osmotic pressure; this 
movement leads to the swelling of the organelle and eventual rupture. What follows 
is the release of membrane proteins including cytochrome c, which may precipitate 
an apoptotic response via Apaf-1 and the activation of procaspase-9 (Desagher and 
Martinou 2000).  
 
Many factors have been noted as having influence over the opening propensity of 
the MPTP; predominantly these factors operate by enhancing or reducing the 
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sensitivity of the pore to calcium (Halestrap, McStay et al. 2002, Halestrap and 
Brenner 2003, Halestrap 2009); for instance cyclosporin A operates through a 
decrease in the pore sensitivity to calcium induced opening. Therefore, as the 
sensitivity can vary independently of calcium concentration, pore opening can occur 
without changes in ambient calcium levels.  
 
Further observations (Szabo and Zoratti 1991, Zoratti and Szabo 1994) have 
previously suggested the possibility that the pore may rapidly transition between 
open and closed states with a range of meta-stable states in between. These studies 
are based upon electrophysiological observation; it is unknown whether these states 
exist in the physiological setting. Indeed, after induction of MPTP opening, 
mitochondria once imaged are seen to be either indistinguishable from the untreated 
appearance, or very swollen, without an intermediate phenotype.  
 
1.3.1 Structural Components of the MPTP 
The precise identity of the components of the MPTP remains unclear; as does much 
knowledge about the dynamics of the formation of the pore and indeed several 
groups have differing perspectives on the composition of the pore. However, several 
Figure 1-6 Schematic of the original model of the MPTP 
(A) The MPTP was proposed to be one contiguous pore composed of VDAC and ANT regulated by CypD, which 
formed at contact sites between the inner and outer membranes.  
(B) (B) Schematic of the new model of the MPTP consisting of Bax/Bak on the outer mitochondrial membrane to 
impart a level of necessary permeability and the F1F0 ATP synthase on the inner mitochondrial membrane 
regulated by CypD in the matrix as the component that responds to stimuli to initiate opening, efflux of Ca2+ 
and loss of membrane potential, and mitochondrial swelling (Karch et al. 2014) 
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proteins have been accepted as being critical both for the pore to form and in the 
regulation of its function (Halestrap and Richardson 2015, Richardson and Halestrap 
2016). A previous, and a current hypothetical model for the structure of the pore is 
shown in Figure 1-6 (Karch and Molkentin 2014); the model has undergone, and 
continues to undergo revision as new discoveries are made and old findings 
reinterpreted.  
 
1.3.1.1 Cyclophilin D 
Halestrap & colleagues initially characterised the target for MPTP inhibition by CsA 
as a peptidyl-prolyl cis-trans isomerase and then identified this as cyclophilin D 
(Connern and Halestrap 1992, Connern and Halestrap 1996) which enhances the 
calcium sensitivity of the MPTP.  Sanglifehrin A had also been previously observed to 
be a potent MPTP inhibitor; it was further found to act on cyclophilin D, albeit at a 
different site to CsA, confirming the role of cyclophilin D in the MPTP (Clarke, McStay 
et al. 2002). Cyclophilin D is not permanently present in the mitochondrial 
membranes; binding is dynamic, and is increased under conditions of oxidative 
stress. Binding of cyclophilin D induces the permeability transition.  
 
This binding is dependent on three proteins in the inner mitochondrial membrane; 
the adenine nucleotide translocase (ANT), the inorganic phosphate carrier (PiC), and 
the oligomycin sensitivity conferring protein (OSCP), which is a component of the 
F1F0- ATPase (Crompton, Virji et al. 1998, Woodfield, Ruck et al. 1998, Giorgio, Bisetto 
et al. 2009, Gutiérrez-Aguilar, Douglas et al. 2014). Both the PiC  and ANT display 
increased cyclophilin D binding under conditions of oxidative stress (McStay, Clarke 
et al. 2002), leading to pore formation.  
 
Further, in mitochondria from CyP-D knockout mice, permeability transition is not 
sensitive to CsA and is also much less sensitive to increases in calcium concentration, 
thus demonstrating the vital role cyclophilin D plays in the formation of the MPTP 
(Baines, Kaiser et al. 2005, Basso, Fante et al. 2005). Nevertheless, in the presence of 
a suitably intense stimulus to pore formation, permeability transition is known to 
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occur in the absence of cyclophilin D (42) such that is not a necessary component of 
the MPTP. 
 
1.3.1.2 Phosphate Carrier (PiC) 
The inner mitochondrial membrane is impermeable under normal circumstances to 
small solutes. The phosphate carrier imports phosphate across the IMM which is 
required in order for oxidative phosphorylation to take place. Phosphate is thought 
to sensitise the MPTP to opening (Hunter, Haworth et al. 1976, Crompton, Ellinger et 
al. 1988) and so evidence began to accumulate implying this carrier as part of the 
MPTP (Varanyuwatana and Halestrap 2012). Further, in phosphate deplete 
environments, CsA is unable to inhibit the MPTP; implying an interaction between 
PiC and CypD (Basso, Petronilli et al. 2008). 
 
1.3.1.3 Adenine Nucleotide Translocase (ANT) 
The adenine nucleotide translocator exchanges ATP for ADP across the inner 
mitochondrial membrane bidirectionally depending upon the electrochemical 
gradients; that is by the relative concentrations of the nucleotides and the 
mitochondrial membrane potential (Klingenberg 2008).   
 
The ANT is also thought to have a significant role in MPTP opening. Regulators of 
apoptosis, including Bcl-2 are thought to mediate this effect via ANT binding and 
modulation of the opening likelihood of the MPTP (Halestrap and Brenner 2003).  
Given what has been shown about the criticality of cyclophilin D to MPTP opening, 
the demonstration of ANT binding cyclophilin D in a manner dependent upon 
cyclosporin A, and also proportionate to induced oxidative stress,  serves to 
strengthen the argument that it too is a component of the MPTP, at least in some 
circumstances.  
 
That caveat exists as doubts over the necessity of the ANT in the MPTP arose with 
the observation of MPTP opening in ANT1/2 knockout mice (Kokoszka, Waymire et 
al. 2004). However, the counterpoint was made by the same group that mitochondria 
from these animals were much less sensitive to calcium induced MPTP opening; 
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therefore the consensus position became that ANT presence was not essential for 
MPTP formation but served an amplifying role in its function, at least in the non-
physiological setting of an isolated mitochondrial preparation. 
 
1.3.1.4 Voltage Dependent Anion Channel (VDAC) 
VDAC is a family of ion channels expressed on the outer mitochondrial membrane. , 
which behaves as a pore for small water soluble molecules, closing when the 
mitochondrial membrane potential rises above c. 40 mV. The role of VDAC in the 
MPTP is controversial. Antibody mediated blockage of the VDAC prevents 
mitochondrial permeability transition (Shimizu, Matsuoka et al. 2001); however the 
antibodies which were used in these studies may or may not be specific to 
membranes containing VDAC (Dermietzel, Hwang et al. 1994). Further biochemical 
evidence against its role is that knockouts of VDAC 1 have a normal permeability 
response to MPTP stimuli (Krauskopf, Eriksson et al. 2006); additionally, pulldown 
experiments demonstrated interactions of CypD with ANT and PiC but not VDAC. This 
argues against the presence of VDAC in the pore, but is not conclusive (Woodfield, 
Ruck et al. 1998). 
1.3.1.5 F1F0  ATPase 
The ATP synthase has recently come to be thought to contribute to MPTP formation 
(Bernardi 2013, Bonora, Wieckowski et al. 2014). Indirect evidence from intact 
mitochondria found that the state of activity of the ATP synthase influenced the 
MPTPs ability to be opened by increased Ca2+; others implied its presence electro-
physiologically (Giorgio, von Stockum et al. 2013). Not all authors have been able to 
replicate these findings nor agree with the conclusion that the whole ATP synthase 
is necessarily present in the MPTP. Pinton, for instance, argues for a role of the c- 
subunit only; these subunits form the ring structure of ATP synthase in the inner 
mitochondrial membrane and so it is enticing to visualise how this ring might become 
a pore, in the absence of the other ATP synthase constituents (Bononi, De Marchi et 
al. 2013). Others have made an observation that silencing of the c- subunit causes a 
reduction in MPTP opening in a similar fashion to that seen with CsA (Alavian, 
Beutner et al. 2014).  
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1.3.2 Physiological Role of MPTP 
Since its discovery, there has been much discussion about whether this pore has a 
physiological role or if it is purely a pathological phenomenon. Most experimental 
investigations have studied CypD, rather than the MPTP as a whole, and in particular 
as it relates to Ca2+ homeostasis and metabolic uncoupling.  
Altschuld, in some of the earliest experiments, showed that treatment of 
cardiomyocytes with CsA as a pore inhibitor prevented mitochondria Ca2+ efflux 
(Altschuld, Hohl et al. 1992). Subsequently Elrod (Elrod, Wong et al. 2010) found that 
in a CypD mouse knockout model the mice became more sensitive to pressure-
overload induced hypertrophic cardiomyopathy, associated with elevated 
mitochondrial matrix Ca2+. The result of this is an increase in glucose utilization as a 
metabolic substrate rather than fatty acids; this limits the metabolic reserve in 
response to stress (Ong, Samangouei et al. 2015). Others have shown that CypD 
mediates Ca2+ transfer from the endoplasmic reticulum to mitochondria via an 
interaction with VDAC in cardiomyocytes (Paillard, Tubbs et al. 2013). It seems then 
that the MPTP may be important in the physiological regulation of Ca2+ uptake and 
efflux from the mitochondria; this role is much less well established than the role of 
the pore during I/R injury, and the significance of these observations is not yet clear.  
 
1.3.3 Role of MPTP in I/R Injury 
Even before CypD was identified as a component of the MPTP, CsA was known to 
have the ability to reduce hepatic injury in a model of I/R injury to the liver 
(Kurokawa, Kobayashi et al. 1992).  In parallel, the MPTP was investigated as a 
mediator of acute myocardia I/R injury which showed MPTP opening was regulated 
by factors such as Ca2+, inorganic Pi, oxidative stress, and purinergic nucleotides in 
studies which contributed to the structural model (Al-Nasser and Crompton 1986, 
Crompton, Ellinger et al. 1988, Ong, Samangouei et al. 2015). These factors are all 
known to change during acute I/R injury, and enhance the opening probability of the 
MPTP in this context. However, during the ischaemic phase, lactate accumulation 
results in strongly acidic conditions, with a pH less than 7.0, resulting in a strongly 
inhibitory effect upon the MPTP despite an environ which would otherwise favour its 
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opening, only becoming permeable early in reperfusion when the washout of lactic 
acid and with ATP availability reactivating NHE normalises pH (Griffiths and Halestrap 






As discussed in Section 1.2, I/R injury involves a complex interplay of features and 
mechanisms interacting to produce injuries in differing modalities and at varying 
rates. However damage is done to the heart, it is important that it is minimised both 
in the adult and in the immature; as even in the developing heart after a certain 
stage, cardiomyocytes killed are not replaced by dividing progenitors (Yellon and 
Downey 2003). Figure 1-7 schematically shows the mechanisms that lead to injury 
and suggests interventions with which they may be targeted.  
Figure 1-7 Mechanistic view of potential sites for cardioprotection(Perricone and Vander Heide 2014) 
 
1.4.1 Intrinsic Cardioprotective Interventions 
1.4.1.1 Ischaemic Preconditioning 
Multiple strategies to protect the heart by non- pharmacological interventions have 
been described. Ischaemic preconditioning is perhaps the best known of these; it was 
hinted at clinically with the observation that the outcome for patients who described 
multiple episodes of angina pectoris prior to a myocardial infarction was improved 
compared to those who did not. However the key experimental study in 1986 
showed that a dog’s heart suffered a reduced size of infarct if the global ischaemic 
insult followed four 5 minute cycles of ischaemia (Murry, Jennings et al. 1986). This 
was then shown to operate by inhibition of MPTP opening in conditions where it 
would be expected to (Javadov, Clarke et al. 2003); the intermediate steps are not 
clear, although reduction in intracellular Ca2+ or in the generation of ROS were 
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proposed. Various signalling modalities were nevertheless known to be involved 
often including the phosphorylation of families of protein kinases; PKB/Akt, ERK 1 & 
2 (Hausenloy, Tsang et al. 2005) as well as Protein Kinase C (Armstrong, Downey et 
al. 1994). A variant of this is ischaemic postconditioning, wherein the application of 
cycles of ischaemia to the heart following a significant ischaemic event- aortic cross 
clamping, or myocardial infarction, for instance- reduces the magnitude of injury 
sustained. The has obvious applicability for unanticipated ischaemia in the clinical 
setting, and is thought to have similar potency as ischaemic preconditioning (Zhao, 
Corvera et al. 2003). 
1.4.1.2 Remote Ischaemic Preconditioning 
An important mechanistic insight came from the observation that ischaemic 
preconditioning could be induced remotely, by shifting the initial ischaemic episodes 
away from the target organs to repeated cycles on a distant limb. A marked reduction 
in infarct size was again observed (Gho, Schoemaker et al. 1996), implying that there 
must be some form of signal imparted from the remote tissue to the heart. 
The nature of this signal is not completely understood; the possibilities which have 
been postulated include a neurological signal from the ischaemic tissue, a release of 
humoral factors, or the triggering of some kind of systemic response. Nevertheless, 
similar mechanisms to those seen in direct ischaemic preconditioning have been 
observed involving activation of PKC (Wolfrum, Schneider et al. 2002, Hausenloy and 
Yellon 2008). 
1.4.1.3 Temperature Preconditioning 
 Another notable protective strategy is temperature preconditioning. This refers to 
induced cycles of hypothermia prior to an ischaemic event reducing the injury that 
results. It also seems to reduce oxidative stress and so produce a relative reduction 
in MPTP opening, so reducing I/R injury. (Khaliulin, Clarke et al. 2007).  Reducing 
temperature to around 26 °C seems to be the optimal strategy (Khaliulin, Halestrap 
et al. 2011). 
 
Temperature protection confers protection by increasing myocardial cAMP and 
subsequent activation of Protein Kinase A (PKA) followed by activation of Protein 
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Kinase C (PKC) (Khaliulin, Parker et al. 2010). This sequence of events was confirmed 
by a finding from our group that the PKA inhibitor H-89 attenuated PKC activation 
following TP (Bain, Plater et al. 2007, Khaliulin, Parker et al. 2010) and led to the 
formulation of a new cardioprotective pharmacological strategy that involves 
cAMP/PKA/PKC signalling through consecutive administration of isoprenaline and 
adenosine.  
 
Recent work in Bristol has shown that the normal adult rat heart can be effectively 
protected against I/R injury by transient and consecutive treatment with clinically 
relevant doses of isoprenaline & adenosine (Iso/Aden) (Khaliulin, Halestrap et al. 
2014). This intervention has also been shown to protect hearts across a spectrum of 
models of pathology, when applied during hypothermic cardioplegic arrest (Khaliulin, 
Halestrap et al. 2011) and in rat models of heart failure and aging (Dudley, Suleiman 
et al. 2014, Khaliulin, Halestrap et al. 2014).  
 
This intervention involves activation of Protein Kinase A (PKA) followed by activation 
of Protein Kinase C (PKC). A possible mechanism for this effect was noted with the 
observation that this treatment results in a decrease in glycogen content in the 
myocardium (Khaliulin, Parker et al. 2010, Khaliulin, Halestrap et al. 2014). Glycogen 
breakdown and subsequent accumulation of glucose-6-phosphate and low pH during 
ischemia triggers dissociation of mitochondrial hexokinase 2 (HKII) which can reduce 
mitochondrial permeability transition pore (MPTP) opening and cardiomyocyte 
death (Chiara, Castellaro et al. 2008, Pastorino and Hoek 2008, Pasdois, Parker et al. 
2012).  
 
1.4.2 Pharmacological Strategies 
1.4.2.1 Protection by NHE inhibition 
The intracellular fall in pH that accompanies ischaemia results in rapid increases in 
[Na+]I, then a subsequent rise in intracellular Ca2+. Therefore, inhibition of the Na+/H+ 
exchanger may ameliorate that rise. Indeed this has been demonstrated 
experimentally (Liu, Cala et al. 2010) and interestingly, clinically, with a 
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demonstration of a fall from 20% to 16% 5 day risk of death in patients whom were 
receiving the NHE inhibitor cariporide in the EXPEDITION trial (Mentzer, Bartels et al. 
2008). This trial however also showed an increased risk of mortality due to 
cerebrovascular events, and so the agent did not progress further. Nevertheless, this 
class of drug may prove useful for clinical cardioprotection. 
1.4.2.2 Protection by NCX Inhibition 
In a similar vein, it should hypothetically be possible to effect cardioprotection by 
directly inhibiting one of the sources of Ca2+ feeding the measured rise inside the 
cardiomyocyte. Inhibition of NCX is pharmacologically possible, with agents such as 
SN-6. Whilst the NCX may be inhibited, the agents are only effective at ameliorating 
the rise in Ca2+ if administered prior to the onset of ischaemia (Akabas 2004). They 
may potentially be useful therefore in circumstances such as surgery, where 
ischaemia may be planned and controlled, but of little use more broadly.  
1.4.2.3 Protection with Antioxidants & MPTP inhibitors 
Supplementation of the endogenous capacity to scavenge ROS should produce 
protection, as excess ROS generation is a key part of I/R injury. Experimental work in 
rats using the novel agent mitoQ initially appeared to reduce ROS production; 
however, in some others and in clinical work some cases of increased injury were 
observed (Gottwald, Duss et al. 2018, Zhou, Prather et al. 2018). Other work is 
ongoing in an attempt to discover an effective intervention- for instance, propofol, a 
GABAa agonist used widely and safely  as a hypnotic agent, has been shown to inhibit 
the MPTP possibly because of its antioxidant activity (Javadov, Lim et al. 2000). Its 
cardioprotective efficacy during cardioplegic arrest has been confirmed in large 
animal studies(Lim, Halestrap et al. 2005). Its benefit in a clinical setting remains 
controversial (Plummer, Baos et al. 2014, Rogers, Bryan et al. 2015). 
The most widely used agent to inhibit the MPTP remains Cyclosporin A, which has 
been used for this purpose since 1988 (Crompton, Ellinger et al. 1988) and exerts its 
effects through binding to cyclophilin D- section 1.3.1.1 (Halestrap and Davidson 
1990). In experimental models, CsA produces protection against I/R injury in the 
isolated perfused whole heart model (Chen, Camara et al. 2007) and reduces necrotic 
cell death in an isolated cardiomyocyte model of simulated I/R injury (Nazareth, Yafei 
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et al. 1991). Given that CsA is acting as an MPTP inhibitor, it should be expected that 
its use during the phases of injury with maximal ROS production should be sufficient 
to produce protection. Indeed, perfusion with CsA is effective if given during 
reperfusion only, demonstrating that most MPTP opening occurs at this point 
(Hausenloy, Maddock et al. 2002, Argaud, Gateau-Roesch et al. 2005, Xie and Yu 
2007). If perfusion with CsA is delayed, past around 15 minutes into ischaemia, no 
protective effect is seen, implying that the early reperfusion period is when MPTP 
opening occurs and determines the degree of injury (Hausenloy, Duchen et al. 2003). 
Other agents which inhibit the MPTP directly via CypD also have a protective effect, 
such as Sanglifehrin A (Clarke, McStay et al. 2002). Despite these promising pre-
clinical results, these agents have not shown success as cardioprotective therapies in 
clinical trials, possibly because of their lack of specificity as pure MPTP inhibitors 





1.5 β-adrenergic receptor and cAMP signalling in the heart 
Physiological signalling through neuroendocrine means is a key effector of 
homeostasis and the stress response. Hormonal release of adrenaline from 
endocrine tissues, and release of other adrenergic agonists through the sympathetic 
nervous system regulates the response of the cardiovascular system to changes in 
the environment, and physiological stressors. 
 
β-Adrenergic receptor (β-AR) signalling is particularly important during conditions of 
acute stress, in order to mediate components of this neurohumoral response. cAMP 
is the main second messenger of the β-adrenergic receptor pathway (shown 
schematically in Figure 1-8), which acts mainly by activation of the cAMP dependent 
protein kinase, Protein Kinase A. There are a family of β-Adrenergic receptors, 
conventionally comprising three subtypes- β1, β2, and β3. The receptors are integral 
membrane proteins and are part of the superfamily whose characteristic feature is 
of seven-transmembrane spanning domains known as G-protein coupled receptors. 
These are a key group of signal transduction proteins broadly involved in a wide range 
of physiological processes from olfaction through to mood regulation through 
interaction with neurotransmitters; however, their cardiac function is primarily 
limited to transmission of autonomic signalling.  
 
There are well-characterised endogenous ligands for each of these receptor 
subtypes, and these substances often have activity at multiple receptors. Adrenaline, 
for instance, has activity at each receptor subtype and on the α- adrenoreceptors. 
However, pharmacological agents exist for selective function at each of these 
receptor types and so have been used as probes for investigating the respective roles 
of each distinct receptor; isoprenaline has long been used as a selective β1 agonist.  
 
Both β1 and β2 receptors are present in the heart, with a predominance of β1 
receptors; roughly 75% vs 25% β2 in the human ventricle (Brodde 1991). Both of these 
receptor subtypes couple with G proteins, which are signalling intermediaries with 
GTPase activity. G proteins, or guanine- nucleotide binding proteins, are key in the 
transduction of receptor signals from the extracellular to intracellular spaces; they 
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are in an active state when bound to GTP, and inactive with GDP bound. For the 
membrane- bound G- proteins, such as those that interact with the β-Adrenergic 
receptors, they consist of three subunits- Gα and a Gβγ complex. They are therefore 
known as the ‘heterotrimeric’ type. Activation of the GPCR to which a G- protein is 
bound, causes disassociation of the inhibitory Gβγ dimer allowing unimpeded activity 
of the Gα subunit. Variation in response to GPCRs occurs therefore through the 
precise identity  and targeting of the G-protein subunits or by ligand- specific 
conformational changes in GPCR (Gether, Lin et al. 1995); once activated and 
disassociated in the active form, the Gα may move away from the membrane to its 
targets for activation. There are multiple subtypes of Gα which couple with the β-AR; 
however, the β1 receptor couples mostly with the Gs family, whose main target is 
adenylate cyclase. This enzyme when activated by Gs catalyses the conversion of ATP 
to cyclic AMP, a key signalling intermediary. Thus, this whole signal transduction 
cascade has both specificity in response, through the balance of G protein subtypes 
associated with receptors, and multiple amplification steps allowing small numbers 
of interactions at the cell membrane to cause a large output of messaging molecules.  
 
Figure 1-8 A schematic representation of β- adrenergic signalling with selected relevant downstream targetsΒ-
AR= β-adrenoreceptor; Gsα= stimulatory G- protein; ACn= adenylate cyclase; cAMP= cyclic adenosine 
monophosphate; PKA= Protein Kinase A; Epac= Exchange protein activated by cAMP; PLC= phospholipase C; PKCε= 
Protein Kinase C epsilon; CaMKII= Ca2+ /calmodulin-dependent protein kinase II; PLN = phospholamban; SR= 
sarcoplasmic reticulum; RyR2= Ryanodine Receptor 2; P= phosphorylated residue From de Rooij., et al., 1998 
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1.5.1 Protein Kinase A 
cAMP, as the molecule at a key nexus in the signalling cascades examined in this thesis, has 
multiple actions in the cardiac myocyte. Its canonical role was to cause activity of Protein 
Kinase A, PKA. This protein phosphorylates key proteins involved in EC coupling, including 
the L- type Ca2+ channel, ryanodine receptor (RyR2), troponin I (TnI) and phospholamban 
(PLN) (Bers 2002, Guellich, Mehel et al. 2014) (Figure 1-8). The key cardiac functions of β-AR 
are unsurprising given these targets; stimulation will cause a positive inotropic and 
chronotropic response in the heart, which follows from increased activity at RyR2 and the 
LTCC increasing calcium availability during systole (Guellich, Mehel et al. 2014).  
 
The cAMP- dependent protein kinase, now known more commonly as Protein Kinase 
A, one the first protein kinases to be discovered (Walsh, Perkins et al. 1968). PKA is a 
tetrameric cytosolic protein consisting of two regulatory and two catalytic subunits 
(Corbin, Sugden et al. 1978). It is a commonly occurring signal transduction 
intermediary. In this form, the enzyme is inactive. When cAMP binds to this form, it 
causes a disassociation of the catalytic from regulatory domains; the resulting 
dimeric holoenzyme is then free to phosphorylate its targets.  
 
In conditions where cAMP density is low, however, the inactive form of the enzyme 
predominates. So the overall activity of PKA is tightly controlled locally by the relative 
activities of adenylate cyclases, producing cAMP, and phosphodiesterases, degrading 
it. Regulation occurs then by the activity of these two influences in the vicinity of the 
PKA molecule, rather than merely by the abundance of PKA or cAMP per se.  
 
Non- canonical influences upon the regulation of PKA have more recently become 
clear. For instance, in the cardiomyocyte under conditions of oxidative stress, 
activation of PKA independently of cAMP may occur bypassing the physiological 
regulatory mechanisms. This occurs by the reperfusion- induced production of H2O2 
leading to the formation of disulphide bridges between RIα subunits of PKA. This 
leads to translocation of the kinase to the myofilaments and phosphorylation of its 
targets there, Troponin I and Myosin Binding Protein C leading to increased 
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contractility independent of the abundance of cAMP (Brennan, Bardswell et al. 
2006). 
 
Thus, activity of PKA is classically tightly regulated and controlled temporally by the 
activity of upstream receptors and associated signalling complexes, by regulatory 
influences upon the abundance of cAMP, but also by other influences such as redox 
signalling within a cardiomyocyte. 
 
1.5.1.1 Spatial Targeting of PKA Signalling 
Many proteins in different tissues contain motifs which may bind PKA and thus 
become phosphorylated. PKA is not free to diffuse passively around the cell, 
however; spatial targeting of PKA takes place through the association of the inactive 
PKA with A- kinase anchoring proteins (AKAP) confining the response to cAMP in a 
cell-type specific manner, allowing specificity in response (Dodge-Kafka, Soughayer 
et al. 2005) (Langeberg and Scott 2015). Without this function, the broad specificity 
of the catalytic subunits’ phosphorylation site would not permit a response 
appropriate to the tissue. These were initially thought to be simple binding proteins, 
but are now recognized to be a very large family of multivalent enzyme scaffolding 
proteins that coordinate complex and highly organised intracellular events (Rubin 
1994) and are even active and dynamic participants in signalling due to structural 
flexibility, and their ability to assemble a range of other regulatory proteins into a 
signalling nexus (Smith, Reichow et al. 2013).  
 
Further regulation occurs by the regulatory subtype composition of PKA leading to 
the designation of PKA subtypes PKA-I and PKA-II (Smith and Scott 2018). Although 
these isoforms were historically thought to have a high degree of functional 
redundancy, differential compartmentalization through AKAPs is thought to provide 





1.5.1.2 PKA and the Mitochondria 
 
This is of particular importance in considering the interaction of PKA with 
mitochondria; an AKAP tethers PKA to the outer mitochondrial membrane (OMM) 
(Figure 1-9) so localising a response which began at the cell membrane to an 
organelle some distance removed (Ould Amer and Hebert-Chatelain 2018) and 
increasing the efficiency and speed of the response.  
  
 
The tightly controlled spatial regulation of PKA activity mentioned above is also seen 
within the mitochondria, where two distinct subpopulations of cAMP are known to 
exist (Ould Amer and Hebert-Chatelain 2018). In the matrix, a soluble form of AC 
generates cAMP is thought to modulate oxidative phosphorylation through post-
translational modification of components of complex IV (Acin-Perez, Salazar et al. 
2009), whereas the transmembrane form of AC found at the OMM elevates cAMP 
there, associated with mitochondrial morphological changes, alteration to the 
mitochondrial membrane potential and seems to protect against apoptosis 
(Monterisi, Lobo et al. 2017) through phosphoinhibition of Bad. This is accomplished 
by PKA recruitment by AKAP121 (Affaitati, Cardone et al. 2003).  
 
The precise nature of signalling at these sites is not solely a consequence of resulting 
PKA activity, either; AKAPs also recruit other populations of enzymes- non PKA 
Figure 1-9 Association of PKA with 
MitochondriaFrom Ould Amer et al., 
2018. PKA is tethered to the OMM by 
AKAPs which bind to the regulatory 
subunits of PKA (R).In the mitochondrial 
matrix, the soluble adenylyl cyclase 
(sAC) generates cAMP, whereas 
phosphodiesterase (PDE) degrades 
cAMP.. IMS: inter membrane space; 
IMM: inner mitochondrial membrane. 
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kinases- creating focal points for signalling pathways and their regulation (Dodge, 
Khouangsathiene et al. 2001, Feliciello, Gottesman et al. 2001, Dodge-Kafka and 
Kapiloff 2006).  
 
Other than by interaction with mitochondrial membrane proteins, PKA has 
widespread influence on other aspects of mitochondrial function. Mitochondrial 
matrix PKA targets complexes I, IV, and V of the electron transport chain; in complex 
IV, for instance becomes phosphorylated by PKA during hypoxia at certain subunits 
decreasing overall complex IV activity (Prabu, Anandatheerthavarada et al. 2006). 
The net effects of these interactions are complex  and incompletely characterised 
(Papa, Scacco et al. 2002) but mutations of these sites lead to significant 
developmental and neurological disorders, hinting at the key role PKA plays in 
ontogeny.  
 
Collectively, it seems that mitochondrial metabolism is finely regulated by PKA 
activity, which is itself under the control of many convergent processes.  
 
However, PKA is not the only effector of cAMP signalling. There are two targets which 
are as yet not well understood, the cyclic nucleotide gated ion channels and Popeye 
domain containing proteins, which are activated by cAMP (Simrick, Schindler et al. 
2013, Brand, Poon et al. 2014), and a family of proteins known as EPAC which is a 




EPAC is a small family of signalling proteins discovered independently by two lines of 
investigation in 1998. de Rooij (de Rooij, Zwartkruis et al. 1998) and colleagues 
successfully identified a guanine- nucleotide exchange factor for Rap1. They were 
investigating stimuli that would activate the oncosuppressive properties of Rap1 (a 
small GTPase with sequence similarity to Ras), and discovered that activation of Rap1 
occurs independently of activation of Protein Kinase A. This was achieved by 
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examination of cAMP- linked Rap1 activation in a cell line (CHO10248) with a mutant 
regulatory subunit of PKA which was essentially unresponsive to cAMP. Forskolin 
stimulation, alongside H89 induced PKA inhibition, of both these cells and a control 
cell line without the mutant PKA, showed equivalent Rap1 activation. Therefore, it 
was concluded that Rap1 was activated by a cAMP- stimulated factor independently 
of PKA. A database search was conducted for a protein with both GEF homology and 
cAMP binding sites. A sequence was identified by this search, and by an RT-PCR 
approach a strand of DNA encoding an 881 amino acid protein was isolated. They 
dubbed this protein EPAC- the Exchange Protein Directly activated by cAMP.  
 
In parallel, another group (Kawasaki, Springett et al. 1998) were investigating the 
observation that several neuronal functions including neuroplasticity and 
neurotransmitter- initiated signalling were clearly involving cAMP but could not be 
convincingly linked to PKA. A search for guanine exchange factors with specificity for 
Rap proteins via a cloning approach resulted in the identification of a brain-enriched 
gene, CalDAG-GEF1 (Kawasaki, Springett et al. 1998). The product of this gene was 
found to have Rap1A specificity, bound both calcium and diacylglycerol, and had 
particularly enriched expression in axon-terminal regions of the brain. These features 
pointed strongly towards a signalling molecule, particularly one linked to the features 
of plasticity and neurotransmission. 
 
1.5.2.2 EPAC Structure 
Schematically, each of the two identified forms of EPAC are similar in their overall 
structure (Figure 1-10). They are made up of two functionally independent regions, 
a C- terminal catalytic region with guanine exchange activity, and an N- terminal 
region which is regulatory (Borland, Smith et al. 2009). EPAC then exists in two main 
conformational states in equilibrium with one another; a closed state, where the 
regulatory region sterically prevents access to the GEF site, and an open state where 
the catalytic site is freely available. In the presence of cAMP, the open state is 
thermodynamically favoured so catalysis is enhanced in high- cAMP states 





Figure 1-10. Schematic representation of the two described forms of Epac (Rehmann 2013)CNB= cyclic 
nucleotide binding domain; Dishevelled-Egl-10-Pleckstrin; REM= Ras exchange motif; RA= Ras association; 
CDC25-HD= CDC25 homology domain. 
There are two main forms of EPAC, 1 & 2, and they have been best characterised in 
mouse and in human. EPAC 1 and 2 differ in the precise make-up of their constituent 
regulatory domains. In EPAC 1, this region consists of a DEP domain (after 
Dishevelled, Egl-10, and Pleckstrin; three initial proteins in which this domain was 
found) which is responsible for membrane localisation, and a single cyclic nucleotide 
monophosphate domain. By contrast, EPAC 2 retains the DEP domain but it is flanked 
on either side by cNMP domains. In both, however, the catalytic region is 
immediately preceded on its N-terminal side by a cNMP domain; the additional cNMP 
region of EPAC 2 does not seem to modify its capacity to be regulated by cAMP; 
indeed it has a relatively low affinity for cAMP of only 70 μM compared to 1 μM for 
the cNMP-B domain shared by both isoforms (de Rooij, Rehmann et al. 2000). 
 
The EPAC 1 and 2 proteins, while broadly similar in their structure and in vitro 
biochemical activity, have differing physiological functions owing to distinct tissue 
distributions (Robichaux-III and Cheng 2018). In the mouse, Rapgef3, which encodes 
EPAC 1, is ubiquitously expressed. However, Rapgef4, which expresses EPAC 2, is 
more limited in distribution. Studies of mRNA abundance in mouse identify elevated 
levels of EPAC 1 in kidney, ovary, muscle, thyroid and brain tissues; EPAC 2 is mainly 
found in the CNS and adrenal, with very limited amounts detected in heart, small 
intestine and testis (Kawasaki, Springett et al. 1998). 
 
Further, rodent studies suggest that EPAC 1 and 2 abundance is developmentally 
regulated. EPAC 2 seems to show more drastic changes through development in 
mice; but EPAC 1 mRNA expression does increase moderately after birth, reaching a 
maximum at 3 weeks post- natal in heart and some other tissues (Robichaux-III and 
Cheng 2018). However, in the brain, spinal cord and dorsal root ganglion tissues (in 
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rat) there is a complex developmental pattern of rising and falling levels of EPAC 1 & 
2 at differing developmental stages (Murray and Shewan 2008).  
 
1.5.3 EPAC function 
Both EPAC 1 and 2 target the same immediate effectors; these are GTPases from the 
Ras superfamily known as Rap1 and 2. Despite this, both isoforms have distinct 
signalling roles and are not redundant due to their unique intracellular localisation 
as well as presence in signalosomes targeting particular partners. The EPAC proteins 
participate in a wide range of physiological functions summarised in Figure 1-11. 
 
Figure 1-11 From Robichaux-III and Cheng 2018. A systems based summary of some the physiological functions 
EPAC proteins are known to be involved in.  
1.5.3.1 EPAC1 
EPAC 1 is known to exist at multiple locations within cells in a variety of tissues, and 
this localisation is dependent on the particular stage of the cell cycle in which a cell 
is examined. During interphase, it is mainly cytosolic in a perinuclear location as well 
as found in the mitochondria; however during mitosis it has been described as 
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translocating to the spindle and centrosome (Qiao, Mei et al. 2002). This tight 
association with translocation through cell division implies that the localization of 
EPAC 1 is strictly controlled and has functional consequences (Robichaux-III and 
Cheng 2018). cAMP, as well as being the activator of EPAC 1, is also responsible for 
influencing its location (Ponsioen, Gloerich et al. 2009). For instance, high 
concentrations of cAMP are associated with membrane localisation of EPAC 1 in a 
manner thought to depend upon a conformational change in the EPAC DEP domain 
contingent on cAMP binding (Consonni, Gloerich et al. 2012). This property allows 
signal transduction to occur in distinct compartments responsible for individual 
function roles of EPAC 1.  
 
1.5.3.1.1 Functions of EPAC 1 at the plasma membrane 
At the plasma membrane, EPAC 1 interacts with a family of scaffolding proteins 
known as ERM (ezrin-radixin-moesin) activated by PIP2 binding and phosphorylation. 
This interaction between EPAC and ERM proteins occurs in a non- cAMP dependent 
manner; thus GPCR induced activation of ERM leads to localisation of EPAC at the 
plasma membrane (Gloerich, Ponsioen et al. 2010) promoting adhesion of the cell to 
the extracellular matrix in a manner important for cell spreading. This seems to occur 
downstream of Rap1 activation (Ross, Post et al. 2011).  
ERM proteins are also capable of acting as AKAPs, through the ability of their helical 
domains to interact with PKA (Dransfield, Bradford et al. 1997). This provides a means 
for functional overlap at the plasma membrane between the roles of EPAC and PKA.  
EPAC 1 itself directly plays a role in the compartmentalisation of this signalling 
through interaction with AKAPs and PDEs; influencing both the temporal and spatial 
characteristics of cAMP signal transduction (Misra and Pizzo 2012).  
This also results in the recruitment of EPAC 1 to a number of membrane receptors, 
channels, and associated proteins through the association of ERMs with these 
structures; significantly this includes the β-adrenoreceptors (McClatchey and Fehon 
2009). As one example of the complex set of interactions EPAC is involved in at these 
receptors, this interaction provides the means by which EPAC 1 participates in β-AR 
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mediated cardiac hypertrophy through  EPAC 1 mediated activation of H-Ras via 
Rap2B-PLC signalling causing remodelling of the cardiomyocyte by the expression of 
pro-hypertrophic genes.  EPAC 1 also interacts with GRK2, a significant regulator of 
GPCR function. GRK2 directly phosphorylates EPAC1 in its DEP domain, inhibiting 
translocation of EPAC 1 to the plasma membrane  (Singhmar, Huo et al. 2016). Thus 
from these few examples it is apparent that at the plasma membrane, EPAC 1 sits at 
the heart of a complex web of interacting regulators and effectors. This complexity 
means that the functional consequences of EPAC activation at the plasma membrane 
occurs in a tissue- and cell-type specific manner.  
1.5.3.1.2 EPAC 1 at the nuclear envelope 
The most prominent intracellular location for EPAC 1 is in the nuclear envelope 
(Dodge-Kafka, Soughayer et al. 2005). In rat neonatal ventriculocytes, the discovery 
of a complex coordinated through mAKAP containing EPAC 1, and PKA as well as 
PDE4D3 and ERK5 demonstrated one means of EPAC 1 targeting to this location. This 
also co-locates the two main effectors for cAMP as well as a temporal regulator into 
a signalling complex. A similar mAKAP & EPAC 1 containing signalosome has also been 
observed in cardiomyocytes, containing phospholipase C-ε, PKC-ε and protein kinase 
D (Zhang, Malik et al. 2013). This complex functions to regulate both nuclear PKD as 
well as the response to hypertrophic signalling. It has been previously noted that in 
this complex EPAC 1 selectively activates phospholipase C-ε through the activation 
of Rap2B (Schmidt, Evellin et al. 2001). 
A non- mAKAP related nuclear membrane targeting mechanism for EPAC 1 also 
exists. Components of the nuclear pore complex, including Ran, the Ran binding 
protein 2 (RanBP2) and nucleoporins associate strongly with EPAC 1. This is especially 
true of the interaction between the RA domain of EPAC 1 and Ran-GTP; this is a 
necessary part of EPAC 1 activation of Rap1, which is its key signalling target, which 
suggests that nuclear localisation is a key part of EPAC 1’s function (Liu, Takahashi et 
al. 2010).  
1.5.3.1.3 EPAC 1 at the Cytoskeleton 
A further functional role has been identified for EPAC signalling in cytoskeletal 
dynamics and organisation. EPAC 1 interacts directly with tubulin at the mitotic 
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spindle assembly where binding promotes microtubule formation (Mei and Cheng 
2005). EPAC 1 also is known to associate with other microtubule binding proteins 
through its CNB domain; thus linking cAMP driven activation of EPAC to cytoskeleton 
dynamics. As interaction with microtubules directly inhibits EPAC 1 driven Rap 1 
activity, and association with the light chains of the microtubule associated protein 
1A (LC1 & LC2) enhances activation of Rap 1, there is dynamic regulation of Rap 1 
activity based upon the relative abundance of these regulators (Borland, Gupta et al. 
2006, Borland, Smith et al. 2009). 
The activity of EPAC 1 at these locations causes an increase in the microtubular 
growth rate towards the cell periphery in a manner dependent on AKAP 9 for 
recruitment, which is also a requirement for the downstream functions of integrin 
mediated cell adhesion(Sehrawat, Cullere et al. 2008, Sehrawat, Ernandez et al. 
2011). 
Signalling via EPAC 1 is also required for hypoxia & ATP induced centrosome-nuclear 
separation; and so EPAC 1 is a vital component of the centrosome positioning 
mechanism under conditions of cellular stress. The significance of this finding is 
unclear, but it does point to the key role of EPAC 1 in the response to stressors. 
(Agircan, Schiebel et al. 2014).   
A further key role for EPAC 1 in its association with the cytoskeleton is through 
involvement in mitochondrial dynamics and positioning. EPAC 1 does localise to the 
mitochondria via an N-terminal targeting sequence and this is known to be of 
importance in mitochondrial fission and fusion during VSMC proliferation after 
vascular injury (Wang, Robichaux et al. 2016). 
Another important role for EPAC 1 at the mitochondria of particular importance for 
this thesis is the observation that EPA 1 activity triggered by mitochondrial cAMP 
inhibits Ca2+ entry, so stabilising the mitochondrial membrane potential and thereby 
inhibiting apoptosis in cardiomyocytes (Wang, Liu et al. 2016). However, these 
observations have not been universally accepted; another study demonstrated 
mitochondrial EPAC 1 activation conversely increased Ca2+ concentrations and led to 
cell death (Fazal, Laudette et al. 2017). The role of mitochondrial EPAC 1 then is 
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unclear; it is clearly of key importance in the study of unanswered questions around 
I/R injury. The heterogeneity of the response to its stimulation by cAMP in the 
context of tightly regulated signalosomes is a subject of ongoing work. 
 
1.5.3.2 EPAC 2 functions 
Whilst EPAC 1 has a very widespread distribution and interacts with a large number 
of signalling partners, the known functions of EPAC 2 are relatively circumscribed by 
comparison. This difference is in large part explained by differences in their sequence 
and structure. As discussed in Section 1.5.2.2, EPAC 2 possess an extra N-terminal 
CNB domain of very low cAMP affinity which is essential for clustering of EPAC 2 at 
signalosomes including the granule docking sites in β cells. This extra domain causes 
steric hinderance over the nuclear pore localisation sequence conserved in EPAC 1, 
and so EPAC 2 primarily localises to the plasma membrane (Robichaux-III and Cheng 
2018).  There are also sequence dissimilarities between  the RA domains of EPAC 1 
and 2. These differences allow EPAC 2 to interact with activated Ras, regulating the 
recruitment of EPAC 2 to the plasma membrane (Li, Asuri et al. 2006). This interaction 
is also required for EPAC 2 to activate Rap1. 
Indeed, one of the main unique known functions for EPAC 2 is as a constituent of 
signalosomes at synaptic vesicles and at exocytosis of insulin- containing granules. 
However, there are no known specific function of EPAC 2 in the heart or wider 
cardiovascular system and it is not thought to be present at all in the rat heart, the 
animal model used throughout the experimental work of this thesis (Khaliulin, Bond 
et al. 2017).  
 
1.5.3.3 EPAC Function in the Heart 
EPAC functions as a cAMP sensor and is responsible for a number of cardiac functions 
both acutely, and over longer periods in response to adrenergic stimulation 
classically ascribed to PKA activity (Schmidt, Dekker et al. 2013). One such function is 
control of intracellular calcium concentration in response to extrinsic adrenergic 
stimulation. Via the PKC epsilon isoform and CaMKII, Epac phosphorylates the 
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ryanodine receptor 2 and phospholamban (Oestreich, Wang et al. 2007, Oestreich, 
Malik et al. 2009), causing increased release of calcium from the sarcoplasmic 
reticulum. Although PKA also causes increased phosphorylation of these targets, it is 
thought although not proven that Epac will phosphorylate them at different sites 
thus providing an avenue for synergistic function. Further, Epac agonists may cause 
increased spontaneous oscillation in intracellular calcium; this is not observed with 
activation of protein kinase A and so is a potential mechanism by which Epac may 
radically alter the process of EC coupling (Hothi, Gurung et al. 2008). This is further 
exaggerated through a PLC mediated phosphorylation of Troponin I and Myosin 
Binding Protein C (Cazorla, Lucas et al. 2009); this enhances myofilament sensitivity 
to calcium so providing a mechanism by which Epac regulates cardiac myofilament 
function differentially to PKA.  
 
Epac will alter cardiac functions over the longer term by influences upon gene 
expression and cardiac structure. Epac increases calmodulin expression (Ruiz-
Hurtado, Domínguez-Rodríguez et al. 2012); a key function of calmodulin is to 
regulate CaMKII, so this mechanism provides a longer term pathway to maintaining 
CaMKII activity and ultimately increased inotropic cardiac pump function. It has also 
been found that Epac stimulation in rat cardiomyocytes induces components of gap 
junction- related elements such as connexin- family proteins as well as N- cadherin, 
as well as being associated with new gap junction formation (Somekawa, Fukuhara 
et al. 2005). This circumstantially implies a role for Epac in cardiac remodelling during 
heart failure, with the concomitant increase in β-adrenergic signalling that is 
observed in chronic disease. Further, Epac is a known regulator of apoptosis through 
the PKB/Akt pathways although Epac activity is not sufficient to cause cell death in 
the absence of other signalling input (Kwak, Park et al. 2008). Relatively little is known 
about the role of Epac in the regulation of cardiac function in health or in disease 
with nothing known about the role of Epac during postnatal cardiac development.  
 
1.5.4 cAMP and cardioprotection 
Section 1.4 discussed various strategies for cardioprotection of the heart. There is 
considerable debate on the final common pathways by which the various 
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conditioning treatments exert their effect. It was observed that preconditioning 
attenuates cAMP levels during ischaemic injuries in the rat and rabbit myocardium 
(Lochner, Genade et al. 1999), and preconditioning also shows multiple cyclic 
increases in cAMP and matched falls in phosphodiesterase activity for cycles of 
ischaemic preconditioning (Lochner, Genade et al. 1998). Thus signalling through the 
cAMP second messenger axis is important in cardioprotection. 
 
Section 1.4.1.3 discusses a pharmacological strategy which mimics temperature 
preconditioning by stimulation of PKA and PKC (Khaliulin, Parker et al. 2010). This 
method reduces Ca2+ induced mitochondrial swelling and this effect is accompanied 
by a reduction in oxidative stress during ischaemia. 
 
This cardioprotective intervention is initiated by an increase in cAMP which has 
already been implicated in cardioprotection (Asimakis, Inners-McBride et al. 1994, 
Lochner, Genade et al. 1999) in mature hearts. However, the downstream effector 
mechanism of cAMP/PKA-induced protection has not been fully elucidated. One 
possibility is glycogen depletion, which results in reduced accumulation of lactate 
and H+ and hence smaller compensatory increases in intracellular Na+ and Ca2+ 
(Cross, Opie et al. 1996). An important advancement in the field of cAMP research 
and in its involvement in cardioprotection has been the synthesis of cAMP analogues 
which allow selective experimentation on components of the downstream signalling 
pathways. 
 
1.5.5 The role of cAMP analogues 
The availability of cell permeable cAMP analogues (Table 1-1) that are selective 
activators and specific inhibitors of PKA and Epac, has helped in elucidating the 
cardioprotective role of cAMP/PKA/Epac signalling pathways (Dudley, Suleiman et al. 
2014). They are key agents in selectively dissecting out the respective signalling roles 
of PKA and EPAC and so are used as probes throughout this thesis. A wide variety- 
over 100- substituted cAMP analogues have been described (Schwede, Bertinetti et 
al. 2015). These agents have been widely used in our laboratory and by others as 
probes to investigate cardioprotection in a range of experimental models and 
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allowed selection of appropriate concentrations for use in the experimental chapters 
of this thesis. Below is a brief description of previous work using these agents which 
has allowed for their validation. Comparison is made with an Isoprenaline 
concentration of 5 nM, which has been used in prior studies of cardioprotection in 
our group.  
The least selective, and most broadly understood of these compounds is 8-Br-cAMP 
which is a widely used compound. (Poppe, Rybalkin et al. 2008). This is known to be 
a compound with good selectivity and affinity as a non-selective agonist of both PKA 
and EPAC (Ogreid, Ekanger et al. 1989, Christensen, Selheim et al. 2003). However, 
this agent is relatively cell- impermeable. A modification of this compound is the 
addition of an acetoxymethyl group which masks the charged polar phosphate; the 
effect of this is to increase cell permeability. Intracellularly, this is cleaved by 
esterases and so releases the original 8-Br-cAMP compound. This allows the study of 
the intracellular effects of this compound at a much lower applied dose than without 
the modification (Kruppa, Keely et al. 1997).  
6-Bnz is a site-selective activator of PKA which does not function as an EPAC agonist. 
It also does not function as a competitive antagonist of EPAC, and so it is suitable to 
be used as an EPAC negative control. It has been widely used for selective 





AM  (CPT) 
Function Activator of both Epac 
and PKA 
PKA activator Epac Activator 
Concentration used 
in this work 
5 µM 10  µM 10 µM 























Table 1-1 List of cAMP analogues used in our studies and in published work.  
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investigation of PKA in a number of settings and tissue types, from hepatocytes and  
haematopoietic systems through to cardiomyocytes. Similarly, an acetoxymethyl 
modification (-AM) exists which significantly increases membrane permeability and 
is again cleaved by intracellular esterases (Leech, Dzhura et al. 2010).  
8-CPT-2′-O-Me-cAMP is a specific EPAC activator which does not activate Protein 
Kinase A. The structural modification here methylates the free 2'-ribose hydroxyl 
group in cyclic AMP which is essential for stimulation of PKA. This makes CPT an 
extremely poor agonist of PKA and so allows specific discrimination of functions 
particular to EPAC (Enserink, Christensen et al. 2002).  
In our laboratory, the effect of cAMP analogues was assessed by measuring 
downstream targets in H9C2 cells. Our group has used these cells to asses Epac 
activity by measuring the expression of the gene c-fos (Chen, Koh et al. 2004). In 
preliminary work (n=3) we found that activation of Epac alone (10 µM CPT) or 
simultaneous activation of Epac and PKA (5 µM 8-Br) resulted in a marked and similar 
increase in c-fos expression (unpublished data). This provides an approximate dose 
relationship for equipotency of effect between 8-Br and CPT; thus in this thesis for 
the comparative work involving CPT, a concentration of 10 µM was used throughout. 
Similarly, Ser-157 phosphorylation on the PKA substrate VASP was used to compare 
inducible PKA activation by 8-Br and 6-Bnz (Khaliulin, Bond et al. 2017). In these 
experiments, equivalency of effect upon VASP was found with 8- Br as 10 µM 6- Bnz. 
Therefore, at these dose the stimulatory effect upon PKA seemed equivalent, and so 





The cardioprotective involvement of cAMP/PKA/Epac signalling pathways was 
determined using cAMP analogues in 
Langendorff-perfused rat hearts were 
subjected to 30 min global 
normothermic ischaemia (37ºC) and 2 h 
reperfusion. Activators (5 µM 8-Br, 
10M 6-Bnz & 10M CPT) were added to 
the perfusate for 5 minutes during the 
stabilisation period and were washed 
out for 5 min before switching to global 
ischaemia. Figure 1-12 shows the acute 
effect of PKA and Epac activators on 
cardiac pump function (product of heart rate and developed pressure, RPP (Khaliulin, 
Halestrap et al. 2014)). All activators (alone or in combination) produced an inotropic 
effect which was highest when both PKA and Epac are activated simultaneously (8-
Br or CPT+ 6-Bnz) and consistent with outcome associated with acute -AR 
stimulation (10nM Iso). Interestingly, using inhibitors of PKA (5 µM H-89) or Epac (1 
µM ESI-09) reduced but did not completely prevent the response to 8-Br.  
Figure 1-13 shows the effect of cAMP analogues on infarct size following I/R. In A, 
hearts perfused with 8-Br (activator of both PKA & Epac) significantly reduced infarct 
size. However, the presence of inhibitors of either PKA (H-89) or Epac (ESI-09) 
blocked the cardioprotective effect of 8-Br. B shows that similar cardiopriection can 
be obtained by silultaneously adding  two activators of both PKA (6-Bnz) and Epac 
(CPT). However, activation of Epac alone (CPT)  did not show any protection whilst 
activation of PKA alone showed a small insignifcant reduction in infarct size. The 
effect of the latter was assocaited with a small but signifcant reduction in cardiac 
Figure 1-12 cAMP analogues are cardioprotective 
The data are presented as percentage change in RPP 
compared to pre-drug levels (taken as 100%). 
Mean±SE (n=5-9/group). **vs. 8-Br and CPT+6-Bnz. 
Peak %RPP levels in all interventions were higher 
(p<0.05) than pre-treatment. No difference between 
Isoproterenol (Iso) & activation by 8-Br or CPT+6-Bnz. 
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enzymes release during reperfusion as well as improved cardiac function (data not 
shown). It is worth pointing out that for all interventions, the extent of infarction 
correlated with functional recovery and cardiac enzyme release.  
Main findings and implications: Our data using cAMP analogues suggest that cAMP 
signalling pathways induce a strong cardioprotective effect independently of β-
adrenergic stimulation and that simultaneous activation of both PKA and Epac is 
required for optimal cardioprotection. These results are consistent with others 
showing  lack of cardioprotection by Epac activation alone (Duquesnes, Derangeon 
et al. 2010) and with data demonstrating cooperative action of Epac and PKA in 
cardiomyocytes (Somekawa, Fukuhara et al. 2005).  Finally, our published work and 
that of others implicate PKC in mediating cardioprotection induced by simultaneous 













Figure 1-13 The effect of cAMP analogues on infarct size in adult hearts exposed to I/R injuryThe addition of 5 
µM 8-Br (an activator of both PKA & Epac) for 5 minutes prior to ischaemia conferred significant protection 
against I/R as shown by a significant reduction in % infarction. This effect was blocked by either ESI-09 or H-89. 
Panel B shows that simultaneous addition of 6-Bnz and CPT (activators of PKA & Epac) produced similar 
response to 8-Br. Insets are representative images showing infarction (white area) for selected interventions. 
Mean±SE (n=5-7/group).*vs. control & CPT. **vs. all other values. #vs. CPT. 6-Bnz showed a strong trend vs. 
control & 6-Bnz+CPT, but was not statistically significant. From Khaliluin.et al., 2017 
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1.6 Cardiac Development 
The neonatal heart in a human is not a small version of the adult organ. It differs 
profoundly in both anatomical and pathophysiological domains. Therefore, it is not 
surprising that a heart at various stages of development will react differently to injury 
than a fully mature one in an adult cardiovascular system. In the UK each year, 9 in 
every 1000 children are born with congenital heart defects, of whom a significant 
proportion will require surgery. This surgery is often repeated, requiring multiple 
instances of anaesthesia, cardiopulmonary bypass and intensive care; each of these 
episodes causes injury to the heart and so finding methods to ameliorate this injury 
is important. These factors lead to a prevalence of over 200,000 people in the United 
Kingdom living with congenital heart disease. An understanding of quite how the 
young heart differs from the mature is then vital to developing protective strategies. 
1.6.1 Anatomical development 
There is rapid development of the post- natal heart as it matures towards the adult 
phenotype at a gross structural and ultrastructural level. During the first 11 post-
natal days in rat, the heart weight increases more than 5-fold (Johnson and Brown-
Borg 2006). After 4 days growth is hypertrophic (Anversa, Olivetti et al. 1980) rather 
than hyperplastic which ceases around the fourth post-natal day (Bicknell, Coxon et 
al. 2004); this is caused by cell cycle arrest of cardiomyocytes in G1 phase, possibly a 
result of regulation of β- adrenergic receptors during neonatal cardiomyocyte 
proliferation & growth (Tseng, Kopel et al. 2001). The overall physical characteristics 
of the neonatal organ differ from the adult as well, having significantly lower 
compliance; this may be a consequence of changes in composition. The neonatal 
heart has proportionately higher amounts of water, and proteins which do not 
contribute to contraction (Marijianowski, van der Loos et al. 1994, Pelouch, Kolar et 
al. 1997). The consequence of this is that the developing heart is less able to vary 
cardiac output by alteration of stroke volume and is more dependent upon heart rate 




The neonatal heart is composed of a higher proportion of non-contractile protein, 
therefore it is less compliant than the adult (Marijianowski, van der Loos et al. 1994, 
Pelouch, Kolar et al. 1997). This has important consequences for how the developing 
heart can respond to external signals requiring an increase in cardiac work; with 
reduced compliance a developing heart cannot alter its stroke volume, and so is 
solely dependent on alterations in cardiac rate to increase or decrease output. 
 
The morphology of cardiomyocytes changes dramatically during postnatal 
development: at birth cells are mononucleate, but after 14 days most cells become 
binucleate (Mayhew, Pharaoh et al. 1997). Soon after birth, the cardiomyocytes stop 
proliferating and instead they grow in size, and develop the rod-shaped striated 
morphology characteristic of adult cardiomyocytes (Figure 1-14)(Seki, Nagashima et 
al. 2003). At an ultrastructural level, from the first postnatal day until the seventh, 
neonatal cardiomyocytes display disorganised myofibrils primarily close to the cell 
periphery- an adaptation for efficient function given dependence on extracellular 
Ca2+ (Vornanen 1996). The intracellular Ca2+ stores are not fully developed, with little 
to no development of the t-tubule system or sarcoplasmic reticulum and so 
immature myocardium requires a higher extracellular Ca2+ concentration to optimise 
contractility (Jarmakani, Nakanishi et al. 1982). 
   7 days old                14 days old                       18 days old                       Adult 
Figure 1-14 T-tubules from membrane-selective fluorescent dye di-8-ANEPPS-loaded rat ventricular myocytesFrom 
Seki. et al 2003  
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1.6.2 Physiological Changes through Development 
1.6.2.1 Calcium Handling 
Cardiac pump function is well known to increase with post-natal age (Figure 1-15), 
but there are also corresponding changes in metabolic activity including glycogen 
storage and utilisation. The respiratory capacity of mitochondria & cytochrome levels 
increase postnatally (Marin-Garcia, Ananthakrishnan et al. 1997) whilst the 
sensitivity of the mitochondrial permeability transition pore to Ca2+ decreases with 
age (Balaska, Halestrap et al. 2005).  
 
In addition, ionic homeostasis, excitation-contraction coupling, and its regulation, 
vary with age (Artman, Henry et al. 2000, Liu, Yasui et al. 2002, Tohse, Seki et al. 
2004). For example there are qualitative and quantitative differences between Ca2+- 
transients in cardiomyocytes from different age groups so that the rate of rise and 
decline are slower in younger animals compared to adult. There are also differences 
in the effects of inotropic and chronotropic agents during development in patients 





Developmental changes in Ca2+ cycling which contribute to these changes include 
altered abundance/ expression and activity of Ca2+ ATPase (SERCA), Na+/Ca2+ 
exchanger (NCX) and L-type Ca2+ channels (Artman, Ichikawa et al. 1995, Vetter, 
























Figure 1-15 Increase in cardiac work, as estimated by rate pressure product, through key 
milestones during development of the rat heart(Suleiman group, unpublished data). 
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et al. 2009, Wiegerinck, Cojoc et al. 2009)(Figure 1-16) as well as the development of 
SR and T-tubules, and the associated changes of protein location.  
 
The sarcoplasmic reticulum and associated T-tubule network is underdeveloped for 
some time postnatally (Seki, Nagashima et al. 2003)(Figure 1-14). This is where the 
majority of proteins responsible for Ca2+ homeostasis are located (Brette and 
Orchard 2003), and so the mechanism of EC coupling in itself is changing markedly 
(Wibo, Bravo et al. 1991, Artman, Henry et al. 2000) through development.  
 
In parallel, the location of the RyR within the developing cardiomyocyte, its density 
and role in the electrical properties of the cell changes throughout development 
(Snopko, Aromolaran et al. 2007) to support the shift towards a more SR dependent 
myocardium (Hamaguchi, Kawakami et al. 2013). The number of ryanodine binding 
sites doubles per unit mass tissue in the first month post-natal, alongside and in 
support of the developing SR (Wibo, Bravo et al. 1991). 
 
The mechanisms for Ca2+ homeostasis are paradigmatically different in the immature 
heart, being much more dependent on extracellular than intracellular reserves, and 















 Figure 1-16 Ca2+ cycling proteins in neonates and infantsWiegerinck et al. 2009 
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1.6.2.2 Metabolic differences 
As discussed in Section 1.1, the adult heart is dependent upon a variety of substrates 
to produce ATP, but the mainstay is the use of fatty acids. This is not thought to be 
the case in the neonate, which has a significantly higher dependence on glycogen 
than the adult, with a shift to fatty acid metabolism taking place as the heart matures. 
Accordingly, the reserves of glycogen which are high in the immediately postnatal 
heart drop between 7 and 14 days of age in the rat (Chen, De Diego et al. 2007) This 
may reflect the switch from a relatively oxygen deprived in utero environment to the 
oxygen rich ex utero world (Ascuitto and Ross-Ascuitto 1996). A consequence of this 
however is that the immature heart shows a reduced ability to produce ATP 
aerobically, with significantly higher fluxes of lactate and glucose in the immature 
heart. In parallel TCA cycle enzymatic activity increases with time post-natal 
(Veerkamp, Glatz et al. 1985). 
Alongside this, there is a significant shift in the number, volume, and distribution of 
mitochondria through early maturation as might be expected to accompany the 
increased utilisation of oxidative phosphorylation. The number of mitochondria, as 
well as their density and size increase by a factor of 2 in the first 5 days post-natal in 
rats (Anversa, Olivetti et al. 1980), alongside development of the fine structure of the 
mitochondria themselves, with the immature mitochondria having relatively less 
prominent cristae, for instance, than the adult. Again, this suggests that the 
immature myocardium is significantly less dependent on oxidative phosphorylation 
as an energy source.  
1.6.3 Age related differences in response to injury 
Whether the resistance of immature mammalian hearts to the damaging effects of 
cardiac insults, such as hypoxia or ischaemia is higher or lower than adult remains 
controversial (Ostadal, Ostadalova et al. 1999), with some authors claiming that the 
immature heart has a greater resistance to ischaemia/ reperfusion injury and others 
the reverse. Most studies have tended to compare adult heart with a single selected 




1.6.3.1 Evidence in favour of increased resistance in the immature heart 
The majority view is that the immature heart has significantly greater resistance 
(Doenst, Schlensak et al. 2003) to insults and tolerance of ischaemia than the adult 
heart (Riva and Hearse 1991, Ostadalova, Ostadal et al. 1998, Ostadal, Ostadalova et 
al. 1999, Ostadal, Ostadalova et al. 2014).  
 
Work from King’s College (Awad, Shattock et al. 1998) and from our laboratory (Modi 
and Suleiman 2004) demonstrated that recovery of developing rat heart following 
ischaemia and reperfusion changes during maturation and appears to follow a bell-
shaped curve (Figure 1-17). Accordingly, 14-day old hearts show the highest 
resistance and adult hearts are the most vulnerable. Rabbit heart follows a similar 
profile (Figure 1-17, unpublished data), and our clinical research has shown age-
related (e.g. neonate, infant, children and adults) differences in cardiac vulnerability 
to cardiac ischaemia/reperfusion in patients undergoing open heart surgery (Imura, 
Caputo et al. 2001, Modi, Imura et al. 2003).  
 
Figure 1-17 Vulnerability to cardiac insults changes during different stages of postnatal development 
Proportionate functional recovery compared to baseline after a period of global ischaemia (parentheses) in 
isolated perfused rat (left panel) and rabbit (right panel) heart. 
 
The mechanisms underlying this profile of vulnerability to I/R during postnatal 
development are not currently known but this should be explicable from the 




Ca2+ loading is key in mediating reperfusion injury and therefore developmental 
changes in Ca2+-mobilisation could be responsible. In fact better preservation of Ca2+ 
handling has been reported in developing hearts following cardiac insults compared 
to adult hearts (Nakanishi, Young et al. 1984). Ca2+ levels during EC coupling are 
tightly controlled, involving mechanisms regulated in part by β-Adrenergic receptors. 
Manipulation of this system has also been linked to cardioprotection against I/R 
injury. 
 
Further, the immature heart is thought to be better adapted to balance ATP 
production over hydrolysis especially in substrate deplete situations (Ostadal, 
Ostadalova et al. 2009); this may in part explain the observed pattern. These may be 
adaptations which reflect a relatively nutrient and oxygen poor in utero environment; 
this may involve reversion back to the fetal metabolism (Singer 2004). 
 
1.6.3.2 Evidence against increased resistance in the immature heart 
Opposing evidence has sought to demonstrate that the developing heart is in fact 
more susceptible to injury than the adult heart (Carr, VanderWerf et al. 1992, 
Portman, Standaert et al. 1996). One group studying the porcine myocardium found 
that in a model of ischaemia the adult took 50% longer before developing 
hypercontracture versus their developing comparator (Wittnich, Peniston et al. 
1987). They explain this by suggesting that the developing heart both accumulates a 
larger acid load during ischaemia, but also has a lower capacity to buffer the H+ 
(Wittnich, Su et al. 2006).  
In observations on human patients undergoing cardiac surgery, others found the 
immature heart more vulnerable than the adult in measurements of postoperative 
troponin release in patients matched for cross-clamp time. However, these studies 
were very heterogenous in the comparisons made, from underlying demographics to 
the nature of the operations performed (Taggart, Hadjinikolas et al. 1996). 
1.6.3.3 Resolution of Conflicting Evidence 
At first glance these observations appear irreconcilable. However, those studies 
which demonstrate an increased tolerance to I/R injury in the adult only compare 
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against one particular age in development, versus every relevant developmental 
milestone. This is important as many groups have shown a rapid change in 
vulnerability throughout development, so by choosing only one time point as the 
comparator may miss the points of maximal resistance (Awad, Shattock et al. 1998, 
Modi and Suleiman 2004). Further, the conflicting experiments used multiple 
differing animal models and unsurprisingly these gave differing results; the 
timescales post- natal at which resistance may be maximal will change as each animal 
will develop at different rates with differing processes in that species also progressing 
at varying speeds; cross species comparisons are therefore fraught with difficulty. An 
approach based upon longitudinal study of the whole developmental period in a well 
characterised animal model would therefore be ideal, subject to the limitations of 




Transient combined PKA and EPAC stimulation prior to cardiac insults protects both 
neonatal and adult hearts and cardiomyocytes despite marked age-related 
differences in sensitivity to insults.  
 
1.8 Objectives  
The overall objectives of this thesis are therefore to define the age-related 
differences in vulnerability to I/R injury across a range of experimental models and 
to investigate how that vulnerability might be modulated using PKA and EPAC 
agonists. To achieve this objective, the following aims were addressed: 
1. Construct a postnatal developmental profile of the expression and 
activation of proteins involved in cardiac cAMP/PKA/Epac signalling 
and Ca2+ cycling.  
2. Investigate the effect of modulation of signalling along the β-
adrenoreceptor axis on cardiac physiological status in the adult and 
immature heart and then compare that to following I/R. 
3. Investigate the effect of PKA and/or Epac modulators on Ca2+ 
transients and contractility in cardiomyocytes under normal condition 
or during simulated ischaemia/reperfusion. 
 
Since the immature heart is less vulnerable than the adult, it will be interesting to see 
whether it nonetheless may be protected by cAMP/PKA/Epac axis stimulation. If so, 
it would imply cardioprotection taking place through differing mechanisms than the 
intrinsic resistance. Further, the insights into the underlying biology may allow the 
suggestion of pharmacological cardioprotective intervention in adult heart to 




2 Materials & Methods 
2.1 Materials  
2.1.1 Buffers 
2.1.1.1 Solutions used throughout the experimental work 
The solution used to rinse tissue recovered from the heart to be used for biochemical 
experiments was a simple buffer based on a cardioplegia solution, composed of 
HEPES, glucose, KCL, MgSO4 and CaCl2 and adjusted to a physiological pH of 7.4. 
Table 2-1. Constituents of cardioplegia solution. Dissolved in ddH2O & made up to 1l.  
pH measured and adjusted with HCl/ NaOH to 7.4.  
 
Table 2-2 shows the constituents of the Krebs- Henseleit (KH) buffer used. This buffer 
is used for Langendorff perfusion of the whole heart and provides a relatively 
physiological ionic environment to support the automatic contraction of the heart in 
an ex vivo context, with glucose as a metabolic substrate. When used, this solution is 
also bubbled through with a gas mixture of 95% O2/ 5% CO2. 
Constituent Concentration(mM) 
NaCl 120 
Sodium Hydrogen Carbonate 25 
Glucose 11 
Potassium Hydrogen Phosphate 1.2 
Magnesium Sulphate 1.2 
Potassium Chloride 4.8 
Calcium Chloride 1.2 
Table 2-2. Components of the Krebs- Henseleit (KH) buffer used for whole heart perfusion prior to mitochondrial 
isolation 
Constituent Mass/ Volume in 1L Concentration 
HEPES buffer(x10) 100 ml 20 mM 
Glucose 2.7 g 15 mM 
KCl 1.09 g 15 mM 
MgSO4 0.935 g 7.8 mM 





2.1.1.2 Cardiomyocyte Isolation 
The main buffer used in cardiomyocyte isolation (Solution A, Table 2-3) is a 
physiological buffer adjusted to pH 7.25. Solution A is used to initially perfuse and 
equilibrate the heart. Two versions of A are produced, with 16 mM glucose and 
without. Glucose is omitted from the A used to produce solutions E, F, and G such 
that the cardiomyocyte experiments are performed without glucose. This was 














Sodium Pyruvate 5 
Table 2-3. Constituents of Solution A. pH adjusted subsequently to 7.25 using NaOH, Glucose omitted from stock 






Perfusion with solution A is then followed sequentially by the solutions shown in 
Table 2-4. Perfusion is first switched to B and then to C; D performs digestion, then 
following recovery of the cardiomyocytes Ca2+ is sequentially reintroduced by 
sequential addition of solutions E, F, and G. 
Table 2-4. Additives added to Solution A to form other Solutions used for cardiomyocyte isolation. 
 
2.1.1.3 Mitochondrial Isolation Buffers 
For isolation of mitochondria, a buffered sucrose solution is first made (Table 2-5) 
some of which is saved for use, and some of which is used as the basis of the other 
solutions used in the mitochondrial isolation experiments.  A Final Wash (AFW) does 
not contain EGTA unlike the other mitochondrial isolation buffers and so is used as 
the last buffer in the isolation process before the addition of Ca2+ in a swelling assay. 
 
 
Constituent Concentration/ mM 
Sucrose 300 
Tris- HCl 10 
Table 2-5. Components of Buffer A Final Wash for mitochondrial isolation. pH adjusted to 7.2. 
 
Buffer AFW was then used to form two other buffers used for mitochondrial 
isolation, A & B (Table 2-6). Both of these buffers contain EGTA to chelate calcium; 
buffer B also contains additional BSA.  
 
Constituent Concentration 
Solution B   750 µM CaCl2   & 16 mM Glucose 
Solution C 90 µM EGTA & 16 mM Glucose 
Solution D 10 mg/ml Type 2 Collagenase 
1 mg/ml Protease 
Solution E 150 µM CaCl2 
Solution F 0.5 mM CaCl2 






Constituent Solution Concentration 
EGTA  Buffer A & B 1 mM 
BSA  Buffer B only 5 mg/ml 
Table 2-6. Components added to Buffer A Final Wash to form both Buffers A & B. pH maintained at 7.2.  
 
 
Once isolated, the mitochondria are assessed for swelling as described in Section 
2.5.3. This is performed in a swelling buffer used for de-energised mitochondria 
(Table 2-7). It contains a metabolic inhibitor, a calcium ionophore (A23187), rotenone 
(a complex I inhibitor), as well as antimycin A, a cytochrome c inhibitor.  
 






A23187 2 µM 
Rotenone 0.5 µM 
Antimycin A 0.5 µM 





There are three synthetic forms of cAMP that were used throughout the experiments 
described in this thesis. They are shown in Table 2-8, with their full systematic name, 
abbreviated form used in the prose and their intended function.  
cAMP Analogue Abbreviation Function 
8’-bromoadenosine 3’,5’- cyclic 
monophosphate- AM 
8- Br Non-selective agonist of PKA & 
EPAC 
N6- benzoyladenosine- 3’,5’- 
cyclic monophosphate- AM 
6- Bnz Selective PKA agonist 
8- (4- Chlorophenylthio) 
adenosine- 3', 5'- cyclic 
monophosphate, 
acetoxymethyl ester 
CPT Selective EPAC agonist 
Table 2-8. cAMP analogues used throughout this series of experiments. Supplied by Biolog, Bremen, Germany.  
 
All other reagents used throughout the work described are listed in Table 2-9 along 


















A23187 Sigma Aldrich, Darmstadt, Germany 
Antimycin A Alfa Aesar, Ward Hill, Massachusetts, 
USA 
Bovine Serum Albumin Sigma Aldrich, Darmstadt, Germany 
Bradford Reagent Biorad, California, USA  
Calcium Chloride, CaCl2 Panreac, ITW Reagents, Barcelona, 
Spain 
Cyclosporin A Sigma Aldrich, Darmstadt, Germany 
Dimethyl sulphoxide, DMSO VWR International, Lutterworth, UK 
ethylene glycol-bis(β-aminoethyl ether)-
N,N,N′,N′-tetraacetic acid, EGTA 
Sigma Aldrich, Darmstadt, Germany 
Fura-2-AM Biotium, California, USA 
Glucose Sigma Aldrich, Darmstadt, Germany 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) 
VWR International, Lutterworth, UK 
Hydrogen Peroxide, H2O2 Sigma Aldrich, Darmstadt, Germany 
Isoprenaline hydrochloride Sigma Aldrich, Darmstadt, Germany 
Magnesium Chloride, MgCl2 Fisher Scientific, Loughborough, UK 
Magnesium Sulphate, MgSO4 Fisher Scientific, Loughborough, UK 
3-(N-morpholino)propanesulfonic acid, 
MOPS 
Sigma Aldrich, Darmstadt, Germany 
Nitrilotriacetic acid, NTA Sigma Aldrich, Darmstadt, Germany 
Nonidet P-40 detergent Sigma Aldrich, Darmstadt, Germany 
Sodium Cyanide, NaCN Sigma Aldrich, Darmstadt, Germany 
Sodium Hydrogen Carbonate, NaHCO3 Sigma Aldrich, Darmstadt, Germany 
Sodium Hydrogen Phosphate, NaH2PO4 Sigma Aldrich, Darmstadt, Germany 
Pluronic Acid Sigma Aldrich, Darmstadt, Germany 
Potassium Chloride KCl Fisher Scientific, Loughborough, UK 
Potassium Hydrogen Phosphate KH2PO4 Sigma Aldrich, Darmstadt, Germany 
Potassium Thiocyanate, KSCN Sigma Aldrich, Darmstadt, Germany 
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Protease (Bacterial, Type XIV) Sigma Aldrich, Darmstadt, Germany 
Rotenone Bio-Techne, Minneapolis, Minnesota, 
USA 
Sodium Chloride, NaCl VWR International, Radnor, 
Pennsylvania, USA 
Sodium Cyanide, NaCN BDH Laboratory Supplies, Poole, UK 
Sodium Deoxycholate Sigma Aldrich, Darmstadt, Germany 
Sodium dodecylsulphate Sigma Aldrich, Darmstadt, Germany 
Sodium Hydrogen Carbonate, NaHCO3 Fisher Scientific, Loughborough, UK 
Sodium Pyruvate VWR International, Radnor, 
Pennsylvania, USA 
Sucrose Sigma Aldrich, Darmstadt, Germany 
Triphenyl tetrazolium chloride, TTC  
Tris Sigma Aldrich, Darmstadt, Germany 
Trypan Blue Dye Sigma Aldrich, Darmstadt, Germany 
Type 2 Collagenase Worthington Biochemical, Lakewood, 
New Jersey, USA 
Hydrochloric Acid, HCl Sigma Aldrich, Darmstadt, Germany 
Table 2-9. Other reagents used throughout these experiments, with systematic name where used elsewhere.  
 
2.1.3 Animals 
The use of the animals described in this thesis conformed to the Home Office 
regulations specified in the schedules of the Animals (Scientific Procedures) Act, 
1986. All animal tissues were obtained from male Wistar rats (immature; from 
Animal Services Unit, University of Bristol) of 7- days, 14- days & 28- days post-natal 
as well as mature (>60- day old; Charles River Laboratories, UK) animals. Killing was 
performed humanely as described in Schedule 1 of this Act; this by stunning by 
cerebral concussion followed by cervical dislocation. Quantities of animals used for 




2.2 Protein expression & quantification 
2.2.1 Extraction of heart tissue 
Hearts were extracted from Male Wistar rats of differing ages. Charles River 
Laboratories supplied adult rats of 250-300g in whole body weight, and 28- day old 
rats of between 100-125g in weight. The University of Bristol Animal Services Unit 
provided immature rats at 7- and 14- days postnatal age. In total, for these proteomic 
experiments 31 rats were used; adult (n=9), 28- day (n=9), 14- day (n=9), and n=4 for 
7- day old. 
 
These rats were rapidly killed by cervical dislocation. A midline incision exposed the 
thorax and then a bilateral thoracotomy incision was made to obtain access to the 
mediastinum. The heart and great vessels were manually lifted out of the chest and 
an incision made posteriorly towards the thoracic inlet in order to release them. 
 
The hearts were then immersed in cardioplegia solution at 4°C and agitated in order 
to remove blood from the ventricles. They were then immediately immersed in liquid 
nitrogen, and stored at -80°C. 
 
2.2.2 Homogenisation of heart tissue 
In order to analyse the myocardial constituents, the hearts from 7- , 14- , and 28- day 
old male Wistar rats were homogenised. The most appropriate buffer for recovery of 
a representative sample protein content of the cardiomyocytes was chosen to be a 
RIPA buffer. Other buffers are used commonly in proteomic work; for instance urea 
based buffers have been commonly used in applications targeting membrane bound 
protein constituents. However as this series of experiments had no particular target, 
it was felt best to use an extraction buffer, which would provide as little bias to the 








PBS Tablet x1 
1% (v/v) Nonidet P-40 
detergent 
0.5% (w/v) Sodium 
deoxycholate 
0.1% (w/v) Sodium 
dodecylsulphate 
Table 2-10. Composition of RIPA buffer used for protein extraction from heart samples. Made up to 200ml with 
ddH2O and pH adjusted to 7.4 with concentrated HCl/NaOH solutions 
 
A 10ml aliquot of RIPA buffer was taken, to which was added 1x tablet of 
phosphatase inhibitor and 1x tablet of protease inhibitor. The hearts were then 
thawed on ice. Small samples from the apex of each were cut from the heart of 
approximately equal size, and weighed. These samples were then placed in 2ml tubes 
containing 50x tungsten beads. To each of these samples was added 10 µl of RIPA 
buffer per mg of tissue.  
 
A tissue homogeniser was then used to lyse the cells in the sample by oscillation. This 
was performed at 4°C; each sample was shaken in two bursts of 10 seconds, and then 
agitated on ice for 30 minutes. The samples were then centrifuged at 10000 g for 10 
minutes at 4°C, which separated them into a pellet and supernatant. 300 µl of 
supernatant for each sample was recovered, split into 100 µl aliquots, snap frozen, 
and stored at -80° C. This supernatant should contain a majority of the protein 
content from the original tissue. 
 
2.2.3 Protein Concentration Estimation & Normalisation 
The Tandem Mass Tagging- Mass Spectrometry technique used subsequently for 
peptide detection and identification is performed at a standardised protein 
concentration. This was set at 2 mg/ml and so in order to achieve this, the 
concentrations of each sample had to be determined, and then diluted to produce 
concentrations at this standard. This was achieved spectrophotometrically by the 




Using the Bradford reagent, a standard curve of light absorbance at 595 nm over a 
range of concentrations of BSA, a commonly used protein reference, was produced. 
The BSA absorbance was measured over a range of concentrations, repeated, and an 
average taken of the measurements. 
 
The protein extract samples were then diluted 3- fold in order for their absorbances 
to appear within the range of this curve. The samples were therefore diluted 2:1 with 
ddH20, and their concentrations calculated using the Bradford method at 595 nm. 
Two measurements were made for each sample, and the average absorbance 
calculated. The post- dilution concentrations were calculated with reference to the 
standard curve, and then corrected for the dilution. A dilution factor required to 
correct each sample to a normalised 2 mg/ml was calculated, and the corresponding 
quantity of ddH2O added to each sample. These samples were then stored at -80°C 
ready for analysis. 
 
2.2.4 Tandem Mass Tagging- Mass Spectrometry Quantitative Proteomics 
The samples were then used for estimation of the whole myocardial proteome, with 
assistance with the technique from Dr. Kate Heesom of the University of Bristol 
Proteomics Facility at the Department of Biochemistry.  
 
The TMT-MS approach involves enzymatic digestion of a sample breaking up proteins 
into constituent peptides (Thompson, Schafer et al. 2003).  
 
The tandem mass tags function as labels by binding to the peptides produced by 
digestion of the sample. The mass tags bind specifically to a certain amine, and so 
each tag- amino acid pair has a defined mass.  The samples, as well as a pooled 
sample created from all the individual samples, were labelled with these tags, then 
fractionated chromatographically. Each fraction was then analysed using an Orbitrap 
Fusion Tribrid mass spectrometer. During this analysis, the tags attached to each 
residue fragment, producing the reporter section of the tag which allows 
quantification of the peptide. Multiple peptides from each protein are produced, so 
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by taking the mean quantification from each of these peptides an accurate 
quantification is produced. Each experiment with the mass spectrometer could 
involve up to ten samples. Therefore, in order to make best use of the samples and 
resources, three runs were planned, consisting of 9 experimental samples and a 
pooled sample created from all of the samples. 
 
The resulting raw data spectra were analysed using Proteome Discoverer version 2.1 
(Thermo Fisher Scientific, Waltham, United States of America). This software 
produces a sequence for the peptides detected on the mass spectrum, a likely protein 
from which that peptide originates, and assigns a confidence level in each peptide/ 
Figure 2-1. The structure of the amine-reactive TMT Reagents:  A. Functional regions of the 
reagent structure. B. TMT10plex reagent structures with 13C and 15N heavy isotope 





protein detected as well as an abundance level of that protein relative to the pooled 
sample. Filters to exclude everything but the peptides with the highest (>95%) level 
of confidence were applied. Subsequent analysis of the data was performed using 
Microsoft Excel 2013 (Microsoft Corporation, Seattle, United States of America) and 
IBM SPSS Statistics 23 (IBM Corporation, Armonk, United States of America). 
 
 
Figure 2-2. Scheme for MS experiments (adapted from ThermoFisher)Protein extracts are reduced, alkylated and 
digested overnight. Samples are labelled with the TMT Reagents and then mixed before sample fractionation. 
Labelled samples are analysed by high resolution Orbitrap LC-MS/MS before data analysis to identify peptides 







2.3 Ex vivo Whole Heart Langendorff Perfusion 
2.3.1 Heart Extraction  
Whole hearts were extracted from male Wistar rats of 14- days post-natal as well as 
adult animals. Animals were killed by cerebral concussion followed by cervical 
dislocation. For each animal, a sternotomy incision was made from the xiphisternum 
to sternal notch to expose the thorax, and then bilateral thoracotomy incisions with 
reflection of the ribs exposed the mediastinum and lungs. The heart was lifted gently 
out of the thorax and an incision made posteriorly along the vertebral column to cut 
through the descending aorta and release the heart. The heart was immediately 
placed in Krebs- Henseleit (Table 2-2) buffer chilled to 4° C and excess tissue around 
the atria and great vessels dissected away. 
 
2.3.2 Perfusion equipment 
Hearts were perfused using a Langendorff system supplied by AD Instruments 
(Sydney, Australia) (Figure 2-3, Figure 2-4). There are broadly two elements to this 
apparatus, a temperature control system and a perfusate delivery system. For 
temperature management, the apparatus consists of a pump, a water reservoir, 
heating element and integrated temperature sensor connected to a tubing system 
passing through the external walls of all the buffer reservoirs. Each reservoir has a 
jacket of two layers of glass with a void in between through which the warmed water 
passed to maintain each chamber at the desired temperature. 
 
For these experiments on rats, the temperature of the system was maintained at 37° 
C which is physiological body temperature for these animals. The temperature of the 
perfusate at the cannula was measured regularly and the settings on the warming 






Figure 2-3 Example of apparatus used for Langendorff perfusion experimentsExperimental buffer placed in 
warmed reservoir, marked blue. 95% O2/5% CO2 bubbled through from cylinder supply, yellow. Flow controlled 
by roller pump. Image- Katie Hall.  
 
Figure 2-4 Close up image of heart perfused on cannulaHere, 14- day old heart seen with 22G cannula entering 





The equipment contains three reservoirs for perfusion buffers with needle valves. 
These valves allow a buffer within the reservoir to have an externally supplied gas 
passed through; this was used in these experiments to dissolve a gas consisting of 
95% O2/ 5% CO2 through Krebs- Henseleit buffer. The purpose of this is to oxygenate 
the buffer so that in perfusing the heart it delivers oxygen; and the carbon dioxide 
acidifies the perfusate in order to maintain a physiological pH.  
 
Each reservoir of perfusate can be individually selected and run through a roller 
pump, connected to a delivery system. The pump rate may be controlled directly, 
allowing delivery of a perfusate at a set rate (“constant flow perfusion”), or directed 
by a controlling computer system. 
 
For these experiments, an AD Instruments Powerlab system was used, along with 
Chart5 for Windows (AD Instruments) running on a desktop computer connected to 
the Powerlab. This setup provided multichannel monitoring of flow and pressure. It 
also allowed for negative feedback control of the perfusion rate for those 
experiments in which pressure was controlled constantly. 
 
The perfusate was delivered to a cannula; this cannula could be exchanged for others 
of differing sizes. It was important to match the size of cannula to the age of heart 
being perfused. For an adult heart, a 16G cannula was used; a 20G for 28 day old 
hearts, and for a 14- day old, a 24G cannula. As the flow rate was controlled by the 
pump, the change in resistance from these different cannula sizes did not impact 
upon the rate of delivery of perfusate.  
 
For monitoring of the perfused heart, the system had two pressure transducers. One 
of these was connected to the column of fluid directly above the perfused heart. This 
was used to measure the perfusion pressure, and through feedback to the controlling 
Powerlab could be used to maintain the coronary perfusion pressure at a desired 




The second of these transducers was connected to small bore flexible plastic tubing 
terminating in a fine blunted needle. Thin plastic film was folded over and around 
this needle to create a sealed balloon at the end; this when filled with ddH2O was 
inserted into the LV of a perfused heart and would measure the LV pressure 
throughout the cardiac cycle. 
 
Both of these pressure transducers were calibrated at the start of the series of 
experiments examining the effects of isoprenaline and adenosine on function and 
cardioprotection. They sensed a pressure on a membrane and transduced that into 
an electrical potential, which was amplified in the Powerlab and the magnitude of 
this amplified potential displayed. Each transducer had a calibration experiment 
performed to convert this potential into mmHg, the conventional unit of 
measurement for biological pressures. A vertical piece of flexible plastic tubing was 
used to apply pressure from a known height (in centimetres) of water to the pressure 
transducer. Values for each of 20, 40, 60, 80 and 100 mmHg were converted to 
cmH2O and used to mark out points on the tubing. The tubing was filled to each of 
these marks with ddH2O and the potential produced by each pressure transducer at 
each of these points measured. This was then repeated, and the mean voltage 
calculated. For each transducer, a standard curve was produced, allowing a 
conversion factor to be used to calibrate the sensor to produce an output in mmHg.  
 
This experimental setup with pressure control proved problematic; with the 
immature hearts it was difficult to maintain a perfusion pressure as slight variation 
with the isolation and cannulation caused large changes to flow rate; and the act of 
inserting an intraventricular balloon itself caused multiple points of failure. 
Therefore, for the experimental sets carried out later using cAMP analogues, a 
constant flow technique without LV pressure monitoring was used. 
 
   
91 
 
2.3.3 Perfusion experiments 
2.3.3.1 Constant flow perfusion 
Once the heart was excised, the aorta was identified. This was incised to produce a 
clean edge, and then fine toothed forceps used to hold two opposing edges of the 
artery. Perfusate flow was started at a rate of 1ml/min, and then the aorta gently 
lifted onto the cannula and clamped in position such that the perfusate would flow 
in a retrograde direction towards the aortic root and from there down the coronary 
arteries. The heart was then secured in position using 2x 2-0 braided polyester 
sutures.  
 
The flow rate was then gradually increased until reaching the target rate for each age 
group. For the 14-day old hearts, this was 4 ml/min, and for the adults, 10 ml/min, 
based upon previous work in our group.  
 
2.3.3.2 Constant pressure perfusion 
For experiments performed with constant pressure perfusion, once the heart was 
cannulated, the flow was started at a conservative rate of 3 ml/min in the immature 
group and 7 ml/ min in the adults. The pump was then switched to a pressure-linked 
negative feedback mode, and the set point slowly increased to the target perfusion 
pressures (80 mmHg for adults, 65 mmHg for 14- day olds). Once that target was 
reached, the Powerlab was switched to a pressure-hold mode, which maintained the 
current pressure sensed by the CPP sensor by alterations in flow rate in response to 
uncontrolled alterations in CVR.  
 
If LV pressure was to be measured, an incision was then made into the left ventricle 
of the heart in order for the pressure transducing balloon to be inserted. Once 
inserted, it was inflated to a relative pressure of 0 -10 mmHg, measurement of the 
output from the transducer produced a pressure- time trace. The Chart5 software 
was programmed to derive several measurements from this trace; 
 -Maximum pressure reached 
 -Minimum pressure reached 
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 -LVDP, which was calculated as the difference between these two 
measurements 
 -Heart rate, which was the number of pressure peaks detected per minute 
At this point the hearts were allowed to equilibrate before being exposed to the 
experimental protocol, detailed in Chapter 4. For those experiments performed with 
constant flow, after cannulation the flow rate was set to 10 ml/min for adult hearts 
and 4 ml/min for 14-day olds. After equilibration, these hearts then followed their 
respective experimental protocols.  
 
2.3.3.3 Protocols for studying function of Langendorff hearts with or without I/R  
2.3.3.3.1 Intraventricular pressure monitoring 
In experiments in which an LV pressure was monitored, a balloon was placed in the 
left ventricle. In order to do this, an arterial catheter (Vygon, Swindon, UK) was 
attached to a pressure sensitive transducer. This transducer was in turn monitored 
using the software Chart5 (AD Instruments). On the end of the catheter was 
fashioned a balloon from thin, flexible plastic of smaller volume than the ventricle to 
be studied and secured in place with a tied suture. The catheter and balloon was 
filled with dH2O and the pressure adjusted so that the gauge pressure read close 0 
mmHg on the transducer.  
The pulmonary artery orifice was then identified on the surface of the left atrium 
once ex vivo heart perfusion was satisfactory, and opened slightly. The balloon was 
then gently placed into this opening, and passed in an apical direction to lie within 
the cavity of the left ventricle. If the pressure in the balloon interfered with the 
contraction of the ventricle, it was adjusted until this could no longer be seen to be 
the case. 
Monitoring of the transducer then provided an LV pressure/ time trace throughout 
the experiment. Subsequent analysis using the software allowed extraction of data 
on systolic and diastolic LV pressures and developed pressure. Rate estimates could 
also be derived.  
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2.3.3.3.2 Coronary perfusion monitoring  
In order to measure coronary perfusion pressure, a pressure sensitive transducer was 
attached to the perfusion apparatus directly above and in continuity with the 
perfusate. Prior to the start of cannulation and perfusion, it was set to 0 mmHg with 
reference to atmospheric pressure; the pressures it would measure were therefore 
in addition to atmospheric as is conventional in the measurement of physiological 
pressures.  
The output from this transducer was measured digitally and converted to a pressure 
using the software Chart5 (AD Instruments). It was then used to drive negative 
feedback control of the perfusion pressure by alteration of the perfusion rate. This 
was set to 60 mmHg for experiments on P14 animals, and 80 mmHg for experiments 
on adult rats, which gave initial perfusion rates equivalent roughly to those used in 
constant flow setups. 
 
2.3.3.4 Markers of necrotic injury 
2.3.3.4.1 LDH Activity Assay 
For all of the hearts used for Protocol 1 & Protocol 2, the effluent was analysed 24 
hours later for LDH activity.  
 
LDH catalyses the following reaction which is bidirectional depending on the 
concentration of substrates: 
Lactate + NAD ↔ Pyruvate + NADH  
 
Aliquots from the effluent were mixed with a reaction buffer as described by the 
manufacturer’s instructions. This reaction buffer consisted of: Pyruvate 1.25 mM, 
NADH 0.11 mM & Triethanolamine 0.1 M and made up to 1L with ddH2O and pH 
adjusted to 7.4 was used. When mixed with the LDH- containing effluent at 37° C, the 
optical density measured at 340 nM declines. For most of the reaction period, the 
pyruvate saturates the reaction kinetics of the LDH and so the change in absorbance 




The activity of the enzyme, measured in mU/ml is calculated using the following 
equation: 
 
A=  𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑔𝑟𝑎𝑑𝑖𝑒𝑛𝑡 ∗  1000000 
  6.22 * 80 * -1 
 
LDH is released when myocardial tissue is injured, and so the activity of LDH in 
coronary effluent may be used as a proxy measure of the degree of injury. Was this 
corrected for heart weight? 
 
2.3.3.4.2 CK Activity Assay 
For the experimental set involving perfusion of hearts with cAMP analogues, the 
coronary effluent was assayed for CK activity using a kit obtained from Randox 
(Crumlin, Co. Antrim, Northern Ireland). 
 
Creatine Kinase is an enzyme released from cardiac tissue when damaged that 
catalyses the phosphorylation of ADP from ATP and creatine phosphate; 
 
                                                                                         
The resulting ATP is used to form glucose- 6- phosphate from glucose in a reaction 
catalysed by hexokinase; 
 
Subsequently the G-6-P is oxidised to 6- phosphogluconate in a reaction reducing 
NADP+ to NADPH catalysed by glucose-6-phosphate dehydrogenase (G6P-DH); 
 
 
Creatine Phosphate + ADP             Creatine + ATP 
      CK 
ATP + Glucose   ADP + Glucose-6-phosphate (G-6-P) 




                                   G-6-P + NADP+                6-phosphogluconate + NADPH + H+ 
 
The availability of substrate, hexokinase and G6P-DH is not limiting, whereas that of 
CK is, so the rate of formation of NADPH is directly proportional to the CK activity in 
the sample.  
 
As this reaction proceeds, the absorbance at 340 nM changes. The rate of this change 
is determined spectrophotometrically; then this rate multiplied by a factor of 8095 
(a conversion factor advised by Randox for use at 340 nM/37C) to obtain an activity 
measure in U/l.  
 
 
2.3.3.5 Measurement of Area of Infarction 
Figure 2-5. Example appearance of slices of heart stained with TTC following 30 minute global ischaemiaShown 
here, an Adult heart from the control protocol. Size reference 1cm x 1cm. 
 
The infarct size generated by each protocol was determined by staining each heart 
with triphenyl tetrazolium chloride. A 1% TTC solution in PBS was used. 20ml was 
injected into each heart via the aortic cannula at the pre-terminal perfusate flow rate. 
The heart was then immersed in the TTC solution for 15 minutes, and then immersed 
in 10% formaldehyde for a further 15 minutes, before being removed and stored at -
20° C. Infarcted areas appear white in colour whilst non-infarcted tissue is stained a 




The frozen hearts were then sliced with a #4 blade scalpel in a transverse direction 
into 5 slices for each heart, and the slices were scanned to produce images.  




2.4 Isolated Cardiomyocytes  
2.4.1 Cardiomyocyte Isolation  
Isolation of cardiomyocytes required preparation in advance of several buffers for 
perfusion of the heart during and following digestion, of which Solution A (Table 2-3) 
formed the basis. 
Perfusion with solution A is then followed sequentially by the solutions shown in 
Table 2-4. Perfusion is first switched to B and then to C; D performs digestion, then 
following recovery of the cardiomyocytes Ca2+ is sequentially reintroduced by 
sequential addition of solutions E, F, and G. 
Table 2-4The heart was then perfused with Solution A at a rate previously determined 
as appropriate for the animal’s developmental stage & heart weight. Once the heart 
was judged to have become stable during perfusion with solution A- with regular 
contraction, and in any event not less than two minutes, perfusion was switched to 
solution B for two minutes then to solution C for four minutes.  
Following this, the heart was then perfused with solution D. This is a collagenase & 
protease- containing solution, circulated continuously until an end point of digestion 
was reached. This was the point at which the heart became soft and very compliant 
to touch, indicating that an appropriate degree of enzymatic digestion had taken 
place. This took between 20 and 30 minutes to occur, and seemed to vary based upon 
the size of heart used for that particular experiment. 
After digestion was judged to be complete, calcium was slowly reintroduced to the 
heart by perfusion with solution E (essentially A with the addition of 150 µM calcium), 
for 4 minutes. The heat was then placed in a dish, and gently pulled apart with 
Constituent Concentration 
Solution B   750 µM CaCl2   & 16 mM Glucose 
Solution C 90 µM EGTA & 16 mM Glucose 
Solution D 10 mg/ml Type 2 Collagenase 
1 mg/ml Protease 
Solution E 150 µM CaCl2 
Solution F 0.5 mM CaCl2 
Solution G 1 mM CaCl2 
98 
 
forceps. If the heart is well digested, this is easily accomplished. The fragments were 
then shaken in Solution E for 4 minutes at 37C, filtered, and then allowed to sediment 
for 8 minutes. The sediment contained cardiomyocytes in suspension. 
 
The next stage in the isolation is to gradually increase the calcium concentration in 
the suspension whilst avoiding overload in the freshly isolated, and vulnerable, 
cardiomyocytes. The supernatant was pipetted away, and replaced with 5ml of 
solution F, which is solution A and 0.5 mM calcium. This is then replaced in a similar 
way with 5 ml of solution G- containing 1 mM calcium, 5 minutes later. As a final 
check, a small sample of the suspension was taken by Pasteur pipette onto a coverslip 
and examined under 20x magnification, to examine the morphology of the isolated 
cells. 5 µL of Trypan Blue dye was then added to the suspension; this dye will be taken 
up by cells in the suspension which do not have an intact cell membrane. Those which 
are intact, will not take up the dye and in this manner an overall viability rate of the 
cell suspension may be calculated.  
 
2.4.2 Simulated Reperfusion in Superfused Cardiomyocytes  
The cardiomyocyte cell suspension was divided into 5 ml aliquots into different 
conical flasks. These flasks of cardiomyocyte suspension were incubated in a water 
bath at 370C. Periodically, a droplet may be removed by Pasteur pipette and 
examined under a light microscope, having been stained with Trypan blue. This 
permits assessment of viability and morphology of the cardiomyocytes. Experimental 
protocols for these studies are described in Chapter 5.  
 
2.4.3 Cardiomyocyte Superfusion 
A droplet of the cardiomyocyte suspension was placed in a custom-designed 
microscope chamber through which a continuous constant flow of perfusate could 
be pumped. The cell suspension was allowed to settle and adhere onto the chamber 
surface for 10 minutes, before perfusion with buffer was started.  
Initially, the cell suspension was perfused at 1.25 ml/min with a HEPES-based buffer 
warmed and maintained at 30°C; this was made up of the Solution A stock from the 
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isolation stage, as well as being made up to a concentration of 16 mM glucose and 2 
mM calcium chloride in order to facilitate the assessment of contractility.  
The cell suspension was then examined under light microscopy at 10x magnification 
(Nikon Eclipse TE2000-U). For subsequent assessment of contractile function, a 
cardiomyocyte had to be identified which was not only firmly adherent to the glass 
of the microscope chamber whilst the perfusate was flowing, but was also not 
arrhythmic (in this context, contracting without stimulation), and with a grossly 
normal rod- shaped morphology. The field was therefore searched to find a cell with 
these characteristics.  
Once a suitable cardiomyocyte was identified under the microscope an electrical 
potential was then applied to the suspension in order to depolarise the 
cardiomyocyte being examined and stimulate contraction. This was performed using 
a GRASS SD9 Stimulator, delivering 100V stimulation at 0.2Hz, with a 1 ms delay 
between pulses which themselves lasted 4.5 ms.   
  
2.4.4 Contractility Using an Edge Tracker  
An Edge Tracker (Photon Technology International) was used to quantify the 
contractions in isolated cardiomyocytes. Alignment of this device’s edge trackers on 
a display to the boundaries of the cardiomyocyte on the longest dimension allowed 
measurement of the degree of contraction relative to the initial size of the cell, 
providing a measurement of fractional shortening of the cell; typically this was on the 
order of around 10% at baseline. This method of measurement allowed a continuous 
trace of cell size vs time; and so contractile function during and after perfusion with 
alteration or addition to the buffer could be estimated.  
 
 
2.4.5 Intracellular Ca2+ Measurements using Fluorescent Microscopy 
The calcium transient through the contractile cycle in cardiomyocytes was also 
assessed, at baseline and following perfusion as before with cyanide and cAMP 
analogues. In order to accomplish this, the cardiomyocytes in suspension were first 
loaded with the fluorophore Fura-2-AM (2 µM) and pluronic acid (5 nM). Fura-2 binds 
to free calcium ions and in doing so its absorption spectrum changes- with a peak at 
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340 nm when bound to calcium, and 380 nm when unbound. Measuring the ratio 
absorbances at these wavelengths allows a relative quantification of calcium. This 
measurement may be carried out continuously, and has a relatively high temporal 
resolution, and so may be used to monitor free calcium levels in real time.  
Once the Fura-2 had been added to the cardiomyocyte suspension, it was shaken in 
a water bath at 50 rpm at 37°C for 30 minutes. Subsequently, the cell suspension was 
separated in a centrifuge to remove the excess; at 100 RCF at 20°C for one minute. 
The supernatant was removed, and then the pellet resuspended in solution A. Care 
was taken throughout to minimize the exposure of the suspension to light, to 
minimize breakdown of the Fura-2. 
 
2.4.6 Ca2+ Transient Measurements  
The microscope chamber (as described in the section on cardiomyocyte contractility 
measurements) was continually perfused with Solution A. A drop of the Fura-2 cell 
suspension was added, and perfusion stopped for ten minutes. This period of no flow 
allowed time for the cells to adhere to the glass of the microscope chamber; with the 
aim of enhancing stability during the period of study. 
 
After this period, the field was examined for a cardiomyocyte which retained a rod-
shaped morphology, was fixed onto the slide- did not move with perfusate flow, and 
which responded to depolarisation with a stimulating field (0.2 Hz at 100 V, pulse 
with of 4.5 ms as previously) and did not show any visible contraction without 
stimulation i.e. was not dysrhythmic. Perfusion flow was then recommenced at 1.25 
ml/min. The microscope and equipment were then enclosed in a curtain to prevent 
bleaching from outside light sources.  
 
The first step in measuring transients by fluorescence was then a quantification of 
background light; a measurement of this intensity was taken over 30 minutes to 
arrive at an average background intensity. The analysis software then subtracted this 
background from subsequent measurements of the cardiomyocyte, in the hope that 





Simultaneous measurements of emission intensities were then taken over time 
whilst the cardiomyocyte was being stimulated and illuminated at 510nm using a PTI 
photomultiplier (Model 814). A reading at 340 nm represented bound calcium, whilst 
another at 380 nm for free calcium. A ratio of these two values was then plotted, 
which modelled the relative intracellular calcium concentration in real time.  
 
2.4.7 Experimental Protocols in Isolated Cardiomyocytes 
 
2.4.7.1 Protocols for measuring effect of cAMP analogue on cardiomyocyte 
contractility 
Following identification of a stably contracting cardiomyocyte, a measurement of its 
baseline contractility was taken. Perfusion then switched to a buffer made up of 
Solution A, glucose, and calcium chloride as before but with the addition of 2.5 mM 
sodium cyanide. The Cyanide ion is an irreversible cytochrome oxidase inhibitor, and 
so causes a reduction or cessation in oxidative phosphorylation flux in a dose 
dependent manner; it is thus a cause of histotoxic hypoxia and may be used as a 
model of acute hypoxia. Perfusion with the cyanide- containing buffer was continued 
for 30 minutes, and the time to development of arrhythmia, the time to cessation of 
contractions and the time to cell death (sudden & irreversible change in 
cardiomyocyte morphology from elongated rod-shaped to spherical) was measured 
as the end- points. 
 
In order to determine the contributions of signalling flux through PKA & EPAC to 
cardiomyocyte contractile function, these experiments were repeated with the prior 
perfusion of engineered cAMP analogues. The cardiomyocytes were perfused with 
the buffer containing either a non-selective EPAC & PKA agonist (8-Br-cAMP-AM), or 
either a selective agonist of PKA (6-Bnz-cAMP-AM) or EPAC (8- (4- CPT)-cAMP-AM) 
(all from BioLog Life Science Institute, Germany). These cAMP analogues were the 
‘AM’ version- indicating that they are conjugated to an acetoxymethyl group which 
increases the permeability of the molecule across the cardiomyocyte cell membrane. 
The concentrations of these agents were chosen so as to be consistent with prior 
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work undertaken for this thesis and in the group, detailed in Khaliulin et al., 2017 
(Khaliulin, Bond et al. 2017) at 5 µM for 8-Br, and 10 µM for CPT and 6-Bnz. 
 
2.4.7.2 Protocol for measuring effect of cAMP analogues on Ca2+ transients 
After a period where a seemingly stable cardiomyocyte was allowed to contract with 
a drug-free buffer and baseline calcium transient measurements obtained, the 
perfusate was switched. The cardiomyocyte was perfused with a cAMP-analogue 
(one of the three agents detailed in Table 2-8) containing solution for 5 minutes, 
followed by a 30 minute period of perfusion with a buffer containing Solution A, 2.5 
mM sodium cyanide, and 2.5 mM Ca2+. Calcium was measured continuously through 
this 30 minute period or until death of the cardiomyocyte or movement of the cell 
from the field of view under the microscope occurred.  
 
2.4.7.3 Protocols for measuring cardioprotective efficacy of incubated cAMP 
analogues & CsA on isolated myocytes in suspension 
Each of 5 ml conical flasks containing cardiomyocytes was used as an independent 
experimental arm; the first of each was used as a control. Flasks 2 and 3 both were 
made up to 0.5 mM H2O2 and 3 mM CaCl2, whilst Flask 3 had 2 µM cyclosporin A (CsA) 
added to the suspension for 10 minutes prior to the addition of hydrogen peroxide 
and calcium or one of the cAMP analogues. The control arm served as a baseline 
monitor of changes in cell viability after cardiomyocyte isolation without further 
intervention; whilst the addition of hydrogen peroxide and high calcium aimed at 
simulating the conditions present during reperfusion following ischaemia. Each of 
these experimental conditions were then incubated and agitated in a water bath at 
37C for 120 minutes. 
 
Each of these flasks were sampled at 30 minute time points following the start of the 
experiment- from a sample taken at the outset as a baseline, to a final sample at 120 
minutes. When sampled, a drop was placed by Pasteur pipette onto a microscope 
coverslip, and 5 µl of Trypan blue added. This enabled an estimation of the 
proportion of viable cardiomyocytes at each sampling interval, as well as their 
morphology (rounded vs. rod shaped).  
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2.5 Isolated Cardiac Mitochondria  
2.5.1 Cardiac Mitochondrial Isolation  
Following Langendorff perfusion, the heart was removed from the aortic cannula and 
washed in Buffer B. The atria and accessory tissues were removed, and the remaining 
tissue cut rapidly into small pieces. The tissue was then immersed in 3 ml of Buffer A 
and transferred to the cold room for homogenisation at 40C. 
The heart was then homogenised using a Kinematica Polytron device, at a speed of 
7000 rpm for 4 bursts of 5 seconds. The probe was then washed with 5 ml buffer B, 
which was added to the homogenate. The homogenate was then made up to a total 
volume of 30 ml with buffer B. This suspension was separated using a centrifuge at 
2000 g for 90s; the supernatant was retained.  
This supernatant then underwent further centrifugation; at 10,000 g for 5 minutes 
(Beckman Optima L-90k ultracentrifuge with a Type 45Ti rotor- this was equivalent 
to 11,300 rpm). The supernatant from this separation was discarded, and the pellet 
resuspended in 1 ml of Buffer A final wash. This suspension was then made up to 30 
ml. A further centrifugation step at the same speed and duration was then used, and 
the pellet then suspended in 200 µl of Buffer AFW; this was considered then to be a 
suspension of mitochondria. 
2.5.2 Determination of Mitochondrial Protein Concentration 
As the subsequent mitochondrial assay described below should be undertaken using 
a known and standardised concentration of mitochondria, a Bradford assay was used 
to estimate the concentration in the mitochondrial suspension.  
5 mg/ml Bovine Serum Albumin (BSA) was diluted in Buffer AFW to a series of 
standards; 0.5 mg/ml, 1 mg/ml, 2.5 mg/ml, and 5 mg/ml. These standards of known 
concentration would form standard curve of absorbances. A sample of the 
mitochondrial suspension was diluted 10x in Buffer AFW in order to place the 
measured absorbance within the range of the standard curve.  
3 ml of Bradford reagent was added to 10 µl of each standard and the mitochondrial 
solutions, mixed, and the reaction allowed to proceed for 15 minutes at room 




Using the absorbances of the concentrations from the known standards, a standard 
curve was plotted. Then, by linear regression, the estimated concentration of the 
mitochondrial suspension estimated by the measured absorbance.  
 
2.5.3 Determination of MPTP Opening Using a Spectrophotometer 
Mitochondrial suspension in swelling buffer (0.2mg/ml) was prepared by adding 1.4 
mg of mitochondria to 7 ml swelling buffer prewarmed to 300C. This suspension was 
then divided into 2 x 3.5 ml aliquots in two large cuvettes. These cuvettes were then 
placed into the experimental and control chambers of a Thermo Scientific Evolution 
201 spectrophotometer, which allows simultaneous real time comparative analysis 
of absorbance between the two chambers. 
Initially, a baseline recording of absorbance at 520 nm was taken, with data being 
recorded at 2 Hz. This recording was made for 120 seconds and allows the baseline 
rate of mitochondrial swelling to be measured without intervention.  
Subsequently, CaCl2 was added to the experimental cuvette to give a calcium 
concentration in the mitochondrial suspension of 3 mM for experiments with non-
ischaemically derived mitochondria, or 1 mM for those isolated from experiments 
involving I/R. The use of 1 mM Ca2+ is conventional in this method of assessing pore 
sensitivity (Abellán, Miró-Casas et al. 2006, Khaliulin, Parker et al. 2010); it allows 
detection of an effect within the sensitivity range of the spectrophotometer. 
Conversely, the use of 3 mM Ca2+ in uninjured hearts is less well described. Initial 
experiments using the lower Ca2+ dose showed a small effect, and so in the 
optimisation of these experiments the use of 3 mM Ca2+ allowed heightening of the 
effect size when the sensitivity is low.  
 
The recording was then restarted and continued for at least 300 seconds or until any 
change in absorbance had ceased in order to measure the change in absorbance 
characteristics that accompanies swelling of the mitochondria as a consequence of 




2.5.4 Protocols for measuring the effect of cAMP analogues on mitochondrial 
swelling 
Hearts from adult, male Wistar rats (Charles River Laboratories) were perfused in the 
Langendorff mode using Krebs- Henseleit buffer (Table 2-2) with 95% O2/5% CO2 
bubbled through, maintained at a temperature of 37.5 0C. Once each heart had been 
established in the perfusion setup, an experimental protocol was started. Several 
protocols were used;  
1) Perfusion of the heart for 30 minutes before termination of perfusion; a 
control experiment without ischaemia/ reperfusion injury 
2) Perfusion of the heart for 30 minutes followed by a 30 minute period of 
global ischaemia, then a 5 minute reperfusion period before termination 
of the experiment; a control experiment with ischaemia/ reperfusion 
injury 
3) Perfusion of the heart for 30 minutes followed by perfusion with a cAMP 
analogue (each from Table 2-8) for 5 minutes, then a washout period for 
5 minutes, followed by a 30 minute period of global ischaemia, then 
perfusate flow restarted for 5 minutes as a period of reperfusion before 
the experiment was terminated. 
 
Each of these experimental protocols was tried in order to show differences in the 
opening characteristics of the MPTP, both under control or physiological conditions 
or with perfusion with a cAMP analogue. In each case, after the perfusion step of the 





2.6 Statistical Analysis 
2.6.1 Proteomics Statistical Analysis 
Each proteomic run of experiments produced an abundance for each peptide for 
each sample. Results with a low or medium level of confidence in interpolation of 
parent protein from the measured peptide were rejected.  
For comparisons between P14 proteins and adult, significance levels were estimated 
by t- test with Bonferroni post hoc correction. One- way ANOVA was performed 
where multiple groups were compared.  
The data were then presented in the form of a logarithmic plot comparing the mean 
fold change against the significance level of that change, such that significant changes 
of notable difference could be identified; this should produce identification of both 
statistical and biologically significant differences.   
2.6.2 Data from Langendorff perfused hearts 
2.6.2.1 Processing of Langendorff perfused heart contractility data 
Where LV pressure/ time data was collected, it was used to calculate developed 
pressure as well as systolic and diastolic pressures. The pressure changes with drug 
treatment were compared with baseline pressures immediately preceding. Statistical 
analysis of these differences were performed by Student’s t-test and reported as 
significant if p < 0.05.  
Rate-pressure product was also determined by analysis of the same trace. Similarly 
comparison was made immediately before addition of a drug and at maximal effect; 
comparisons were made by Student’s t-test and reported as significant if p < 0.05.  
2.6.2.2 Processing of Enzymatic release from perfused heart data 
An enzyme activity measure (of CK or LDH) was estimated for each 5 minute 
reperfusion fraction, and normalised to the perfusate flow rate at the time of 
sampling and to the mass of tissue perfused. Each fraction was compared by 
Student’s t-test. The area under the activity- time curve was also estimated 
geometrically, to allow for comparison across the reperfusion period.  
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2.6.2.3 Processing of area of infarction data 
The proportion of the heart that was infarcted was determined planimetrically using 
the software ImageJ (Abramoff 2004) (National Institute of Health, Bethesda, United 
States). The whole heart is at risk of infarct in global ischaemia, and so the infarcted 
proportion is the size ratio of the infarcted area vs. the area of the whole heart; 
therefore the magnitude of the infarct could be expressed in percentage form. 
Comparisons between experimental groups were then made by Student’s t-test 
between intervention groups and the same age group control. 
 
2.6.3 Data from Isolated Cardiomyocytes 
2.6.3.1 Processing of Isolated Cardiomyocyte Contractility Data 
For each contracting cardiomyocyte trace, time points at 5 minute intervals from the 
start of the experiment until 35 minutes were examined. Cardiomyocyte size values 
from a window of 15 seconds either side of the instantaneous time point were 
assessed; this would reliably capture at least 3 whole contractile cycles at the 
stimulation rate of 2 Hz. For those cycles, maximal and minimal output values were 
selected and converted to actual sizes through an initial calibration and a mean value 
for the maxima and minima taken across the cycles observed. This was then 
expressed as fractional shortening, and then normalised to the initial value for that 
cardiomyocyte. Comparisons were then made by two- tailed, unpaired t-test against 
the data at 5 minutes and 35 minutes for the cyanide- alone control to determine the 
effects of the cAMP analogues on the unpoisoned cardiomyocyte (at 5 minutes) for 
the baseline pharmacological effect, and after 30 minutes of cyanide perfusion (35 
minutes after the start of the experiment) representing protective efficacy in this 
model of hypoxia.  
 
2.6.3.2 Statistical processing of calcium transient data from superfused myocytes 
Calcium transients (Fura ratio) were computed from the diastolic and systolic Ca2+ in 
electrically stimulated cardiomyocytes throughout the superfusion experiments. 
Data were sampled at 5-minute intervals throughout each experiment- from 0 to 25 
minutes, and exported from the imaging software for analysis. At these time points, 
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the bound/free calcium activity was calculated and then expressed as a ratio of the 
baseline at the t=0 timepoint. 
 
For each cell studied, 3 contractile/transient cycles either side of the selected time 
points were sampled, and the mean calculated as well as the standard error of the 
mean as a measure of spread. Comparisons by t-test were made of the data at 5 
minutes (for the physiological effects of the cAMP analogues) and at 25 minutes (for 
preservation of calcium transients despite histotoxic hypoxia from the NaCN 
perfusion). 
 
2.6.3.3 Statistical processing of data from cardiomyocytes in suspension 
Each experimental condition was measured at 30-minute intervals. 5 random fields 
were selected from a droplet examined under 20x light microscopy and 
photographed. Each of these fields were subsequently assessed; the number of 
dead/ hypercontracted/ normal cells counted and a mean value/ SEM calculated for 
each group at each time point. Between group comparisons of viability and 
morphology were calculated at each time point by two- way repeated measures 
ANOVA with a Bonferroni post-hoc modification. 
 
2.6.4 Statistical processing of data from isolated mitochondria 
Each experiment resulted in a trace of absorbance at 520 nm vs. time, with a baseline 
trace and a trace after the addition of supplemental Ca2+. For each experiment, the 
Ca2+ induced swelling trace was corrected for the background rate of drift. Then, the 
maximal rate of change of absorbance (dA/dt, over a 3 second window of recording) 
and the absolute difference between baseline and experimental arms was measured 
to estimate the opening sensitivity of the MPTP in each group. A two- way ANOVA 
was then performed with Tukey’s post-hoc test of significance to assess the 




3 Molecular Developmental Changes Associated with I/R 
injury and cAMP/PKA/Epac signalling  
3.1 Introduction 
The information provided in the Introduction suggest that signalling downstream 
from cAMP by alterations in activity and targeting of intermediates may, at least in 
part, explain the finding that the immature heart differs in its sensitivity to ischaemia/ 
reperfusion injury compared to the adult. Therefore, elucidating and identifying the 
proteins involved in cAMP signalling pathways would help to understand the 
difference in vulnerability. 
The field of proteomics, in concert with sister disciplines in genomics, metabolomics, 
transcriptomics amongst others has emerged over the last two decades due to 
parallel advances in technology allowing for the identification and identification of 
complex organic molecules rapidly, with precision, and from a relatively small 
sample. These techniques allow rapid and precise assessment of how the scope of 
the whole proteome changes across a range of experimental conditions; rather than 
being limited to studying one or a small number of proteins.  
 
3.2 Aims  
There are three aims for the experiments described in this chapter.  
1. To examine the comparative cardiac proteomes of rats at various stages of 
maturation and identify thematic changes over that period of development.  
2. To look in detail at the cAMP signalling axis where it appears in the proteome 
and use that to examine the differences that are supposed based up on the 






The techniques for extraction, digestion, mass spectrometry and peptide 
identification are discussed in the Methods chapter of this thesis, but are reiterated 
here in brief.  
Rats of 7 (n=4), 14(n=9), and 28(n=9) days postnatal as well as adults(n=9) were killed 
by stunning by occipital concussion and then by cervical dislocation. Their hearts 
were rapidly extracted and agitated in chilled cardioplegia buffer. A small piece of 
tissue from the apex of each heart was cut off and snap frozen in liquid nitrogen, then 
stored at -80 °C for later use. 
 
The samples were then homogenised, and the protein content from each sample of 
tissue was then extracted. This was performed by rapid oscillation in RIPA buffer, 
followed by centrifugation at 10,000 x g. The supernatant in which the extracted 
protein content was in solution was then recovered. The concentration of the protein 
in the supernatant was quantified by Bradford assay, and then normalised at 2mg/ml. 
The samples were then analysed at the University of Bristol Proteomics facility with 
the assistance of Dr. Kate Heesom. They were assessed through a TMT-MS/MS 
protocol for identification of unmodified peptides. This involved multiple sample 
runs through the mass spectrometer. Each of these experiments was limited to 10 
samples at a time. The number of the original extracts that could therefore be used 
in a limited number of runs, and provide intra-experimental comparison and cross 
run validity was therefore limited. As each run required a pooled sample of all 
extracts in order to provide cross-run normalisation, there were 9 experimental 
samples per run. There were three runs performed, with age groups scattered across 
each run randomly in order to prevent an experimental bias. This limited the total 
number of samples to 27 (3 runs of 30 – 3 pooled samples altogether). The total 
number of extracted hearts per age group ultimately studied is shown in Table 3-1. 




A bioinformatic approach then assigned those peptides to their likely protein of 
origin, with an estimated degree of confidence. The results were returned as an 
abundance relative to that in a pooled sample. The first stage of analysis was 
performed in Proteome Discoverer 2.1 (Thermo Fisher Scientific, Massachusetts, US), 
which returned a list of proteins as well as their abundance per sample and in the 
pooled sample. The functional category of these proteins was assessed over the 
whole proteome by age group by importing the list of proteins from each age group 
into the categorisation tools at PantherDB.org. This provided a breakdown by 
function of the proteins identified in each age group.  
The 14- day old results were then selected and compared with the results for the 
adult age group. Statistical comparison between these age groups was performed by 
Student’s t-test and Bonferroni correction; a fold- change was also calculated dividing 
the mean abundance in the P14 group by the mean abundance in the adult group- 
so a fold change greater than 1 represented an increase in the P14 vs. the adult, and 
a fold change less than 1 the reverse. These two values, of p-values and fold change 
were then plotted logarithmically against one another for each protein to produce a 
‘volcano plot’; a graphical representation of the entire proteome- Figure 3-3, for 
example. 
Subsequent analysis also performed in Ingenuity Pathway Analysis (Qiagen 
Bioinformatics, Hilden, Germany). This software allowed assessment of whole 
interacting networks of proteins rather than individuals; and produced scores for 
these networks reflecting their overall change in the age groups compared.  
  





Table 3-1 Numbers of hearts used to produce protein extracts for each age group. Each heart produced one 
sample, which was independently run through the TMT-MS/MS process.   
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3.4 Baseline proteomics 
3.4.1 Characterisation of Output 
Each of the three runs involved different samples, and a different proportion of each 
age group was represented; consequently, a differing subset of proteins was 
identified from each run.   
The results of these experiments were combined and demonstrated 6976 unique 
proteins across all three experimental runs, although not all of these proteins were 
identified in all samples or in all age groups; only 46% were common to all groups 
and experimental runs. Whilst in large part the identities of proteins identified was 
the same between groups, there was still considerable heterogeneity. Figure 3-1 
shows graphically the age groups with uniquely identified and overlapping proteins 
and Table 3-2 a comparison of number of proteins in common between two age 
groups. Once those results with missing values were excluded, if all samples were 
analysed together there were 5038 unique proteins common to all groups 
representing 73.9% of the total proteins identified in at least one sample of at least 







Figure 3-1. Venn diagram showing numbers of proteins identified from each experimental group with high 
confidence. Adult group n= 7; P28 group n=8; P14 group n=8; P7 group n=4.Overlapping areas show proteins 
extracted in common between each different age group. No details for expression levels nor significance testing 
were included in this analysis. (Oliveros 2007-2015) 
In order to further characterise the proteome and gain an overview of how these 
broke down functionally, the accession numbers of the identified proteins were 
queried against a database of GO Molecular Function terms (Ashburner, Ball et al. 
2000, Consortium 2015) using the tools available at PantherDB.org (Mi, Poudel et al. 
2016), cross-referencing to the UNIPROT database (2015).  The results are shown in 




Comparison Proteins identified in all 
samples of group 
Proportion of all 
uniquely identified 
proteins 
7 vs adult 4578 65.6% 
14 vs adult 4040 57.9% 
28 vs adult 4081 58.5% 
Table 3-2. Numbers of proteins identified per age group vs. total proteins identified. Not every sample from each 




















GO   Molecular Function Term  Number of Proteins   
 7 Day 14 Day 28 Day Adult 
Transporter Activity 
(GO:0005215) 
180 203 188 177 
Translation Regulator Activity 
(GO:0045182) 












62 59 54 
Signal Transducer Activity 
(GO:0004871) 
56 66 60 54 
Antioxidant Activity 
(GO:0016209) 
17 18 19 17 
Structural Molecule Activity 
(GO:0005198) 
216 212 214 215 
Binding (GO:0005488) 1182 1235 1168 1154 
  
Figure 3-2 & Table 3-3. Proportion of proteins identified from each age developmental age group classified into 
functional groups according to the Gene Ontology Consortium’s Molecular Function Terms. Adult group n= 7; P28 
group n=8; P14 group n=8; P7 group n=4. 
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Broadly, these categories were very similar in frequency across the age groups- so 
there did not seem to be an age-related bias in types of proteins detected by this 
method. The proteins identified are not identical to the complete proteome, and so 
the possibility for significant systematic bias exists; it is therefore important that the 
age groups appear similar in this regard. This analysis thus far has not considered 






3.5 Comparison of 14- day and Adult Proteomes 
In rats, 14- day old hearts are thought to be the group most resistant to injury 
compared to those of adults (Introduction 1.6.3). These groups were therefore 
selected to be directly compared against one another in order to attempt to find 
potential explanations for this observation, in order to make the analysis more 
tractable. 
A 2- tailed heteroscedastic Student’s T-test with a Bonferroni post-hoc correction for 
multiple testing was performed across all the proteins identified in common from the 
8 14- day hearts and 7 adult hearts comparing the significance of their relative 
abundances. The relative/ proportionate change was also estimated for each protein. 
It was decided based upon convention in the proteomic literature to regard a fold- 
change of >1.2 fold in either direction as potentially of interest. 
 Fold change >1.2 
(more abundant in 
14 –day old) 
Fold change <0.8 
(more abundant in 
adult) 
p <0.05 
n. proteins 3740 (75.4%) 402 (8.1%) 3296 (66.5%) 
Table 3-4. Number of proteins left in results after fold change and significance filter applied to proteins identified 
in all 14- day old and adult samples. Parentheses –proportion of all proteins. 
All proteins which were found to meet the statistical significance threshold also met 
the fold- change threshold, so this analysis did not significantly reduce the number 
of candidate proteins to study. Subsets of interest of this proteome were therefore 
identified in order to facilitate analysis. 
The GO terms described earlier provide a straightforward and relatively unbiased 
means by which to filter the data set, albeit dependent upon the validity of the 
annotation in the databases. Given that the 14- day old hearts display the greatest 
degree of resistance to injury, based upon previous experimental work, it was 
decided to focus the analysis on those sets and use the well-described adult 
phenotype as a comparator. The whole 14- day and adult proteome was annotated 
with GO terms for Molecular Function as well as subcellular localisation which 
permitted selection of subsets of interest.  The proteome was searched for the terms 
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“channel”, “calcium”, “signal*” “redox” and the location “mitochond*” as these 
parameters were felt to delimit the search to those factors known to be of 
importance in I/R injury. 
 
3.5.1 Calcium- related proteins 
This group consisted of 296 proteins. From those, 184 were over the p-value 
threshold on Student’s T-test of 0.05. All aside from 30 were greater than the 1.2 fold 
difference from the counterpart set. Selected proteins of particular interest, either 
from prior observation or standing out as an unexpected or particularly marked 
change, are highlighted in Figure 3-3 and Table 3-5. 
 
Figure 3-3. Logarithmic plot of fold change of Calcium- related dataset identified in 14 day- old hearts compared 
to adult samples vs. p- value derived from Student’s T-test. Bonferroni post-hoc correction for multiple testing 
used. Adult group n= 7; P14 group n=8.Reference lines denote a fold change < 0.8 or >1.2 fold on the x- axis, or a 
p- value < 0.05 on the y- axis. Positive values of fold change represent an increase in the 14- day heart.  
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 Protein Name Accession Fold Change  
(14-day/Adult) 
p- value 
Calcitonin gene-related peptide 
type 1 receptor 
Q63118 3.766 0.000 
Calcium homeostasis endoplasmic 
reticulum protein  
D3ZAX5 3.697 0.000 
Calcium uptake protein 2, 
mitochondrial 
F1LMJ8 3.287 0.001 
Sodium/calcium exchanger 1  Q01728 2.733 0.000 
Calcium/calmodulin-dependent 
protein kinase II inhibitor 1  
Q9JI15 2.265 0.000 
Sodium/hydrogen exchanger 1  P26431 1.773 0.001 
Ryanodine receptor 2  B0LPN4 1.619 0.016 
Cardiac phospholamban P61016 1.586 0.000 
Cardiac-type ryanodine receptor  D7UNU1 1.583 0.008 
Calcium/calmodulin-dependent 
protein kinase type II 
P15791 1.543 0.001 
Caveolin-1  P41350 1.461 0.000 
Calcium channel, voltage-
dependent 
A0A0G2JSZ0 1.442 0.000 
Calcium-transporting ATPase D3ZH00 1.372 0.001 
Sodium/potassium-transporting 
ATPase  
P07340 1.308 0.006 
Cardiac-type ryanodine receptor D7UNT4 1.296 0.009 
Calmodulin P62161 1.273 0.011 
Cardiac troponin C Q4PP99 0.770 0.038 
Troponin I, cardiac muscle P23693 0.609 0.001 
Sodium/potassium-transporting 
ATPase 
P06686 0.474 0.001 
Table 3-5. Selected proteins of interest from the calcium- related dataset. Fold change= ratio of relative abundance 
of mean P14 result to mean Adult result. P- value is the result of a two- tailed Student’s T- test comparing the two 
groups with the Bonferroni correction for multiple testing. Sorted by order of decreasing fold change. Positive 





3.5.2 Signalling Proteins 
Here, 822 proteins were identified. Of these, 654 reached the significance threshold 
of p >0.05 on a Student’s T-test; the majority of these 654- 611- were more abundant 
in the 14- day old heart, with only 43 more abundant in the adult heart. In all of these 
cases their fold change was >1.2. Selected proteins, either based upon prior 
observation or those that were unexpectedly up/downregulated, are highlighted in 




Figure 3-4. Logarithmic plot of fold change of signalling subset of proteins identified in extracts from 14-day old 
hearts compared to adult samples vs. p- value derived from T-test. Reference lines denote a fold change < 0.8 or 
>1.2 fold on the x- axis, or a p- value < 0.05 on the y- axis. Positive values of fold change represent an increase in 





Protein Name  Accession 14day/Adult fold 
Change 
p- value 
A-kinase anchor protein 5 F1LPP6 8.041 0.000 
A kinase (PRKA) anchor protein 1 D4A9M6 2.670 0.000 
Rho-related GTP-binding protein RhoB  P62747 2.606 0.000 
G kinase-anchoring protein 1  Q5XIG5 2.581 0.000 
Adenylate cyclase 6 F1LSD1 2.562 0.000 
Phosphoinositide phospholipase C  G3V845 2.159 0.000 
Protein Rap2a A0A0G2JTW1 2.052 0.000 
cAMP-dependent protein kinase  P68182 2.036 0.000 
Phosphatidylinositol 3-kinase O88763 1.997 0.001 
A-kinase anchor protein 6 Q9WVC7 1.952 0.000 
Phosphoinositide phospholipase C  A0A096MJW5 1.939 0.000 
Protein kinase C epsilon P09216 1.802 0.001 
Caveolin-3 P51638 1.789 0.000 
Protein Akap9 F1LPB4 1.752 0.000 
Rho guanine nucleotide exchange factor 2 Q5FVC2 1.708 0.007 
Caveolin  A0A0A0MXU8 1.506 0.001 
Caveolin-1 P41350 1.461 0.000 
A kinase (PRKA) anchor protein F1M3G7 1.283 0.020 
Table 3-6. Selected signalling- related proteins of interest. Fold change= ratio of relative abundance of mean P14 
result to mean Adult result. P- value is the result of a two- tailed Student’s T- test comparing the two groups with 
the Bonferroni correction for multiple testing. Sorted by order of decreasing fold change. Positive values of fold 
change represent an increase in the 14- day heart. Adult group n= 7; P14 group n=8. 
3.5.3 Mitochondrial Proteins 
816 proteins were identified with the mitochondrial cellular localisation GO term. 
This is not synonymous with the proteins having been extracted from the 
mitochondria, just that they are known to localise to the organelle but not 
(necessarily) exclusively. 557 of these met the significance threshold, of which 465 
were 1.2 fold or greater more abundant in the 14- day old group. Only 82 of these 




Figure 3-5. Logarithmic plot of fold change of “Mitochon*” subset of proteins identified in 14-day old hearts 
compared to adult samples vs. p- value derived from T-test. P- value is the result of a two- tailed Student’s T- test 
comparing the two groups with the Bonferroni correction for multiple testing. Positive values of fold change 
represent an increase in the 14- day heart. Adult group n= 7; P14 group n=8. Reference lines denote a fold change 
< 0.8 or >1.2 fold on the x- axis, or a p- value < 0.05 on the y- axis.  
Selected proteins of interest, either of those that are previously known to be 
significant, or those that were significantly down/ upregulated unexpectedly, are 










 Protein Name Accession 14 v Adult fold 
change 
P- Value 
Ubiquinol-cytochrome-c reductase complex 
assembly factor 3  
P0CD94 4.843 0.000 
Peroxiredoxin-4  Q9Z0V5 2.393 0.000 
Catalase  P04762 2.349 0.000 
Cytochrome c oxidase  P10818 1.791 0.000 
Glutaredoxin-1  Q9ESH6 1.757 0.000 
NADPH:adrenodoxin oxidoreductase, 
mitochondrial  
P56522 1.496 0.001 
NADH dehydrogenase  G3V644 1.395 0.006 
Cytochrome C oxidase assembly protein  Q76MV3 1.390 0.005 
Acad9 protein  B1WC61 1.371 0.003 
Thioredoxin, mitochondrial  P97615 1.312 0.049 
Cytochrome c oxidase subunit 7A2, 
mitochondrial 
P35171 1.311 0.000 
Glutaredoxin-2, mitochondrial Q6AXW1 1.243 0.031 
NADPH--cytochrome P450 reductase  P00388 1.221 0.012 
Mitochondrial import inner membrane 
translocase subunit TIM44  
G3V640 1.220 0.046 
Mitochondrial import inner membrane 
translocase subunit Tim21  
Q5U2X7 1.219 0.020 
NADH-cytochrome b5 reductase  G3V9S0 1.201 0.008 
NADH dehydrogenase [ubiquinone] 
flavoprotein 3, mitochondrial  
Q6PCU8 0.782 0.010 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex assembly factor 3 
O08776 0.709 0.033 
Peroxiredoxin 3  G3V7I0 0.703 0.018 
Cytochrome b5  P00173 0.606 0.000 
Hexokinase-2  P27881 0.573 0.003 
Superoxide dismutase [Mn], mitochondrial  P07895 0.471 0.001 
Peroxiredoxin 5, isoform CRA A0A0G2JSS8 0.453 0.001 
Glutathione peroxidase  M0RAM5 0.387 0.000 
Adenylate kinase 4, mitochondrial  Q9WUS0 0.256 0.000 
Table 3-7. Selected mitochondrial proteins of interest. Fold change= ratio of relative abundance of mean P14 result 
to mean Adult result. P- value is the result of a two- tailed Student’s T- test comparing the two groups with the 
Bonferroni correction for multiple testing. Sorted by order of decreasing fold change. Positive values of fold change 
represent an increase in the 14- day heart. Adult group n= 7; P14 group n=8. 
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A subset of these proteins was identified that showed marked change in this analysis, 
and were also known to be of critical importance in both the handling of calcium 
during excitation and contraction of the heart, and involved in the process of cell 
death and injury or cardioprotection following ischaemia and reperfusion. 
 
This subset was then examined across all four of the age groups; significant post- 
natal age-related variation was observed in a pattern maintained across the majority 
of proteins in this group (Figure 3-6). 
3.5.4 Developmental changes in calcium and oxidative stress related proteins  
Proteins including PLC, PKA, PKCε, LTCC, NCX, RyR and phospholamban all displayed 
significant age- related variation in a pattern which is similar to that the age- 
vulnerability relationship shown in Figure 1-17. Similar variation was shown in the 
analysis for catalase (Figure 3-7). Strikingly, however, other antioxidant enzymes, 
such as superoxide dismutase in both cytosolic and mitochondrial variants as well as 
glutathione peroxidase were up to 2- fold more abundant in the adult vs. pool; they 




Figure 3-6 Selected proteins of importance to EC Coupling and I/R injury vs relative change in abundance in 
proteome of cardiac extracts of noted post-natal ages compared to poolError bars represent 95% confidence 
intervals. All results significant p< 0.05 (P14 vs adult) aside from for SERCA. 
P- value is the result of a two- tailed Student’s T- test comparing the two groups with the Bonferroni correction 
for multiple testing. Positive values of fold change refer to change vs pooled abundance. Adult group n= 7; P28 
group n=8; P14 group n=8; P7 group n=4.Figure 3-7. Abundance of key anti-oxidant enzymes in proteome of 
126 
 
cardiac extracts from differing post-natal age groups showing age related variation in expression. Bars denote 
mean value. Asterisks represent significance p <0.05 vs pool. Error bars represent 95% confidence interval. P- value 
is the result of a two- tailed Student’s T- test comparing the two groups with the Bonferroni correction for multiple 
testing. Ratio refers to abundance in sample vs pooled abundance. Adult group n= 7; P28 group n=8; P14 group 
n=8; P7 group n=4.  
3.6 Pathway analysis 
The proteomes were then analysed using Ingenuity Pathway Analysis (Qiagen, 
Germany) in order to assess the data without the drawback of subjectively looking at 
proteins or classes of interest. Figure 3-8 shows selected relevant signalling pathways 
compared to the expected abundance of all constituents of that pathway for both   
P14 and adult heart extracts colour coded by z-score for that difference. It shows that 
there are significant differences in the expression of members of key signalling and 
metabolic pathways. Key observations are that the adult shows an 
overrepresentation of oxidative phosphorylation, TCA cycle components and 
gluconeogenesis; there is also a mild increase in the level of β-AR pathway 
components. Conversely, the P14 group shows a relative increase in the level of PKA 
signalling as well as multiple pathways involved in the processes of development; 






Figure 3-8 Mean expression of components of selected signalling pathways from P14 and adult age groups 
performed by automated pathway analysis. Colour intensity represents change from expected expression by z-
score; orange colours are greater than expected and blue less than expected. Comparison to hypothesis of no 
significant difference between age groups. Group sizes- Adult n=7 P14 n=8. Output from Ingenuity Pathway 





Figure 3-9 Changes in expression of selected relevant functional categories of biological importance comparing 
P14 day old and adult proteome. Significance value is shown on y- axis and direction of change by colour. Colour, 
representing z-score; negative scores represent relatively higher results in the adult, whilst positive in the P14. 
Significance testing performed by a 2-tailed T-test with correction for multiple testing. Group sizes- Adult n=7 P14 
n=8. Output from Ingenuity Pathway Analysis, Qiagen, Germany.  
The data were then assessed by functional category of protein rather than by 
signalling pathway in a comparative analysis between the P14 and adult groups; this 
analysis for selected categories of interest is shown in Figure 3-9. The changes in 
categories responsible for ATP production seen in Figure 3-8 are also noted here, but 
the most striking observation is that of the very significant representation of 
components labelled as involved in mitochondrial dysfunction. However, the analysis 
reports as no overall change in direction measured by z-score. 
This category was then examined in closer detail (Figure 3-10). This shows 
diagrammatically the proteins identified in their schematic spatial location of origin. 
Then, a colour overlay is superimposed labelling those proteins by their relative 
abundance compared between the P14 and adult groups. This shows a mixed 
pattern; both complex I and complex IV constituents show age-dependent variation 
in abundance. However this pattern is not consistent across all constituents; whilst 




Figure 3-10 Detailed comparative view of known proteins involved in mitochondrial dysfunction with colour 
overlay denoting comparative changes between P14 and adult age groups. Expression logarithmic fold difference 
overlaid in colour; red= higher in P14, green= higher in adult. Group sizes- Adult n=7 P14 n=8. Output from 




These findings are relatively broad but however the dataset that has been generated 
is novel. The rat is a well studied animal model in translational research as well as in 
the proteomic literature, and along with other mammals have also been used as a 
model of physiological human development. This relies upon the underpinning 
assumption that the patterns of gene/transcript/protein expression remain 
conserved across the species barrier. Recently, as large scale phenotyping techniques 
of genomics, transcriptomics and proteomics have become more established, many 
authors have attempted to validate or challenge these assertions. A recent study by 
Cardoso- Moreira & colleagues (Cardoso-Moreira, Halbert et al. 2019) studied the 
transcriptomes of multiple organs through key developmental timepoints across 
multiple species including the rat and the human. This is an extremely comprehensive 
study, validating the use of these species for comparative work through 
development. However, as far as could be found in searching the literature and public 
databases of available proteomes, to date no such similar work exists using a whole 
proteome approach. This work examined the changes in the unselected proteome 
with time through development at key milestones. Whilst many others have 
published on cardiac proteomics, these studies tend to be focused on the proteome 
of particular organelles in the rat (Ferreira, Vitorino et al. 2014), or pathological 
conditions- particularly in human studies- (O’Reilly, Lindsey et al. 2018), or have 
examined other organisms entirely. The most widely studied animal model in 
searching for other comparable work seems to be the mouse. Talman & colleagues 
(Talman, Teppo et al. 2018) have published a proteomic and metabolomic atlas of 
postnatal mouse heart development, studying molecular changes at a range of 
postnatal ages broadly similar to the milestones examined in this work. No similar 
published proteome exists for rattus norvegicus. Examining the PRIDE (PRoteomics 
IDEntifications) archive (Vizcaíno, Csordas et al. 2015) maintained by the EMBL-EBI 
(European Molecular Biology Laboratory- European Bioinformatics Institute), which 
is a world-leading repository of MS- based proteomic data, the archive lists 19 
submitted cardiac proteomes. None of these survey the post-natal developmental 
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changes in the proteome, or address immaturity at all, and so the data presented in 
this chapter is novel at least amongst publicly available and acknowledged sources.  
3.7.1 Summary of findings 
Thousands of peptides and their parent proteins were identified in the proteomic 
comparative experiments. By automatically annotating them and filtering them by 
recognised subset categories, an attempt was made to avoid a selection bias in the 
analysis of changes in abundance between age groups.  
Nevertheless, after this analysis it was necessary to focus on a tractable sample of 
these proteins within each set which were significantly and reliably altered between 
the groups being compared. This inevitably risks overlooking heretofore unknown 
proteins or correlations, but within the scope of the project is necessary.  
The output from the experiments identified almost 7,000 unique proteins; however, 
Uniprot lists 29,951 proteins identified as members of the rat proteome. There are 
several reasons which might account for this difference. Firstly, the cardiac proteome 
is expected to be a subset of the whole. In the human, the cardiac proteome contains 
roughly 62% of the proteins expressed in the whole organism (Fagerberg, Hallström 
et al. 2014). However, the results here are proportionately lower than that ratio, 
albeit in the rat rather than in human; the other explanations are likely technical (e.g. 
protein extraction method) and are discussed in the limitations section; 8.2.2.  
There were several main findings from the proteomic experiments comparing P14 to 
adult hearts.  
• A significant trend towards overexpression of calcium homeostasis related 
proteins and selected signalling intermediaries in the P14 heart 
• An overrepresentation of proteins localised to the mitochondria in the P14 
heart 
• A reduction in abundance of proteins involved in signalling via cAMP with 
increasing post-natal age 
• A correlation between age and abundance of antioxidant protein expression 
• Upregulation of TCA cycle and oxidative phosphorylation proteins in the adult 
vs the P14 heart 
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• Marked differences in many proteins regulating mitochondrial energy 
production, oxidative stress, and fission/fusion but split patterns for 
up/downregulation in the P14 vs the adult.  
  
3.7.2 Changes in Ca2+ cycling proteins during development 
The sodium-calcium exchanger (NCX) was 2.7- fold more abundant in the 14- day old 
vs. the adult samples. Other proteins intimately involved in calcium homeostasis 
were also identified as being significantly more abundant in the neonate vs. adult. 
The ryanodine receptor, which gates Ca2+ release from the SR was 1.6 fold more 
abundant. Phospholamban and CaMKII- targets for PKA and Epac signalling- were 
similarly upregulated, as well as others critical for excitation- contraction coupling.  
Although the precise ultrastructural changes in the neonate as it develops towards 
adulthood are not precisely known, it is thought that the sources of intracellular 
calcium including and in particular the sarcoplasmic reticulum are relatively 
underdeveloped. The cardiomyocyte is therefore much more dependent upon 
extrusion of calcium as a means of terminating calcium, and so NCX, operating in the 
reverse mode, is relatively more important (Huang, Hove-Madsen et al. 2008). This 
explanation, however, would not account for the relative increase in RyR or the 
voltage- gated calcium channel; this may in an effort to maximise the release from 
the underdeveloped intracellular calcium stores; studies localising these proteins in 
developing hearts may be necessary to further account for this finding. 
3.7.3 cAMP signalling proteins are downregulated with age 
Of the 822 signalling proteins to be identified in the proteomic experiments, found 
prominently were those involved in cAMP linked signalling and the control of 
excitation- contraction coupling. cAMP dependent protein kinase- PKA- was found to 
be significantly upregulated over two- fold in the 14- day old heart as compared to 
the mature heart, as well as the (direct or indirect) Epac targets CaMKII, 
Phospholamban, and PKCε. Given the importance these targets have to 
cardioprotection, it is striking that the pattern of expression they display matches the 
vulnerability profile of developing heart to injury. 
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Proteins involved in shaping the spatial compartmentalisation of the cellular 
response to a signal were also found to be significantly upregulated in the developing 
heart. Caveolin- 3, an important scaffolding protein and the member of the caveolin 
family of most significance in cardiomyocytes (Lin, Hung et al. 2009), was 1.7 fold 
more abundant in the neonate than the adult comparator. Caveolin- 3 is known to 
interact significantly with and recruit the sodium calcium exchanger to caveolae; 
(Bossuyt, Taylor et al. 2002) caveolae in general act to produce foci for signalling 
proteins, recruiting regulatory and transducing elements to produce tight control of 
cellular responses. A- kinase anchor proteins (AKAP) similarly act to recruit PKA to 
these signalling complexes and are upregulated almost two- fold in the 14- day old 
compared to the adult. 
Therefore it is unsurprising that in the environ of a developing heart, with a high level 
of ontological signalling and development occurring, that these specialist signalling 
structures should be relatively over-represented. This, however, is inferential 
evidence and should be confirmed by ultrastructural examination of the 
cardiomyocyte at each stage of development of the organism. 
 
3.7.4 Age Related I/R Vulnerability correlated with Antioxidant activity 
An unexpected pattern of variation was seen with several proteins involved in the 
response to oxidative stress; a key event in myocardial damage following ischaemia 
and reperfusion. Catalase, which catalyses the conversion of hydrogen peroxide, a 
key source of oxygen radicals, into water and molecular oxygen, seems to follow the 
same bell- shaped curve of vulnerability as the animal as a whole (Figure 1-17; Figure 
3-7). However, glutathione peroxidase, which mainly reduces lipid hydroperoxides 
and superoxide dismutase (cytosolic and mitochondrial forms), which catalyses the 
conversion of superoxide radicals into molecular oxygen or hydrogen peroxide, 
showed a distinctly different pattern (Figure 3-7), rising steadily in abundance 
towards maturity. The reasons as to why the predominant antioxidant enzyme 
should shift as a heart develops towards adult are unclear. As the heart develops 




There may also be alterations in mitochondrial function or oxidative capacity and this 
might be an interesting topic for further study which would account for these 
observations. 
 
3.7.5 Mitochondrial Dysfunction- related proteins vary with age 
The output from the pathway analysis in the main confirmed the patterns observed 
from more manual inspection of proteins of interest. The most significant deviation 
from this was in the observation of marked variation in the expression of many 
mitochondrial proteins, in the domains of energy production- mostly observed in 
Complex I and Complex IV, as well as in assemblies responsible for fission and fusion 
dynamics, and some mitochondrial antioxidant activity. The mitochondria are 
complex multifunctional structures whose regulation is still not well understood, so 
to conclude that these observations must be responsible for other physiological 
phenomena is overly reductive; however it does suggest areas for investigation.  
There are many marked areas of variation in the proteome as the heart develops 
towards its mature state. A full examination of each individual protein and signalling 
network as they change is beyond the scope of this work, but broadly surveying them 
does hint that the areas of Ca2+ homeostasis, signalling networks and mitochondrial 
biology play important roles in the physiological and pathophysiological features of 
ontology. The next chapter examines the differing response of the immature heart 
to ischaemia and reperfusion injury compared to the adult, and following chapters 
examine that response at the cardiomyocyte and mitochondrial level. The 
observations described here have suggested the mitochondria and the physiological 
role it plays in homeostasis and signalling may have bearing on the phenomena of 
I/R injury; subsequent chapters aim at exploring and delineating that relationship. 
 





4 The cardioprotective efficacy of cAMP signalling pathways in 




In Chapter 1, an effective intervention to protect the ex vivo perfused heart, from an 
injury due to global ischaemia and reperfusion, was described involving consecutive 
activation of PKA & PKC using isoprenaline and adenosine. However, it remains 
unclear as to whether this intervention can protect the immature heart.  
 
This question arises because unlike the adult heart, the vulnerability of postnatal 
hearts to I/R changes rapidly over a timescale of days during development. It is 
thought to follow a triphasic pattern in rats studied in fundamental science models, 
with those of a postnatal age of 1 day, and also in the period between 14-21 days, 
being most resistant to I/R injury (Riva and Hearse 1991, Ostadalova, Ostadal et al. 
1998, Modi and Suleiman 2004, Ostadal, Ostadalova et al. 2014).  
 
Clinical research has also recapitulated this pattern of developmentally-related 
differences in cardiac vulnerability to I/R in patients undergoing open heart surgery 
(Imura, Caputo et al. 2001, Modi, Imura et al. 2003). The underlying mechanisms in 
clinical practice or in the experimental models are not well understood, but they may 
include developmental changes in caloric intake & lean mass (Ost'adalova and 
Babicky 2012, Ostadal, Ostadalova et al. 2014) and in Ca2+ mobilization and ROS 
production. This metabolic link could also involve cAMP/PKA signaling pathway, 
which is important in the regulation of cardiac Ca2+ cycling.  
 
The mechanism by which this cardioprotective intervention through PKA & PKC is 
thought to occur is by pharmacologically mimicking the phenomenon of 
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temperature- preconditioning (Khaliulin, Parker et al. 2010). This depends upon 
activity of PKC for efficacy of the intervention (Khaliulin, Clarke et al. 2007).   
 
That this intervention using isoprenaline is cardioprotective means that it necessarily 
involves the activation of both protein kinase A, as was evident at the time of its 
discovery, but also EPAC; this was a much less well understood cAMP sensor whilst 
the initial studies on ischaemic and temperature preconditioning were undertaken. 
It is then unclear as to which of these targets are sufficient and necessary for the 
observed cardioprotective effect.  
 
In the physiological setting, β- AR activation should activate PKA and EPAC to a 
consistent degree based upon their respective responses to cAMP. Khaliulin & 
colleagues (Khaliulin, Bond et al. 2017) used cell permeable engineered cAMP 
analogues as molecular probes, capable of selectively activating PKA and EPAC. This 
method allows isolation of the physiological and pathophysiological roles of these 
effectors, and so an examination of the contributions of these pathways to 
protection from ischaemia & reperfusion injury.  
 
4.2 Aims 
Whilst the cardioprotective efficacy of adrenergic receptor stimulation as a means of 
modulating cardioprotection in the heart is well established in adult heart (Khaliulin, 
Parker et al. 2010), little is known about its efficacy in immature heart. However, as 
previously discussed (Chapter 1), the physiology of the immature heart at all levels, 
from gross structure and function through receptor pharmacology and calcium 
homeostasis differs enormously from the adult phenotype. There is therefore 
insufficient cause to a priori assume that effective interventions in the adult will 
necessarily operate identically in the immature heart.  
 
The proposed work in this chapter was designed to address the hypothesis that 
simultaneous PKA & Epac stimulation or consecutive Iso/Aden stimulation confer 
protection in immature as well as in adult heart. To tackle this hypothesis, the 
following aims were addressed: 
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1. to establish the physiological function of isoprenaline in the immature heart 
as compared to the adult. This was measured by assessment of contractile 
function in a Langendorff perfusion model in a constant pressure mode, 
which then further allowed surrogate assessment of coronary vascular 
resistance as a proxy of coronary flow rate with constant perfusion pressure. 
 
2. to assess if and to what extent consecutive perfusion with isoprenaline and 
adenosine is cardioprotective against a global ischaemic & reperfusion injury 
in the immature heart and to what extent.  
 
3. To move downstream from the β-adrenergic receptor and use synthetic cell 
permeable cAMP analogues to directly stimulate PKA and EPAC.  This will 
allow assessment of the protective effect in a similar model of global 
ischaemia and reperfusion used for the second aim, in both adult and 






Hearts, obtained from male Wistar rats, were perfused in the Langendorff mode as 
described in Chapter 2. Briefly, however, animals were killed by cervical dislocation 
after stunning by concussion. Hearts were then rapidly excised, immersed and rinsed 
in chilled buffer. The aorta was identified and secured onto a cannula through which 
warmed & oxygenated Krebs- Henseleit (KH) buffer was being pumped.  
 
In order for reasonable cross experimental comparison, exclusion criteria were used 
for all Langendorff experiments such that hearts were excluded if cannulation took 
more than two minutes to establishment of the equilibrium conditions, if regular 





4.3.1 Experimental Protocols 
The following protocols involving ex vivo heart perfusion were adopted: 
Protocol 1: The initial set examined the physiological effects of isoprenaline 
perfusion in adult and P14 hearts. Controls in this protocol were perfused in the same 
manner but with standard KH buffer instead of buffer with the addition of 
isoprenaline. 
 
Protocol 2: the second, using the same hearts that had been treated with 
isoprenaline- the cardioprotective benefits of isoprenaline and sequential adenosine 
perfusion with a comparison between the effects in adult and P14 hearts. For both 
Protocols 1 & 2, the intervention arm hearts- those receiving a drug treatment- had 
a 30 minute equilibration period, followed by 2 minutes perfusion with 5nM 
isoprenaline in KH buffer with 5 minutes perfusion with KH buffer and 300nM 
adenosine immediately following (Protocol 2 only). Similar to the control arm, they 
then had a 30 minute period of global ischaemia and a 120 minute period of 




Control experiments in this protocol used perfusion with standard KH buffer for 7 
minutes instead of 2 minutes isoprenaline and 5 minutes adenosine, followed by 30 
minutes global ischaemia induced by cessation of flow, followed by a 120 minute 
reperfusion period. These were performed by constant pressure perfusion, with an 
intraventricular balloon connected to a pressure transducer in order to provide 
continual measurements of left ventricular pressure. 
 
For these experiments, a second pressure transducer in line with the perfusion circuit 
was used to provide feedback control of the perfusion pressure. This was maintained 
at 60 mmHg in the immature group and 80 mmHg in the adult group. 
 
Throughout these protocols, functional measurements (LVDP & Flow Rate) were 
made continuously and for the purposes of analysis exported at 5 minute intervals. 
Coronary effluent was collected at the end of equilibration and at 5 minute intervals 
throughout the reperfusion period.   
 
 
Protocol 3:  examined the cardioprotective effects of perfusion with cAMP analogues 
in both adults and P14 hearts, in the same model of ischaemia & reperfusion injury 
as the first set. This protocol is also shown graphically in Figure 4-1.  
 
The control hearts in this group also had a 30 minute equilibration period, followed 
by a 30 min period of global ischaemia, and subsequently a 120 minute reperfusion 
period; intervention hearts were given a 5 minute period of perfusion with a cAMP 
analogue (8-Br/ 6-Bnz/ CPT), followed by a 5 minute washout period and then a 30 
minute period of ischaemia with a 120 minute period of reperfusion.  
 
These hearts were perfused at a set flow rate. Experience with the constant pressure 
group above was that that technique led to a high experimental failure rate due to 
variability in the resistance that could be generated to flow especially in the 
immature heart; in some circumstances it was difficult to generate sufficient pressure 
to meet criteria at a reasonable range of perfusate flow rates and so these 
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experiments were carried out with a more traditional constant flow arrangement. 
Therefore, the flow rates were set based on the resultant initial flow rate from the 
earlier constant pressure experiments, which produced results consistent with other 
published data; 10 ml/min for the adult hearts and 4 ml/min for the immature. 
Consequently, in this group LV and CP pressures were not measured, and the 
outcome measures were solely histological and biochemical.  
 
For all protocols, global ischaemia was produced by stopping the pump which 
delivered the perfusate. During this period, the hearts were immersed in KH buffer 
maintained a 37° C by a water jacket connected to the main reservoir and thermostat.  
 
 
Figure 4-1. Graphical representations of the experimental protocols used for ex vivo heart perfusion for Protocols 
1, 2 & 3showing the durations of each phase of the protocol and the drugs added to the perfusate at each 
stage.Numbers in each bar represent the duration of that stage, in minutes. Control refers to the controls used in 
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Experiments
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Washout Global Ischaemia Reperfusion
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4.3.2 Exclusion Criteria 
Hearts were rejected and not included in further analysis based upon the following 
exclusion criteria; these are essentially all surrogate markers for inadequate ex vivo 
perfusion of the heart.  
1. If the cannulation time (time from excision from the animal until flow 
restored ex vivo) was greater than 2 minutes. This represented an excessive 
as well as uncontrolled and non-analysed degree of ischaemic stress to a 
heart and so was presumed to render a result uninterpretable and certainly 
non-comparable to other hearts cannulated more rapidly.  
2. If the heart had multiple (3 or greater) attempts at cannulation. Multiple 
attempts at cannulation were associated with damage both to the aorta 
through vessel wall injury, as well as to structures such as the root & coronary 
vessels as well as the aortic valve. Such attempts were likely to fail later in the 
experimental protocol due to a failure of adequate perfusion and so were 
recognised and excluded early in each experimental run.  
3. If the insertion of the LV pressure balloon caused distortion which was 
impeding contraction by external inspection or if insertion caused damage. 
The insertion of the LV balloon is necessarily traumatic. However, occasionally 
the particular combination of balloon insertion and balloon pressure inside 
the LV cavity, as well torque from the catheter associated with the balloon 
caused a distortion to the anatomy of the heart being studied such that 
adequate perfusion and contractile function could not be obtained. In these 
cases, in experimental series requiring measurements of LV pressure, the 
heart was excluded.  
4.  If the heart rate did not stabilise at >200 beats per minute after the 30 minute 
equilibration period. Failure of normalisation of the heart rate may have a 
range of causes in the perfused heart- incorrect buffer, exclusion of a certain 
coronary artery from perfusion by occlusion/ aortic dissection/ embolization, 
complete failure of cannulation, aortic valve inadequacy; for instance. Failure 
of these issues to be simply corrected meant that the heart was not suitable 
to be included.   
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5. If more than one episode of ventricular arrhythmia was encountered during 
the stabilisation period. Physically evident or electrically detected ventricular 
dysrhythmia or arrhythmia following cannulation prior to experimental 
ischaemia was also felt to reflect a failure of the isolation process. Again, this 
had a variety of causes from incorrect electrolyte concentrations within the 
perfusate through to mechanical issues with cannulation and inadvertent 
aortic valve rupture leading to LV overload. However for all these processes 
the effect of episodes of ventricular fibrillation, for instance, would render 
the heart incomparable to hearts which had not suffered a similar injury and 
so these were excluded from further experimentation.  
 
A total of 19 hearts fell into these exclusion categories and were not included in the 
analysis. However, all hearts which had a successful run through their stabilisation 
period and started the experimental phases were included in subsequent analysis. 
The numbers of hearts analysed from each age group for these experiments are 
detailed in Table 4-1 for experimental protocols 1 & 2. Table 4-2 shows the numbers 
of hearts used for experiments in Protocol 3 and the associated controls, subdivided 
by the cAMP analogue used.  
Age Group Control Protocol 1 Protocol 2 
Adult 8 7 7 
P28 5  6 
P14 5 6 6 
Table 4-1 Numbers of hearts included in analysis of  ex vivo perfusion experiments for each age group studied vs 
experimental protocol as described in 4.3.1. Protocols 1 & 2 and associated controls only. P28 hearts used for non- 
functional experiments only.  
 
Age group Control 8-Br 6-Bnz CPT 
Adult 6 6 6 6 
P14 (30 min ischaemia) 6 6 6 6 
P14 (50 min ischaemia) 6 6 6 6 
Table 4-2 Numbers of hearts included in analysis of  ex vivo perfusion experiments for each age group studied in 





Measurements were made of coronary flow rate (CFR) at the set perfusion pressure 
(so coronary flow rate was a function of coronary vascular resistance), of heart rate 
derived from the LV pressure trace, and of the LV developed pressure. The rate- 
pressure product was then calculated as the arithmetic product of the developed 






4.4.1 The effect of isoprenaline on Cardiac Function in adult and developing heart 
4.4.1.1 The Effects on Coronary Flow Rate  
The CFR was significantly increased in both groups following administration of 5 nM 
isoprenaline (Figure 4-2). The adult group increased from an average value of 7.7 
ml/min to 11.7; the P14 group showed an increase from 3.4 ml/min to 4.8. Both 
increased around the same proportion; there was no significant (intergroup) 
difference in the percentage increase (151.9% vs baseline in the adult, 140.2% in the 
14- day old animals.  
 
Figure 4-2. The effect of isoprenaline upon coronary flow rate.  Left panel; Absolute coronary flow prior to and 
following addition of 5 nM isoprenaline to perfusate in P14 (n=6) and adult (n=7) male perfused Wistar rat hearts. 
Right panel; proportionate changes relative to control for each age group. Error bars represent 95% confidence 


































4.4.1.2 The effects on Developed Pressure  
Similar to the results for CFR, developed left ventricular pressure increased 
significantly in both the adult (mean from 51.2 mmHg to 87.2) and the 14- day old 
group (mean from 33.3 mmHg to 55.8) (Figure 4-3). There was no difference between 
the groups in the proportionate increase in developed pressure, however. The adult 









Figure 4-3.  The effect of isoprenaline upon developed pressure in the isolated perfused heart.  Left panel; Absolute 
pressure developed in the left ventricle prior to and following addition of 5 nM isoprenaline to perfusate in P14 
(n=6) and adult (n=7) male perfused Wistar rat hearts. Right panel; proportionate changes relative to control for 
each age group. Error bars represent 95% confidence interval. Asterisk- p< 0.05 vs pre- intervention result. 




4.4.1.3 The effects on Rate Pressure Product (RPP) 
The rate- pressure product is the arithmetic product of the developed pressure and 
the heart rate at that time point and is considered to be a surrogate marker of cardiac 
work. In both the P14 group and in the adults a significant rise in RPP was observed 
after treatment with isoprenaline (208.2 % from 9591 mmHg min-1 to 19,970 in 
neonates, 160.8% from 14,793 mmHg min-1 to 23,790 in adults, Figure 4-4). However, 
a significant intergroup difference was also observed in the response to isoprenaline. 
Whilst the RPP in both groups increased markedly and significantly after exposure to 
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Figure 4-4.The effect on Rate- Pressure product of isoprenaline. Left panel; Absolute rate- pressure product 
measured in the left ventricle prior to and following addition of 5 nM isoprenaline to perfusate in P14 (n=6) and 
adult (n=7) male perfused Wistar rat hearts. Right panel; proportionate changes relative to control for each age 
group. Error bars represent 95% confidence interval. Asterisk- p< 0.05 vs pre- intervention result. Significance 





4.4.2 The cardioprotective efficacy of Iso/Aden treatement in Developing & Adult 
Hearts  
As the hearts used in this work were the same as those in section 4.4.1 for Protocol 
1, the numbers used for each protocol and age group as well as the success rates are 
the same. That is- 37 hearts were perfused and had a technically successful run 
through the experimental or control protocol, with 19 others excluded by the 
experimental criteria. Of those included, 15 were of the adult age group (7 
experimental, 8 control), and 11 14- day old (6 experimental, 5 control). An additional 
group of 11 28 day- old (6 experimental & 5 control) was added post hoc as an 
additional comparator which was only assessed for LDH release and infarct size. The 
criteria for inclusion or exclusion remained the same as in section 4.4.1. A typical 





Figure 4-5 Representative LV pressure- time trace from adult heart perfused 
with Isoprenaline then Adenosine. Y- axis; LV pressure/mmHg; X-axis; 
time/min.Letters represent differing experimental conditions. A- Equilibration; 
B- Isoprenaline perfusion; C-Adenosine Perfusion 
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4.4.2.1 Functional Recovery  
The summary of recovery at the end of the experimental protocols is shown in Figure 
4-7, whilst Figure 4-6 shows the recovery vs time after reperfusion for both age 
groups and experimental groups. There was no significant difference between 
control and intervention arms in the 14- day old hearts, but there was a significant 
difference between the two arms in the adult group either expressed as a 
comparison between control and intervention group RPPs at the end of the 










Figure 4-6 Mean LV Developed pressure vs. Time after reperfusion for adult and immature (P14) hearts given 
isoprenaline/adenosine treatment or control. Error bars represent Mean ±SE. Adult group n= 7 intervention, n= 8 





4.4.2.2 Effect on LDH Activity in effluent  
For LDH activity (Figure 4-8, Figure 4-9, Figure 4-10), all age groups showed a 
reduction in LDH released into coronary effluent between the control and 
intervention arms which appeared to be significant. In the adult group, this release 
of LDH seemed to go on beyond the period over which fractions were collected but 
in the 14- and 28- day old groups the activity fell towards the end of the collection 
period. For the adult, the maximum difference occurred at 25 minutes following 
reperfusion where the mean difference was 55.5 mU/ml vs 102.7 showing that the 
release of LDH in hearts exposed to I/A protocol was 54% of that in the controls. For 
the 14- day old hearts, the peak difference occurred at 20 minutes following 
reperfusion, with a mean LDH activity of 44.6 mU/ml for the I/A group compared to 
117.3 in the control group, so the LDH release in the treatment group for 14- day olds 
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Figure 4-7 Proportionate haemodynamic outcomes for adult (n=7 iso/aden, n= 8 control) and immature (P14, n=6 
iso/aden n=5 control) hearts following recovery from ischaemia/ reperfusion injury comparing control to those 
treated with isoprenaline/ adenosine. Plotted as proportion (Mean ±SE) of developed pressure from equilibration 
period attained at 30 minutes and 2 hours of reperfusion.Control = no intervention, Iso/ Aden= consecutive 




occurred at 15 minutes into reperfusion where the control group had an LDH activity 
of 86.5 mU/ml whereas the interventions had 39.2 mU/ml/, 45.3% of the untreated. 
However, for this group, by the end of the coronary effluent collection period, there 
was no discernible difference in LDH activity unlike in the adult and 14- day groups. 
 
Figure 4-8. LDH activity in coronary effluent vs time after start of reperfusion for intervention (isoprenaline & 
adenosine treatment) and control experiments for 14 day old hearts exposed to 30 min global ischaemia. Time= 
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Figure 4-9. LDH activity in coronary effluent vs time after start of reperfusion for intervention (isoprenaline & 
adenosine treatment) and control experiments for 28 day old hearts exposed to 30 min global ischaemia.Time= 
0 is from a pre-ischaemia fraction. Error bars represent Mean ±SE (n=6 intervention, 5 control). 
 
Figure 4-10. LDH activity in coronary effluent vs time after start of reperfusion for intervention (isoprenaline & 
adenosine treatment) and control experiments for adult hearts exposed to 30 min global ischaemia.Time= 0 is 
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4.4.2.3 Effect on Infarct Size 
 
 
Figure 4-11. The effect of isoprenaline/ adenosine perfusion upon infarct size following ischaemia/ reperfusion 
injury. Infarct size expressed as cross sectional area proportionate infarct. Intervention here means consecutive 
isoprenaline/ adenosine treatment. Error bars represent Mean ±SE; *= p< 0.05 vs same aged control tested by 
Student’s T-test. Group sizes- adult n= 7 intervention, 8 control, P28 n=6 intervention, 5 control, P14 n=6 
intervention, 5 control.  
 
There were also significant differences in the area of myocardial tissue infarcted after 
exposure to the two protocols (Figure 4-11). In the adult, the difference was 
significant (p< 0.05) with an infarcted area of 56.1% for the controls vs 29.9% in 
intervention group. For the other two groups, the results showed a similar trend but 
did not reach statistical significance in either the 28- day old group (44.1% vs 38.5%) 
or the 14- day old group (32.0% vs 24.2%). The intra- group control comparison does 
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4.4.3 Cardioprotective effects of cAMP analogues  
For the set of experiments used for assessment of the effect of perfusion with cAMP 
analogues (Protocol 3), 6 hearts per drug per age group were included. That is 6 
adults and 6 14 day old rat pups for each experiment with 8-Br, 6-Bnz, and CPT, with 
a further 6 in each of those age groups for controls. Post- hoc, another group of P14 
experiments were carried out with a longer ischaemic duration of 50 minutes in order 
that the magnitude of infarct in the control matched that of the adult controls, to 
increase the magnitude of injury to the heart and enable cross age group comparison 
of the effect of the drugs independent of the magnitude of injury.  
 
For these experiments, an intraventricular balloon was not used due to the 
experience of the variation and excess failure its use had caused in the isoprenaline 
± adenosine experiments. Further, creatine kinase (CK) activity was measured instead 
of lactate dehydrogenase (LDH) due to differing availability of reagents when these 
experiments were carried out. 
 
4.4.3.1 The effects on CK Activity in the effluent 
Figure 4-12, Figure 4-13 and Figure 4-14 show the activity of creatine kinase in the 
coronary effluent taken at 5 minutes intervals from adult and P14 hearts, perfused 
with cAMP analogues prior to ischaemia, normalised to the coronary flow rates used 
in those experiments. Figure 4-15 shows an estimate of the area under each of the 
activity-time curve as a collective measure of CK release in the period following 
reperfusion. 
 
The adult hearts, Figure 4-12, show that CK release occurs rapidly in the control 
group, peaking in the 5- minute fraction. This is in contrast to the activity from those 
hearts perfused with either 8-Br, 6-Bnz or CPT prior to ischaemia. All of those groups 
had a delayed peak, and a reduced total release vs. control. CPT and 6-Bnz had an 
indistinguishable effect from one another, but 8-Br produced the greatest reduction 






Figure 4-12 Activity of creatine kinase in coronary effluent from adult hearts in prior to (t=0) and following 
reperfusion after 30 minutes of global ischaemia measured at 5 minute intervals with preceding perfusion with 
cAMP analogues vs control. Normalised to coronary flow rate. Error bars represent Mean ±SE; n=6 per group. 
 
 
The data for P14 hearts exposed to 30 minutes of global ischaemia is shown in Figure 
4-13. In these hearts, the control group demonstrated a peak activity level of 58.6% 
that of the adult; this peak was arrived at significantly later than in the adult, in the 
15 minute fraction rather than in the 5 minute sample. In this group, however, none 
of the cAMP analogues significantly reduced the overall CK activity in the period 
studied. The ratio of areas under the activity-time curve for the control in this group 
vs. that in the adult was 57.1%; so the degree of injury sustained as measured by the 
CK release was significantly lower. 
 
However, for the group of P14 hearts exposed to 50 minutes global ischaemia, Figure 
4-14, this ratio was 97.06%; so the longer period of ischaemia resulted in a more 
directly comparable degree of injury. In this group, there was a marked reduction in 





















Time Post Reperfusion/ minutes
CK Release vs. Time After Reperfusion; Adult Hearts
Control 8Br 6Bnz CPT
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a reduction in AUC was seen with both CPT and 6-Bnz as well. This was statistically 




Figure 4-13 Activity of creatine kinase in coronary effluent from 14- day old hearts in prior to (t=0) and following 
reperfusion after 30 minutes of global ischaemia measured at 5 minute intervals with preceding perfusion with 




















Time Post Reperfusion/ minutes
Effect of cAMP analougues on CK Release from 14-day hearts 
during reperfusion after 30 min ischaemia
Control 8Br 6Bnz CPT
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Figure 4-14 Activity of creatine kinase in coronary effluent from 14- day old hearts in prior to (t=0) and following 
reperfusion after 50 minutes of global ischaemia measured at 5 minute intervals with preceding perfusion with 
cAMP analogues vs control. Normalised to coronary flow rate. Error bars represent Mean ±SE; n=6 per group. 
 
Figure 4-15 Total CK activity in coronary effluent following reperfusion in hearts exposed to ischaemia/ reperfusion 
injury with or without perfusion with a cAMP analogue. The P14 hearts were divided into a 30- minute and a 50 
minute ischaemia group. N=6 per analogue per age group. Total activity taken as estimated area under activity-
time curves summed by trapezoidal addition of mean values for each time point. Bars represent mean AUC ± SE; 
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Effect of cAMP analogues on CK Release from 14 day hearts 
during reperfusion after 50 min ischaemia
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4.4.3.2 The effect of cAMP analogues on Infarction size 
The resulting infarct sizes for all the hearts treated with cAMP analogues, Protocol 3, 
are shown in Figure 4-16. In adult hearts, a 30- minute ischaemic injury in the control 
group produced a mean infarct area of 56.8%. This is consistent with the degree of 
injury sustained in adult hearts in the earlier (4.4.2.3) experiments performed with 
constant pressure perfusion.  
 
For the drug treated hearts, perfusion with 8-Br, the non-selective cAMP analogue, 
produced a marked and significant reduction of the area infarcted, to a mean of 
24.8% representing an infarct 43.7% the size in the control group.  Neither perfusion 
with 6-Bnz to stimulate PKA, nor CPT to increase EPAC activity were associated with 
























Infarct Size vs. Age Group & Drug Treatment
Control 8-Br 6-Bnz CPT
Figure 4-16 The effect of cAMP analogue perfusion upon infarct size following ischaemia/ reperfusion injury. 
Infarct size expressed as cross sectional area proportionate infarct. Mean ±SE; *= p<0.05 vs. same age group 
control by Student’s T-test. The P14 hearts were divided into a 30- minute and a 50 minute ischaemia group. N=6 
per analogue per age group. 
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The group of P14 hearts subjected to an ischaemic injury of 30 minutes in length, 
showed an average infarct size of 34.75%. None of the cAMP analogues in this group 
produced a statistically significant reduction in the area infarcted.  
 
However, when the ischaemic time was increased to 50 minutes, the infarcted area 
increased to 55.6%, comparable to the adult hearts given a 30 minute cessation of 
perfusion. In this group, addition of 8-Br prior to ischaemia did produce a reduction 
in the infarct size- to 26.4%, a significant difference. Again, perfusion with 6-Bnz or 
CPT did not meaningfully reduce the infarct size; so in no group was perfusion with a 





The key findings from this work are that firstly isoprenaline is at least as effective 
inotrope in the immature heart as in the adult. It increases developed pressure and 
coronary flow to the same degree as in the adult heart, whilst rate-pressure product 
increases to an even greater extent. Secondly, it has been shown that sequential 
perfusion with isoprenaline & adenosine is an effective cardioprotective intervention 
in the adult, but not in the immature heart. Finally, stimulation of the β adrenergic 
signalling pathways (cAMP/PKA/Epac) seems to produce cardioprotection in the 
adult and immature heart. 
 
 
4.5.1 Isoprenaline -induced inotropic effect is more marked in immature compared 
to adult heart. 
The perfusion data presented here demonstrates, broadly, the expected 
physiological response of stimulation of the β-AR by isoprenaline. Developed 
pressure and coronary flow rates both significantly increased after addition of 
isoprenaline, as did the rate- pressure product.  
 
Isoprenaline is an agonist at the β-AR with no selectivity between the β1, β2, or β3 
isoforms of the receptor (Ahlquist 1976). Therefore, it would be expected to have 
predominantly β1 mediated actions upon the heart, which canonically lead to G-
protein mediated activation of adenylate cyclase and raised intracellular cAMP levels. 
This in turn leads phosphorylation of components of the E-C coupling machinery 
including Ca2+-cycling proteins and Troponin I and thus enhancing the overall 
contraction-relaxation cycle of the heart. The resultant increase in intracellular Ca2+ 
increases the force of contraction and also stimulates energy production by 
activating mitochondrial dehydrogenases (Halestrap & Denton 1980). 
 
There is a significant increase in developed pressure in both the 14- day and adult 
groups, consistent with the expected cardiac response to β-AR stimulation. For the 
14- day old group, there was a 67% increase vs a 70% increase in the adult- an 
insignificant difference within the accuracy of the measurement techniques used. 
162 
 
This confirms that isoprenaline is functioning as a positive inotrope at the cardiac 
adrenoreceptors in both age groups. 
 
The results for RPP are at first glance fairly similar. However, there is a marked 
difference in the proportionate response to isoprenaline, in contrast to that for DP. 
The RPP for 14-day old animals increased 79% more than it did in the adults. This 
variation implies profound differences in the response to elevation in cAMP in the 
adult compared to the neonate- the HR elevation in response to isoprenaline was on 
average 35.7% greater in the neonate than in the adult. Typically, the neonate will 
increase cardiac output through increases in HR due to a multifactorial limitation in 
increasing contractility –so the observation here that, albeit in a non- physiological 
model- potent stimulation of PKA and Epac simultaneously can achieve a significantly 
higher increase in cardiac work in the neonate compared to the adult is striking. 
However, these observations occur at differing sites; an effect upon developed 
pressure occurs directly at the ventricular cardiomyocyte, whereas an organised 
increase in heart rate would be driven by effects at the sinoatrial node.  
 
In the controlled pressure Langendorff system, there is a constant and steady flow of 
coronary perfusate. This allows a simple model to be conceived of for coronary flow 
rates; the coronary perfusion pressure (CPP- the set pressure in the perfusion 
system) should be proportional to the product of the coronary flow rate and the 
coronary vascular resistance (CVR). Or, the coronary flow rate is proportional to 
CPP/CVR. If the CPP is externally controlled, then the only influence on the varying 
CFR is the coronary vascular resistance. 
 
There are two main possibilities to account for the observations regarding coronary 
blood flow. The most likely explanation is that isoprenaline, as a potent agonist at 
cardiac β adrenoreceptors, directly causes potent vasodilatation and thus an increase 
in CFR in the context of a constant CPP. 
 
Another possibility is intrinsic alteration of the CVR. Under normal physiological 
conditions, the coronary vascular resistance is autoregulated; this is under local 
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control (from a variety of factors including hypoperfusion and wall shear stress) with 
wider autonomic influence also contributing. In the Langendorff system the extra 
cardiac influences are removed but it is possible that the intrinsic mechanisms of 
autoregulation remain intact. However, in human models of autoregulation, 
traumatic and surgical injury to an organ can attenuate or abolish the effect. It cannot 
be excluded that in the context on increasing cardiac work through the use of a 
potent positive inotrope such as isoprenaline that local hypoperfusion contributes to 
vasodilation rather it being solely a direct pharmacological effect. 
 
4.5.2 Functional effects of isoprenaline & adenosine perfusion 
These experiments showed a significant protective effect for consecutive 
administration of isoprenaline and adenosine across in adults. This reaffirms the 
previous observation (Khaliulin, Parker et al. 2010) that this provides a 
cardioprotective intervention in the well- studied adult heart. Thus, it reaffirms that 
cAMP modulation can precondition the heart against ischaemic insults. This 
intervention, however, is dependent upon an unselective PKA/ Epac agonist in 
isoprenaline. It is not clear to what extent each of the parallel signalling pathways 
that extends from PKA & Epac is responsible for the observed preconditioning, nor 
whether this changes in the differently aged groups which were studied. Others have 
reported that in Langendorff systems at least, Epac stimulation in adult rat hearts 
does not produce preconditioning or cardioprotection (Duquesnes, Derangeon et al. 
2010). 
 
It is interesting that despite signs of biochemical and histological protection (4.5.3.1, 
4.5.3.2) that no functional benefit was observed in the 14- day old group, and only a 
trend to significance with a large degree of variability in the 28- day old group. These 
contradictory findings may represent an increased propensity for the phenomenon 
of ‘myocardial stunning’ following ischaemia in the developing age groups, or it may 




4.5.3 Protective effects of Consecutive PKA & PKC activation 
4.5.3.1 Biochemical Markers of Injury 
All three experimental age groups showed a reduction in LDH release and activity, as 
a measure of injury, in their intervention arms compared to control. This was 
significant at almost all time points. Comparing age groups shows that peak injury 
occurs a little later- at 10 minutes rather than 5 minutes- in the 14- day old age group 
compared to the 28- day or adult. The youngest group also demonstrates slightly less 
LDH release into the coronary effluent than in the adult. That said, differences in the 
heart weight were not explicitly controlled for; rather the differential coronary flow 
rate provided by the constant pressure control perfusion method was relied upon in 
order to normalise perfusate flow. However, in each of these groups the intervention 
arm had significantly less LDH release than control, so on an intra- group comparison 
basis it seems reasonable to conclude that the intervention was protective. This is 
confirmed with the histological data showing a reduction in infarct size in each group 
vs. control. 
 
4.5.3.2 Histological Parameters  
Measurement of infarct size by TTC staining demonstrated a significant reduction in 
infarct area in all three groups. Considering just the control arms, the pattern of 
vulnerability observed in Figure 1-17 seems to be maintained; the adult is the most 
vulnerable to ischaemia and reperfusion injury, with the 14- day old relatively 
resistant (32% infarction in the neonate compared to 56.2% in the adult). This 
matches previous experience in our group, showing a bell-shaped distribution to 
ischaemic vulnerability. However, others (Ostadalova, Ostadal et al. 1998) have 
shown a bimodal distribution, with an earlier (prior to the 7th post- natal day) peak in 
resistance as well as that found around the 14th day post- natal.  
 
The adult group showed a significant protective effect from the isoprenaline and 
adenosine treatment with an infarct size in the intervention arm 53.3% of that in the 
controls; although the other two groups showed some relative benefit, it was both 




Thus on a number of measures this treatment of consecutive activation of PKA and 
PKC by isoprenaline and adenosine perfusion seems to be markedly cardioprotective 
in the adult male Wistar rat. However, this protective effect, although there were 
hints that it may be present in the neonatal groups, was not so marked and so did 
not reach significance on any measure other than LDH release. This may reflect the 
fact that these groups, were more resistant at baseline to the ischaemic stimulus, 
and so a protective effect would be somewhat masked by this innate resistance.  It 
may be that if the length of time the global ischaemia had been applied for had been 
extended from 30 minutes in the neonatal groups to produce an identical degree of 
ischaemic damage as the adult in the existing protocol that a more marked protective 
effect may have been seen.  
 
There are known to be significant metabolic differences between adult and immature 
heart which may be relevant. Previous work in our group has established significant 
variation in glycogen content; Figure 4-17 from (Lewis, Szobi et al. 2018). 
 
4.5.3.3 Glycogen levels correlate with vulnerability   
Unlike adult hearts, the immature heart has a lower level of glycogen content which 
is depleted relatively quickly during index ischemia. Thus, it is likely that 
isoprenaline/adenosine pre-treatment, by depleting the relatively lower levels of 
glycogen at an early stage during index ischemia, blunted any expected potential 
benefits from this intervention, probably due to a significant dysfunction of ATP-
dependent ion channels (Kalogeris, Baines et al. 2012). Although the role of HKII 
association and dissociation to mitochondria and the link to glycogen content has 





Figure 4-17 Glycogen levels in hearts during development. Data analysed by 1-way ANOVA with Fisher’s PLSD as 
a post-hoc test of significance. *=p<0.01 vs. both 2 days of age and 7 days of age. †= p<0.001 vs adult hearts. Data 
points represent mean ± standard error. From (Lewis, Szobi et al. 2018).  
 
Cardiac protection through temperature preconditioning has been well described, 
and shown to be necessarily dependent upon PKA and PKCε signalling for effective 
transduction of the  
protective effect which involves inhibition of mitochondrial permeability transition 
pore (MPTP) opening on reperfusion. (Khaliulin, Clarke et al. 2007, Khaliulin, Parker 
et al. 2010).  
 
Adenosine causes association of PKC, HSP 90 and a mitochondrial import complex 
TOM70 ultimately resulting in import of PKCε to the mitochondrion, and 
pharmacological inhibition of this translocation abolishes the cardioprotective action 
of PKCε (Yang, Sun et al. 2012). The ultimate mitochondrial targets of PKCε are 
unclear, although some have suggested interactions with the MPTP (Baines, Song et 
al. 2003, Budas and Mochly-Rosen 2007). The pore is more likely to open in ischaemic 
conditions- that is, high intracellular calcium, acidosis, and depletion of ATP, and 
opening of the pore in the context of ischaemia is associated with the onset of 















































c (subunit IV in particular) and the ATP sensitive mitochondrial K+ channel. Thus these 
targets give plausible mechanisms to account for the role of adenosine linked PKC in 
cardioprotection from ischaemia and reperfusion injury.  
 
Isoprenaline acting via β-AR results in an increase in intracellular cAMP, leading to 
activation of PKA & Epac with downstream signal transduction. Ischaemic and other 
forms of preconditioning have for some time been known to attenuate cAMP levels 
during a sustained ischaemic injury (Lochner, Genade et al. 1999), with an increased 
cAMP level during an insult following a preconditioning stimulus being associated 
with a protective effect. This effect is observed not only with β-AR stimulation via 
isoprenaline but also using other means of modulating cAMP levels- via cAMP 
modulators, phosphodiesterase inhibitors, or direct activation of adenylate cyclase 
(Sanada, Asanuma et al. 2004).  
 
There are multiple intracellular events that follow from a rise in cAMP levels within 
the cardiomyocyte; PKA and Epac act as sensors for the cAMP levels and so the 
cardioprotective effect of this rise must be mediated by their downstream targets. 
These targets are known to include a number of proteins involved in calcium 
homeostasis and excitation- contraction coupling, including phospholamban, the 
ryanodine receptor, and, via Epac induced Phospholipase C activity, PKCε. Thus, there 
is the possibility for cross- talk between stimuli causing increased cAMP activity via a 
β-AR, and, through Epac activity, cardioprotective mitochondrial PKCε activity.  
 
That the cardioprotective effect is synergistic between these two pathways, with PKC 
and PKA/Epac as their primary effectors, acting in parallel suggests that it is the 
downstream targets that are significant for cardioprotection rather than any 
intermediary acting in common for both pathways. So the next set of experiments, 
involving the study of cAMP analogues stimulating PKA or Epac or both are important 




4.5.4 The cardioprotective effects of PKA & Epac activation in whole heart perfusion 
4.5.4.1 Direct and indirect activation of PKA & EPAC & cardiac function 
In this study, I have not shown evidence of the functional effects of PKA and EPAC 
stimulation using the described cAMP analogues on intact perfused heart. These 
experiments were omitted because of the difficulty in reliably obtaining pressure- 
time traces from the immature perfused heart. Their effects upon the contractility of 
individual isolated cardiomyocytes are discussed in Chapter 6. 
 
However, as discussed in Section 4.5.2, the functional effects may be important 
mechanistically through depletion of metabolic substrates including glycogen. It is 
therefore important to know to what extent perfusion with the cAMP analogues used 
in these experiments replicates the inotropic and chronotropic effects of isoprenaline 
perfusion when considering their cardioprotective properties. This has been 
demonstrated by others, at least in the adult heart. Khaliulin & colleagues, (Khaliulin, 
Bond et al. 2017) in our group performed a similar set of experiments, on perfused 
adult rat heart, using the same agents at the same concentrations. They show a 2.5 
fold increase in RPP after perfusion with 5 µM 8-Br, for 5 minutes followed by a 
washout period where the RPP returns to baseline. This is broadly similar in 
magnitude to that shown in these experiments for the effects of isoprenaline in 
Figure 4-4. They further show that using the selective agonists 6-Bnz and CPT for 
activity at PKA and EPAC respectively, each agent individually does not produce an 
equivalent result. Only when administered in combination does the cardiac work 
increase to the same level as that seen with 8-Br, and isoprenaline in the results 
presented here. Given that the functional effects of isoprenaline on the immature 
heart are similar to those in the adult, it is reasonable to expect that the cAMP 





4.5.4.2 Combined stimulation of PKA & Epac provides maximal protection against 
injury in the adult heart 
The experiments described here show that PKA and Epac stimulation produces 
cardioprotection in the ex vivo perfused adult rat heart. Consistent with previous 
findings, (Khaliulin, Bond et al. 2017) simultaneous stimulation of both parallel 
signalling pathways appears to be necessary for maximal cardioprotection in this 
model of ischaemia & reperfusion injury; stimulation of either PKA or EPAC alone 
does not produce the same effect as with both; an intermediate response is seen.  
 
Section 4.4.2 showed that β- adrenoreceptor stimulation was in part responsible for 
a cardioprotective effect following a short period of activation. However, it is known 
from long clinical experience and multiple studies that sustained activity at this 
receptor family does produce deleterious consequences for the heart at both the 
subcellular and whole organ level, including mitochondrial dysfunction, hypertrophy, 
heart failure, and death (Dorn, Tepe et al. 2000, Appukuttan, Kasseckert et al. 2012, 
Rau, Wang et al. 2015). The potential for these untoward consequences of chronic 
receptor stimulation, as well as the unintended off-site consequences in the whole 
organism of receptor activation, mean that it is important that this work confirms 
prior findings of a receptor independent pathway to cAMP linked cardioprotection.  
 
In order to explain why both PKA and Epac must be stimulated in order to observe 
this effect, the most obvious explanation may be that they have differing 
downstream effectors of this cardioprotection and so exhibit synergism. 
 
Activity of PKA following stimulation with isoprenaline is known to be associated with 
glycogen depletion (Khaliulin, Parker et al. 2010); this secondarily leads to elevations 
of lactate as well as hydrogen ions, leading to increases also in sodium and calcium 
levels (Cross, Opie et al. 1996). Further others have described this depletion of 
glycogen, by these mechanisms or unknown others, to disassociation of 
mitochondrial hexokinase II. This enzyme appears to be an integral part of the MPTP 
apparatus (Pasdois, Parker et al. 2012) and so loss of this component leads to 
inhibition of the MPTP. Thus by this means PKA activity leads to cardioprotection; 
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however, other authors have linked alternative signalling pathways through PKA to 
cardioprotection; significantly phosphorylation of GSK-3β (Juhaszova, Zorov et al. 
2004, Gomez, Paillard et al. 2008), but also others less directly connected to the 
MPTP such as IKK/IκB and phosphodiesterases (Omori and Kotera 2007, Zhang, Wang 
et al. 2013).  
 
The reasons and mechanisms by which Epac may have a cardioprotective effect, or 
may potentiate the effect due to the activity of PKA are less clear. Others have not 
found that CPT stimulation in similar models produces an isolated protective effect 
(Duquesnes, Derangeon et al. 2010, Khaliulin, Bond et al. 2017). It has been 
speculated that activation of PKCε, shown to be necessary for cardioprotection in 
Section 4.4.2 and known to be activated in Temperature Preconditioning as the 
archetype for this phenomenon, is a downstream consequence of Epac activity.  
 
4.5.4.3 The immature perfused heart shows increased resistance to injury 
These results in the immature heart also show the increased resistance of the 
developing heart to ischaemia & reperfusion injury. The developing heart does not 
display the same injury as that of the adult from a time- matched 
ischaemia/reperfusion injury; the duration of ischaemia needed to be extended from 
30 to 50 minutes to obtain an injury which was comparable to that shown by the 
adult heart after a 30 minute ischaemic stimulus. This is consistent with previous 
work showing a significant resistance to injury at this developmental stage, with an 
increase towards adulthood.  
 
4.5.4.4 Immature heart is protected against injury by a combination of PKA & Epac 
stimulation 
Once the injury was significant enough that a hypothetical cardioprotective effect 
could be observed, a significant reduction in infarct size and in biochemical markers 
of injury was seen with 8-Br perfusion. This effect was only convincingly seen with 8-
Br; 6-Bnz did seem to produce a reduction in CK activity relative to control, but this 
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effect was not matched with the change in infarct size; whilst CPT seemed to have 
no significant effect. 
 
Thus, it seems as though in the immature heart activity of both PKA and EPAC is 
necessary for a protective effect just as in the adult. PKA activity alone has a small 
protective effect, and EPAC activity alone does not seem to produce protection. Only 
by simultaneous activation does the maximal protective effect become apparent,  
implying a synergistic mechanism of action.   
 
4.6 Summary  
This chapter has examined physiological and pharmacological differences between 
the immature and adult whole perfused heart. It has been shown that the 
physiological responses to signalling at the β- adrenergic receptor are similar 
between the two age groups. 
 
However, moving to the pathological situation of simulated ischaemia and 
reperfusion injury, the experiments described here show that the immature heart is 
indeed more resistant to injury than the adult. Whilst previously described 
cardioprotective interventions were shown to be ineffective in the immature heart, 
this may be because of the intrinsically elevated resistance to injury either acting via 
the same mechanism as the putative cardioprotective intervention or because the 
injury becomes too small to detect a benefit.  
 
Further, in the adult heart it was shown that inducing activity downstream from the 
β-AR was also sufficient to produce cardioprotection, although this required 
simultaneous activation of PKA and EPAC; either on their own was not adequate. A 
temporally equivalent injury in the 14-day old heart did not show this effect; however 
when the duration of ischaemic injury was extended to 50 minutes from 30 minutes 





A key question that arises from these observations then is what makes the immature 
heart have an intrinsic protection against I/R injury. Further, since the adult heart 
shows a cardioprotective effect resulting from activity throughout the β receptor 
signalling axis, does that cardioprotective effect stem from differences in expression 
through that pathway.  
 
Chapter 4 examines the proteome of the immature and adult heart and attempts to 
explain these observations with reference to the abundance of some of these key 
intermediaries. Chapters 5 and 6, examining isolated cardiomyocytes and 
mitochondria respectively, examine the differences at the cellular and organelle level 











5 The effect of cAMP analogues on freshly isolated quiescent 
cardiomyocytes exposed to simulated I/R in suspension  
5.1 Introduction 
In Chapter 3 it was shown that transient activation of β-AR receptor of the whole 
perfused heart is cardioprotective. The cardioprotection is also seen when directly 
activating the cAMP/PKA/Epac signalling pathways without directly activating the β-
AR receptor in both adult and immature heart. This was done using cAMP analogues 
which are permeable and can directly activate PKA or Epac or both. Further, one of 
the underlying hypotheses of this thesis is that protection from I/R injury is due to 
inducing desensitisation of the MPTP in cardiomyocytes in response to elevated Ca2+. 
However, in addition to cardiomyocytes, the cardiac tissues also contain other 
structures including the vasculature which can also influence vulnerability to I/R.  It 
is important therefore to show that the protection from injury results from an 
intracellular process within the cardiomyocyte, rather than any other cell type in the 
heart. 
 
5.1.1 The Use of Cardiomyocytes as an Experimental Model  
To establish whether the cardioprotective effects of the cAMP analogues in whole 
hearts are due to direct action on the cardiomyocytes and to other cell types, it is 
then necessary to study their cardioprotective effects using isolated cardiomyocytes. 
Although Langendorff perfused heart has been used for over 100 years, success at 
isolating cardiomyocytes using enzymatic digestion was only achieved in the late 
1970s.  Whilst there are advantages and disadvantages to using the ex vivo perfused 
heart as an experimental model, the same can be said of the isolated cardiomyocytes. 






Method Advantage Disadvantage 
Langendorff 
Perfused Heart 
• Technically Straightforward 
• Physiologically relevant 
measures of function 




• Good for histological and 
molecular studies 
 
• Loss of neurohumoral regulation 
• Absence of physiological response 
to preload & afterload 
• Time limited preparation- function 
changes with time 
• Mostly uses Non-physiological 
metabolic substrates (e.g. 
glucose) 
• Measurement of function with LV 
balloon is invasive (esp. in 
immature) 
• Endpoints cannot be extrapolated 
to cell levels due to heterogeneity 
(SAN, atrial, ventricular cells and 
other cell types) 
Freshly Isolated 
Cardiomyocyte 
• Allows measurement of 
intracellular changes not 
accessible in whole heart (e.g. 
channel activities & E-C 
coupling) 
• Direct assessment of effects 
on individual cells 
• Allows culture of 
cardiomyocytes for less 
temporally limited 
experimentation 
• Significant injury incurred in 
isolation process 
• Selection bias- only stronger cells 
survive isolation 
• Can be technically challenging 
with high failure & spontaneous 
death rate 
• They are unloaded 
• Ca2+ tolerant 
• Quiescent  
• Characteristics change in culture 
Table 5-1 Comparative advantages and disadvantages of perfused heart and isolated cardiomyocyte as a model 
of ischaemia & reperfusion injury. 
Freshly isolated cardiomyocytes are the gold standard for electrophysiological 
studies including patch clamping and whole cell studies. Although isolated 
cardiomyocytes are sometimes maintained for several days in culture, it has been 
shown that such cells do show morphological and electrophysiological changes (see 
Mitcheson (Mitcheson, Hancox et al. 1998). Freshly isolated neonatal myocytes can 
be cultured are good for investigating characteristics of differentiating neonatal cells. 
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Freshly isolated myocytes can also be cultured and kept for more than one day but 
they do undergo electrophysiological and morphological changes. 
Considering cell culture as a means of studying the cardiomyocyte, there are some 
advantages. Clonal expansion of the population allows a relatively homogenous 
group of cells to study. Further, the separation of an experiment from the process of 
obtaining the cardiomyocyte allows for a recovery from damage sustained during 
isolation (Borg and Terracio 1990). Cells in culture may also be studied over the 
longer time scales than are possible just examining the freshly isolated 
cardiomyocyte for instance for genetic, hormonal, or environmental manipulation. 
Also, for repeated observation, a cell should be stationary and the location marked. 
This is much more straightforward in a cell culture setup (Diaz and Wilson 2006). 
However, these advantages are not pertinent to the questions posited here. There 
are significant disadvantages, also. Marked morphological and ultrastructural 
changes have been noted in cardiomyocytes in cell culture (Decker, Simpson et al. 
1990, Decker, Behnke-Barclay et al. 1991) which may markedly alter their electrical 
and contractile properties. They therefore cannot be used for electrophysiological 
studies, nor for assessment of contraction.  
These issues are avoided through the use of freshly isolated cardiomyocytes, which 
allow for real time visualisation of at least some aspects of excitation contraction 
coupling, and ready changes to the extracellular environ in order to alter the ionic 
gradients or add pharmacological stimulation. Indeed in part due to these 
advantages, isolated cardiomyocytes have been used to study cardiac conditioning 
for some years, with a key early example using isolated cardiomyocytes to model 
ischaemic preconditioning (Vander Heide, Rim et al. 1990), whilst the enzymatic 
separation of cardiomyocytes from the heart has been viable for even longer 
(Altschuld, Gibb et al. 1980, Altschuld, Hostetler et al. 1981).  
However, the use of this model does increase the degree of abstraction from the 
clinical phenomenon of ischaemia/ reperfusion injury. A key feature of this for 
instance is hypercontracture, in which disruption of the cytoskeleton and 
sarcolemma occurs leading to a marked release of Ca2+ into the affected cells (Piper, 
Garcia-Dorado et al. 1998, Piper, Meuter et al. 2003). Vascular effects, such as 
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alterations in vessel permeability as an inflammatory consequence, cannot be 
observed in this model. The various whole heart preparations are more appropriate 
models of these effects. The isolated cardiomyocyte, however, offers a suitable 
vehicle for the examination of models of ischaemia & reperfusion and potentially 
protective interventions. 
 
5.1.2 Modelling Reperfusion injury 
Numerous models are available to simulate ischaemia & reperfusion injury. An 
obvious possibility for modelling would be to simply immerse the isolated 
cardiomyocytes in an oxygen-deplete medium lacking in metabolic substrates. 
However, isolated cardiomyocytes are inherently quiescent, and lacking in the load 
to which they would be exposed working as part of a heart. Therefore their metabolic 
requirements, and so rate of injury in these conditions, are very low. A widely used 
alternative is to bypass the ischaemic phase due to these difficulties and replicate the 
conditions in the medium that occur during reperfusion; that is of high oxidative 
stress and high Ca2+ concentrations. The production of reactive oxygen species is a 
key feature of early reperfusion injury (Garlick, Davies et al. 1987, Grill, Zweier et al. 
1992, Sun, Wang et al. 2005); and they play a significant role in the deleterious effects 
of reperfusion (Josephson, Silverman et al. 1991).  
H2O2 is a key member of the family of ROS produced during reperfusion. The 
consequences of its actions include direct damage to organelles and DNA, but also 
oxidation of ion channels and transporters and interruption of signalling cascades 
through activation of intermediaries such as CaMKII; all of which can lead to Ca2+ 
overload in the intracellular environment of cardiomyocytes (Gen, Tani et al. 2001, 
Zima and Blatter 2006, Erickson, He et al. 2011). It can also lead to stimulation of the 
RyR Ca2+ release mechanism in SR, as well as increase NCX activity, all of which further 
contribute to Ca2+ overload in the cardiomyocyte (Boraso and Williams 1994, 
Goldhaber 1996, Belevych, Terentyev et al. 2009), an important intermediate step 
leading to cell death (Garcia-Dorado, Ruiz-Meana et al. 2012). The use of a buffer 
enriched in H2O2 with a high concentration of Ca2+ recreates these conditions. This 
laboratory has previously tested H2O2 at 200 µM and found that it can produce 
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hypercontraction in (contracting) cardiomyocytes relatively rapidly. It therefore 




The aim of this chapter was to establish whether protection by cAMP/PKA/Epac 
signalling seen in the whole heart can also be seen in isolated cardiomyocytes, and 
to show that that protection is similar to that elicited by direct MPTP inhibition.  
 
1) Optimise conditions for monitoring the viability and morphology of 
isolated adult & immature cardiomyocytes in suspension  
2) Show that exposure to H2O2 and a high concentration of Ca2+, similar to 
intracellular conditions on reperfusion, triggers cardiomyocyte death in 
this model 
3) Examine the effects of cAMP analogues incubated with the 
cardiomyocytes on this simulated reperfusion injury 
4) Compare that with the protective effect of CsA to demonstrate 






5.3.1 Cardiomyocyte isolation 
The methods by which cardiomyocytes were isolated is discussed in detail in Chapter 
2, including the composition of the various solutions used. Briefly, P14 and P28 as 
well as adult rats were stunned by concussion and killed by cervical dislocation. Their 
hearts were rapidly extracted and immersed in chilled buffer B. 
 
The apparatus for the isolation of cardiomyocytes is shown in Figure 5-1. The hearts 
were cannulated via the aorta and perfused with solution B for at least 2 minutes. 
The perfusate flow rates were constant, at 2.8 ml/min for P14 hearts, 6.4 ml/min for 
P28, and 8.6 ml/min for adults based upon previous optimisation work for this 
technique in our laboratory. Once stable, perfusion was switched to the EGTA 
containing solution C in order to chelate Ca2+ for a further 4 minutes, then perfusion 
was switched to solution D containing a collagenase and protease which perform the 
digestion. As this technique for cardiomyocyte isolation begins with the same  ex vivo 
perfusion process used in Chapter 4, the exclusion criteria for recognising failed or 
problematic isolation is identical to that discussed in Section 4.3.2. Once a heart had 
been successfully digested it was included in the analysis.  
 
The end point for digestion was judged subjectively by touch but was relatively 
consistent within an age group. Ca2+ was then slowly reintroduced with solution E 
whilst the heart was removed from the cannula and gently pulled apart with forceps.  
This solution was agitated at 37 °C for 4 minutes, then filtered and allowed to 
sediment. The supernatant was then removed, replaced by solution F then G for 5 
minutes each respectively in order to slowly increase the Ca2+ concentration back to 
physiological. A droplet of the resulting suspension was then examined under a 20x 
light microscope to confirm the success of the isolation. The isolation was regarded 
as having failed if more than 30% of the observed cells across multiple fields had lost 
their characteristic shape (Figure 5-2). These cardiomyocytes were then used for 
both the experiments involving the effect of cAMP analogues and CsA on simulated 
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reperfusion injury in Sections 5.4 and 5.4.3, and also the effect of cAMP analogues 
on contractility and transients in a model of ischaemic injury in superfused 
cardiomyocytes, described in the following chapter. 
 
5.3.2 Experimental protocols for Incubation Experiments 
5.3.2.1 cAMP analogue experiments 
For these experiments, the cardiomyocyte isolate was divided into 5 conical flasks, 
each of which would be used for the incubation of a different experimental condition. 
These experiments were performed in an immature P14 group (n=5 per condition), 
and in an adult group of isolated cardiomyocytes (n=6 per condition). It is important 
to be clear about sample sizes with respect to these experimental conditions- 
because a digested heart provided a very large number of cardiomyocytes, and to 
exclude unaccounted variation in the isolation process, cardiomyocytes from a 
particular heart were used to test all experimental conditions together. However, in 
the analysis by microscopy, 5 random fields from each condition for each heart were 
analysed. The total numbers of hearts used are shown accordingly in Table 5-2. 
 
Figure 5-1 Perfusion apparatus for cardiomyocyte isolation experiments.  
















Age Group Numbers of hearts digested 
Adult 6 
P14 5 
Table 5-2 Numbers of hearts from each age group tested digested and used in experiments incubating 
cardiomyocytes with cAMP analogues, divided by age group. Each digested heart was used for all experimental 
arms- control, simulated I/R and simulated I/R + drug; in order to limit variation.  
Control- This aliquot was agitated and warmed to 37 °C in a water bath, but had no 
further intervention. It served as a baseline of the intrinsic death rate of the 
population of cells after isolation 
Simulated Ischaemia/Reperfusion (I/R): as for control but with the addition of 0.5 
mM H2O2 and 3 mM CaCl2 and the glucose omitted from the buffer. 
Simulated I/R + drugs: as above but with the addition of a cAMP analogue, incubated 
in the suspension for 10 minutes. The supernatant containing these drugs was then 
removed prior to the addition of the H2O2 and CaCl2 in an equivalent volume of 
unadulterated buffer. Concentrations used were 5 μM 8-Br, or 10 μM 6-Bnz, or 10 
μM CPT. 
 
Figure 5-2 Example of appearances of isolated cardiomyocytes.  
Those cells which remain viable are those which retain their characteristic rod shape; those that are 
significantly injured become rounded, and once their membrane integrity is compromised take up Trypan 
Blue.  





5.3.2.2 CsA experiments 
The cardiomyocyte suspension was divided into 3 aliquots of 5 ml, with each for a 
separate experimental condition. These experiments were performed in a P14 group 
(n=5 per condition), an adult group (n=5 per condition) and an additional P28 group 
(n=6 per condition) 




Table 5-3 Numbers of hearts from each age group tested digested and used in experiments incubating 
cardiomyocytes with CsA, divided by age group. Each digested heart was used for all experimental arms- control, 
simulated reperfusion and simulated reperfusion + CsA; in order to limit variation. 
Control- this aliquot was gently shaken and incubated at 37 °C for 120 minutes but 
was left otherwise untouched.  
Simulated Reperfusion- as for control but with the addition of 0.5 mM H2O2 and 3 
mM CaCl2. 
Simulated I/R + CsA- as above but with the addition of 2 μM CsA, incubated in the 
suspension for 10 minutes prior to simulated I/R. 
 
 
For both of these sets of experiments, samples of the suspensions were then taken 





Simulated I/R Incubation for 2 hours 
Incubation for 2 hours 
Incubation for 2 hours 
Figure 5-3 Experimental protocols for investigating the effects of I/R with or without drugs on viability and 
morphology of cardiomyocytes isolated from adult and 14-day hearts.  Arrows indicate time of assessing viability 
and morphology of cardiomyocytes. Time= 0 for results data to follow refers to start of incubation phase. 
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were placed on a cover slip with the addition of 5.5μl of Trypan Blue (0.4%, Sigma) 
and examined under 20x optical magnification. 5 fields were randomly selected and 
images captured.  
 
The images were assessed using the software ImageJ (NIH, Bethesda, US) which was 
used to count dead, hypercontracted, and rounded cells. A mean for each time point 
across each sample and experimental condition was calculated, and then normalised 
to the viability from the initial sample which was defined as 100% to allow cross 
experimental comparison.  
 
Statistical analysis where noted was by way of two- way repeated measures ANOVA 
using the Bonferroni correction. This was performed in SPSS v. 23.0 (IBM, New York, 
US). Data are presented graphically as means ± SEM. 
 
5.4 Results 
5.4.1 Viability of Cardiomyocytes following Isolation Protocol 
After the process of isolation, the cardiomyocyte suspension was observed and the 
proportionate viability estimated. This varied significantly between groups but was 
relatively consistent within each age group. The mean proportionate viability 
immediately after isolation is shown for each age group in Table 5-4. Values are 
calculated from all isolations in a given age group, as these are not particular to any 
experimental protocol, and are expressed as a proportion of viable to non-viable and 







Age Group Relative Mean viability ± SEM 
P14 57.6± 2.9% 
P28  59.1 ± 5.6% 
Adult 70.3 ± 3.8% 
Table 5-4 Mean proportion of viable cardiomyocytes obtained following isolation for each age group studied ± 
SEM. Total numbers of hearts for each group- P14= 10, P28= 6, Adult= 11. 
 
5.4.2 The effect of cAMP analogues on adult and immature cardiomyocytes exposed 
to simulated I/R 
Figure 5-4 and Figure 5-5  show the results of pre-incubation of the cAMP analogues 
on adult and immature cardiomyocytes prior to simulated reperfusion injury. For the 
adult group, after 120 minutes observation, the viability of the control group had 
fallen to 78 ± 1.73% of the initial. In this group, exposure to the simulated reperfusion 
condition with H2O2 and Ca2+ without any additional intervention caused that viability 
to fall to 46.3 ± 5.90%. The cAMP analogues caused a stepwise improvement in that 
viability by the end of each experiment. CPT and 6-Bnz caused a non-significant 
improvement in viability but 8-Br was significantly improved vs. the simulated 

















Time since start of I/R injury/ minutes
Proportionate Viability in Adult Cardiomyocytes with 
cAMP analogues
Control I/R I/R and 8Br I/R and 6Bnz I/R and CPT
Figure 5-4 Change in proportionate vulnerability of adult (n= 6 hearts) isolated cardiomyocytes incubated in simulated 
I/R conditions vs time after incubation with cAMP analogue. Normalised to starting viability defined as 100%. Points 
plotted as mean ± SE. 
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In the P14 group, a similar pattern was observed. A striking finding was the increased 
death rate in the control group- after 120 minutes the viability was 55 ± 3.46%, 
compared to the adult group which was 78 ± 1.73%. The same pattern of changes 
with the different experimental conditions was seen, however, notwithstanding the 
increased background rate of death; non-significant improvements in vulnerability 
with 6-Bnz and CPT but a significant partial rescue with 8-Br (at 120 min, 35.4 ± 4.98 
vs 55 ± 3.46% p=0.0014). 
 
 
Table 5-5 Initial death rates at 30 minutes for cardiomyocytes incubated with cAMP analogues in simulated I/R 
conditions  expressed as percentage per hour ± SEM. Asterisk= p<0.05 vs same aged control result. Tested by 



















Time since start of I/R injury/ minutes
14 Day Old Cardiomyocytes with cAMP analogues
Control I/R I/R and 8Br I/R and 6Bnz I/R and CPT
Figure 5-5 Change in proportionate vulnerability of P14 (n= 5 hearts) isolated cardiomyocytes incubated in 
simulated I/R conditions vs time after incubation with cAMP analogue. Normalised to starting viability defined as 





5.4.3 The effect of Cyclosporin A on adult and immature quiescent cardiomyocytes 
exposed to simulated reperfusion injury  
The adult cardiomyocytes in suspension showed a change in viability with time as 
shown in Figure 5-6. After 120 minutes following the start of measurement, the 
control cells (those with no additional intervention) showed a mean viability of 
76±6.5%. This was identical (76±7.4%) to those cells exposed to the simulated 
reperfusion injury condition, with a high calcium concentration and hydrogen 
peroxide as well as CsA; those exposed to the injury condition alone showed a 
significantly lower viability, with a mean of 53±5.3% after 120 minutes.  
 
Figure 5-6. Change in proportionate vulnerability of adult (n= 5 hearts) isolated cardiomyocytes incubated in 
simulated I/R conditions vs time after incubation with CsA. Normalised to starting viability defined as 100%. 


















Time since start of I/R injury/ minutes
Effect of CsA on Viability of Adult Cardiomyocytes ± Simulated I/R
Control I/R I/R and CsA
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This pattern was not repeated in the two immature cardiomyocyte groups, of 28 and 
of 14 days post- natal. Figure 5-7 shows the pattern of viability vs time in 28 day old 
hearts, and Figure 5-8 that in 14- day old cardiomyocytes.  
 
 
Figure 5-7. Change in proportionate vulnerability of P28 (n= 6 hearts) isolated cardiomyocytes incubated in 
simulated I/R conditions vs time after incubation with CsA. Normalised to starting viability defined as 100%. Points 
plotted as mean ± SE. 
 
In the 28- day old cardiomyocytes, the viability of cells treated with CsA at the end of 
120 minutes incubation was intermediate between those not exposed to a simulated 
reperfusion injury and those just exposed to the injury with no CsA- that is, there was 
a partial amelioration of the injury. The control arm in this age- group showed an 
80±3.1% viability at the end of the experiment, as compared (not significantly 
different) to the CsA + reperfusion injury arm which showed a viability of 55±7.9%. 
However, this was nonetheless significantly greater than the reperfusion injury alone 

















Time since start of I/R injury/ minutes
Effect of CsA on Viability of 28-day Cardiomyocytes ±Simulated I/R




Figure 5-8. Change in proportionate vulnerability of P14 (n= 5 hearts) isolated cardiomyocytes incubated in 
simulated I/R conditions vs time after incubation with CsA. Normalised to starting viability defined as 100%. Points 
plotted as mean ± SE. 
 
 
The 14- day old cardiomyocytes did not show any significant difference between the 
arms containing hydrogen peroxide/ high calcium (the simulated reperfusion injury) 
with or without the addition of CsA. The control arm in this group showed a greater 
rate of decline than in either of the two previous age groups, declining to a mean 
viability of 57% by the end of the two hour experiment; this is approximately 40% 


















Time since start of I/R injury/ minutes
Effect of CsA on Viability of 14-day Cardiomyocytes ± Simulated 
I/R







Adult/ % hr-1  P28/ % hr-1 P14/ % hr-1 
Control 22 ± 5.6 2 ± 1.3 14 ± 7.4 
I/R 52 ± 5.2 * 56 ± 4.5 * 78 ± 9.6 * 
I/R and CsA 14 ± 5.0  8 ± 3.9 36 ± 6.7 
Table 5-6 Initial death rates at 30 minutes for cardiomyocytes incubated with CsA expressed as percentage per 
hour ± SEM. Asterisk= p<0.05 vs same aged control result. Significance tested by Student’s T-test.  
An additional experimental outcome for each of these arms was also considered- the 
cardiomyocyte morphology at each time point, classified into normal i.e. rod-shaped 
morphology, rounded but not taking up Trypan blue dye, or rounded and blue in 
colour in response to the stain. The results from this measurement are shown in 
Figure 5-9 and Figure 5-10. 
 
Figure 5-9. Change in morphology expressed as proportion of physiological rod shape of adult (n= 5 hearts) 
isolated cardiomyocytes incubated in simulated I/R conditions vs time after incubation with CsA. Normalised to 


















Time since start of I/R injury/ minutes
Effect of CsA on Morphology of Adult Cardiomyocytes ±
Simulated I/R




Figure 5-10. Change in morphology expressed as proportion of physiological rod shape of P28 (n= 6 hearts) isolated 
cardiomyocytes incubated in simulated I/R conditions vs time after incubation with CsA. Normalised to starting 
morphology defined as 100%. Points plotted as mean ± SE. 
 
For the adult group, the trend in morphology mirrors closely that for viability. At the 
end of the two- hour experimental period, the proportion of normal rod- shaped 
cardiomyocytes in the control and CsA/reperfusion group was indistinguishable, at 
78±7.0% vs 74±7.7%. However, the reperfusion group showed a marked change in 
morphology, with the rods making up only 45±5.5% of the identified cells after 120 
minutes. This was significantly different from the CsA/reperfusion and control groups 
(p<0.01). 
 
The 28- day old group did not display the same pattern as the adult. In this group, 
the addition of cyclosporin A to the buffer did not cause surviving cardiomyocytes to 
retain their rod shape; the CsA/reperfusion and reperfusion arms were 
indistinguishable. Both of these groups were significantly different to the control arm 
at every time point measured from 30 minutes. The P14 day group is not shown. 

















Time since start of I/R injury/ minutes
Effect of CsA on Morphology of P28 Cardiomyocytes ± Simulated 
I/R
Control I/R I/R and CsA
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cardiomyocytes are stellate in shape intrinsically, and so differentiating their normal 
morphology from hypercontracture is challenging using this method. This interaction 
between developmental changes in morphology and pathological observations 
makes using this outcome measure in order to assess cardioprotective interventions 






5.5.1 Summary of findings 
In these experiments on viability of cardiomyocytes in suspension, there were three 
key observations. Firstly, that freshly isolated cardiomyocytes are fragile in 
suspension, and that the intrinsic rate of death following isolation is higher in P14 
and indeed P28 cardiomyocytes than in the adult. Secondly, activation of both PKA 
and EPAC via incubation with 8-Br prior to simulated I/R injury is ameliorates 
cardiomyocyte death in both adult and P14 cells. Finally, whilst adult cardiomyocytes 
show rescue from simulated I/R injury with incubation with Cyclosporin A, P14 
cardiomyocytes do not appear to, whilst P28 as an intermediate group show a partial 
response.   
 
5.5.2 Adult cardiomyocytes in suspension are less vulnerable to death than P14 
cardiomyocytes 
This work shows that freshly isolated cardiomyocytes from adult and 14-day old 
hearts, are vulnerable to a simulated reperfusion injury caused by an environment 
supplemented with H2O2 & high Ca2+. This was observed in both sets of experiments 
involving CsA and cAMP analogues.  
However, the magnitude of this injury seemed to be greater in the 14- day old group 
than in the adult; after 120 minutes the viability had been reduced to 53% in the 
adult vs. 10% in the immature group (CsA group of experiments; in the cAMP 
analogue group, carried out separately, the pattern is the same although the 
numerical values differ at 78% for adult and 55% for P14).  
These observations are in contrast to the prior observation (Riva and Hearse 1993, 
Ostadalova, Ostadal et al. 1998) that there is a bell- shaped vulnerability curve to the 
response to I/R; it is thought that vulnerability to injury falls until a minimum at 14- 
days of age, before increasing again towards adulthood. However, these 
observations were made on the whole heart, rather than isolated cardiomyocytes. 
My previous findings, outlined in Chapter 3, included experiments on whole heart 
perfusion of adult and 14- day old hearts, confirmed the finding that immature hearts 
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are less vulnerable than adult hearts to damage from reperfusion injury. Therefore, 
these findings are not representative of findings in the literature or my own prior 
data on whole hearts. This may reflect damage to cardiomyocytes as they are 
isolated. The process by which cardiomyocytes are isolated involves perfusion for 
variable periods with collagenase and protease; these enzymes by nature are 
damaging. Further, the endpoint for digestion of hearts was not constant either 
within or between age groups; for each heart, it was determined subjectively. This 
may have led to a systematic overdigestion of the immature hearts leading to this 
increase in injury, seen both in the control arm and in the experimental groups 
deliberately exposed to intervention.  
Another distinction between this present study, and those prior, is that this study 
attempted to isolate the effect of simulated reperfusion injury distinct from that 
caused by ischaemia; this is uniquely possible in the isolated cardiomyocyte 
preparation. In the previously studied whole heart preparations, the hearts were 
exposed to the combination of ischaemia and reperfusion; the addition of ischaemia 
may possibly account for the difference, or a deficiency in the representation of 
reperfusion injury in this method of simulating it. 
There are however, alternate explanations. There is a strong selection bias in the 
method of digestion; if there is a spectrum of vulnerability in cardiomyocytes, those 
most resistant to injury will survive resulting in a systematic bias in results. The 
environment in which isolated cardiomyocytes sit, whilst the buffer is carefully 
composed to attempt to recapitulate the usual extracellular milieu, is not the same 
as their physiological condition in the heart (Nippert, Schreckenberg et al. 2017). One 
clear difference is that in the heart, cardiomyocytes sit in an organised structure; 
communicating between themselves electrically and chemically through gap 
junctions, paracrine signalling and other means (Vornanen 1996). In suspension, 
these cardiomyocytes are mechanically unloaded through this lack of structure, 
which is clearly an aphysiological situation. 
Protective mechanisms may exist that depend upon these modalities of intercellular 
communication; these would be disrupted in this isolated cardiomyocyte 
preparation, and so might explain this observation; these observations may well be 
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different in a cardiomyocyte culture in media. Also, cardiomyocytes also are not the 
only cells present in an intact heart, nor is contractile tissue the only tissue type 
present.  It is possible that, for instance, cardiac fibroblasts, or the cardiac vasculature 
has an important role to play in protection from injury; these effects would 
necessarily not be apparent in a suspension of isolated cardiomyocytes. 
 
5.5.3 MPTP inhibition by CsA is protective against simulated reperfusion injury in 
isolated adult but not immature cardiomyocytes 
It is thought that a common final pathway for cell death following reperfusion injury 
involves opening of the mitochondrial permeability transition pore (Ong, Dongworth 
et al. 2015). The hypothesis for this set of experiments was therefore that 
administration of a known inhibitor of that pore would be protective for 
cardiomyocytes of any age exposed to a simulated reperfusion injury with agents 
thought to act by promoting pore opening. In these experiments, I showed that CsA 
does completely ameliorate the effect of reperfusion injury on isolated 
cardiomyocyte viability in cells isolated from adult hearts. However, this effect was 
only seen to an intermediate extent in 28- day old cardiomyocytes and was 
completely absent from the 14- day old cardiomyocytes. 
It has been previously shown, albeit to a lesser extent, that CsA is capable of 
inhibiting cell death from reperfusion injury in adult cardiomyocytes (Griffiths, 
Ocampo et al. 2000). That this agent completely reverses the increase in death from 
the administration of the injurious stimulus corroborates our model of reperfusion 
injury as causing damage in the mode that we had hypothesised a priori. 
It is interesting to note that this finding is not replicated in immature cardiomyocytes. 
A statistically significant improvement was seen in the 28- day old cells, placing the 
group treated with CsA in an intermediate position between the control and 
reperfusion injury arms. In the 14- day old group, there was no protective effect 
found by administration of CsA. It may be supposed that the MPTP in 14-day old 
cardiomyocytes is much less prone to opening per se, or in any event by the stimuli I 
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have used to simulate reperfusion injury, and so that the administration of CsA does 
little to modify the process of injury and cell death in this group.  
However, a relative increase in injury and death rate was seen in the immature cells 
even in the absence of any damaging intervention. Therefore, this observation of a 
lack of effect must be treated with a little caution, given the observed increase in 
death rate in immature cells not exposed to any injurious stimulus. With this low 
viability, a putative effect would be difficult to observe. Nevertheless, even with this 
increase in spontaneous death rate, there is a significant difference in response in 
the 14- day old group  compared to the adult. 
 
5.5.4 Combined PKA & EPAC stimulation ameliorates death rate from simulated 
reperfusion injury in both adult & immature isolated cardiomyocytes 
These experiments have shown that pre- incubation with 8-Br prior to simulated 
reperfusion injury can significantly reduce cardiomyocyte death in both adult and 
immature cardiomyocytes. Either 6-Bnz or CPT alone did not have this effect. It 
therefore appears as though the effect is dependent upon synergistic activation of 
both PKA and EPAC, and that neither is adequate to produce a protective effect 
alone. This is consistent with the effects seen on the whole heart in Chapter 3.  
It also therefore seems that the cardioprotective effects of these agents is not 
dependent upon vascular, or other organ-level pharmacodynamic effects, or indeed 
upon intracellular communication via gap junctions. The cardiomyocytes in these 
freshly isolated preparations exist as single cells in suspension and so any effect seen 
due to these agents is most likely a consequence of intracellular action alone. 
It is notable that whilst the cAMP analogue 8-Br provided partial rescue of the P14 
cardiomyocytes from simulated reperfusion injury, incubation of CsA with 
cardiomyocytes of this age does not. Whilst this may be an artefact of the 
preparation used for the CsA experiments having an unexpectedly high death rate so 
obscuring benefit from CsA, it may also hint at the regulation of mitochondrial 
permeability being governed by alternate mechanisms or mediators in the immature 
heart than CsA.   
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Chapter 6 next examines some of the intracellular consequences of perfusion with 
the cAMP agents, and therefore provides some insight into their possible mechanism 




6 The effect of cAMP analogues on contractility & Ca2+ cycling 
in isolated adult cardiomyocytes under both physiological 
and simulated ischaemic conditions 
 
6.1 Introduction 
Previously, in Chapter 4, it was demonstrated in the whole heart that analogues of 
cAMP can produce protection against ischaemia and reperfusion injury, and that that 
protection depends upon joint stimulation of both PKA and EPAC. In Chapter 5 it was 
shown that in a model of reperfusion injury those same agents were protective in 
quiescent freshly isolated cardiomyocytes. However, it is not clear what 
pharmacodynamic effects these agents are having upon the cardiomyocyte, and if 
these effects may explain the observed protective properties. Furthermore, it is 
important to establish cAMP/PKA/Epac signalling pathways involvement in Ca2+ 
cycling and E-C coupling using cAMP analogues. As mentioned in the previous 
chapter, cardiomyocytes are used to study E-C and change in Ca2+ cycling using Ca 
dyes. However, whereas studies involving I/R using intact perfused hearts is well 
established, such an intervention does not work in the case of isolated perfused 
cardiomyocytes. These myocytes are unloaded and when perfusion is stopped, it will 
take a very long time to see changes leading to death. Additionally, single myocytes 
do die spontaneously with time. Anoxia has been used (N2 bubbled buffer) but this 
also takes a long time. Therefore, more than 20 years ago, the team in Bristol have 
adopted a chemical hypoxia approach to study insults in cardiac perfused myocytes. 
 
6.1.1 Chemical Hypoxia model 
The purpose of these experiments is to assess the changes in contractility that occur 
under conditions of cardiac ischaemia. The most obvious direct way to study this 
would be to remove oxygen, and metabolic substrates from the perfusion medium. 
Chemical hypoxia (addition of Cyanide to solutions perfusing cardiomyocytes) has 
been widely used and its metabolic effects and effects on Ca and contractility reflect 
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changes in myocytes exposed to anoxia(Griffiths 1997, Griffiths, Lin et al. 1998, 
Williams, Kerr et al. 2000, Williams, King et al. 2001, King, McGivan et al. 2003). 
Cyanide is a complex IV mitochondrial inhibitor (Ball and Cooper 1952) and so inhibits 
mitochondrial production of ATP via oxidative phosphorylation similar to what occurs 
during anoxia. Superperfusion of field stimulated cardiomyocytes triggers changes 
that are similar to is seen during anoxia of cardiomyocytes and also during I/R in 
intact heart. Like anoxia, metabolic inhibition of field stimulated cardiomyocytes 
induces a gradual cessation of contractility associated with rigor (since the myocytes 
are not loaded, if they hypercontracted, they do not relax). Upon reperfusion with 
normal buffer, the myocytes can either recover contractility or hypercontract further 
and die (confirmed using trypan blue). More importantly, these changes are 
paralleled by changes in cytosolic Ca2+ that are similar to what is seen in I/R of intact 









Figure 6-1 Example Ca2+ transient trace. Isolated perfused adult rat cardiomyocyte and stimulated at 0.2Hz to 
measure Ca2+ transients and monitor morphology. Perfusion with 2.5mM NaCN causes a gradual increase in 
transient amplitude and in diastolic Ca2+. This is followed by cessation of  response to field stimulation and going 
into rigor (critical fall in ATP) associated with elevated Ca2+. Upon reperfusion transients resume but cells can either 




The aims of this chapter are therefore; 
1) Assess the effects of the cAMP analogues on contractility and Ca2+ transients 
in superfused isolated cardiomyocytes from P14 and adult hearts 
2) Determine how metabolic inhibition with NaCN injures those populations of 
isolated cardiomyocytes 
3) Assess whether the organ- level protection previously observed with 8-Br, 
and to a lesser extent CPT and 6-Bnz, is replicated on the cellular level with 
the measures of contractility, Ca2+ transient amplitude as well as gross 






Cardiomyocytes were obtained for these experiments from adult and P14 rats as 
outlined in Chapter 2 and Chapter 5, during the experiments discussed in Chapter 5 
and so those details are not repeated. The details for how the isolated 
cardiomyocytes were superfused and their contractility and transients measured are 
discussed in Section 2.5, but will be briefly reiterated here. The same batch of 
cardiomyocytes freshly produced from an individual heart were used for one 
experimental repeat across all conditions studied in order to limit between-arm 
variation due to unaccounted variation in the isolation process. The total number of 
hearts used for these experiments are summarised in Table 6-1. For each of these 
hearts, at each time point assessed, 5 cells/ fields were chosen to study.  




Adult 6 6 
P14 6 6 
Table 6-1 Numbers of hearts from each age group tested digested and used in examining the response of 
cardiomyocytes to simulated ischaemia, divided by age group  and type of study. Each digested heart was used to 
provide cardiomyocytes for all experimental treatments in order to limit between- arm variation. For each heart 
and time point, 5 data points were assessed.  
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6.3.1 Contractility experiments 
A microscope, Figure 6-2, was used with a custom chamber which allowed for 
perfusing buffers to be pumped through. A droplet of the cardiomyocyte suspension 
was placed in the chamber and allowed to settle. A standard HEPES based buffer was 
used to perfuse the chamber, which was then examined under 10x magnification. A 
suitable cardiomyocyte or field was selected and the chamber was then stimulated 
100V stimulation at 0.2Hz, with a 1 ms delay between pulses. The experimental 
details are described in Sections 2.4.7.2 and 2.4.7.3. Briefly, an edge tracking device 
was then used to quantify the contractions observed. Baseline measurements were 
taken of contractility. Perfusion was then switched to an identical buffer with the 
addition of 2.5 mM NaCN for 30 minutes, recording of contractility continued, and 
note taken of the time to the endpoints of contractile arrest, arrhythmia, 
hypercontracture, and cell death.  
In order to process the contractility data, time points at 5 minute intervals from the 
start of the experiment up to 35 minutes perfusion were selected. The raw 
contractility data for each of these time points were examined, and three contractile 
cycles either side of the time point marker were chosen for further analysis. The 












Figure 6-2 Apparatus used for contractility and transient measurements. The microscope chamber is continually 
perfused with a buffer solution via the pump, and is also intermittently stimulated through peripheral electrical 




maxima- were manually identified, and then these converted back from the 
software’s arbitrary units to measurements of cell size. This was accomplished using 
a previously calibrated relationship for the equipment; a linear relationship existed 
between the output voltage from the edge tracker and size; it was straightforward 
to convert from the measured potentials to instantaneous cell size.  
 
These estimates of cell size for diastole and systole could then be combined into a 





= 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑠ℎ𝑜𝑟𝑡𝑒𝑛𝑖𝑛𝑔 
 
The resulting value was then normalised by correcting for the value at baseline (initial 
value at time 0); it was thus expressed as a ratio of the initial fractional shortening.  
Comparisons of the data at 5 minutes vs baseline, and at 35 minutes vs. 5 minutes 
were then made by two-tailed Student’s T-tests; this enabled an analysis of the 
pharmacological action of the cAMP analogues on the cardiomyocyte’s physiology 
(at 5 minutes); and at 35 minutes the data could be examined for a potentially 
protective effect against hypoxia. 
 
 
The experimental design is shown in Figure 6-3. Example contractility traces are 
shown in Figure 6-4, for contraction in standard buffer, in Figure 6-6, the effect of 
Figure 6-3 Experimental design for contractility studies. Control group cardiomyocytes were perfused 
with the baseline buffer followed by 30 minutes with the addition of NaCN. Those in the intervention 
groups had a 5 minute period of perfusion with buffer containing the cAMP analogue before switching 
to the NaCN containing buffer. 
30 minutes 
5 minutes 30 minutes 
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addition of cyanide, and in Figure 6-5, perfusion with 8-Br before the addition of 
cyanide.  
 
Figure 6-4 Example edge tracking recording of single cardiomyocyte contractions during perfusion with normal buffer at 






6.3.2 Ca2+ transient experiments 
These experiments were repeated making measurements of the Ca2+ transient with 
an identical experimental design, methodological detail for which is again described 
in Chapter 2. Briefly, cardiomyocytes were loaded with the fluorescent dye Fura-2-
AM which is cell permeable.  
8-Br perfusion Cyanide perfusion 
Figure 6-5 Example edge tracking output from PTI of cardiomyocyte contractility during perfusion with 8-Br and 
subsequently with cyanide 




This dye hydrolyses under ultraviolet light to Fura-2, which binds free Ca2+ within the 
cell. The bound and unbound forms of Fura have two differing excitation wavelengths 
(340 nm vs 380 nm bound and unbound respectively) and so therefore the ratio of 
these allows estimation of the proportion of free Ca2+ in the cardiomyocyte. This ratio 
was measured continuously throughout the periods of perfusion with the baseline 
buffer, the cAMP analogues, and with NaCN containing buffer. An example trace is 
shown in Figure 6-7. 
 
The experiments upon isolated cardiomyocytes examining their contractile 
behaviour and calcium transients had two phases; the first, was their stimulated 
behaviour under the influence of perfused cAMP analogues. The second was an 
examination of their behaviour following simulated hypoxia. I therefore analyse 
these two phases separately, as a purely pharmacodynamic phenomenon to begin 
with, followed by the pathophysiology of histotoxic hypoxia.  
  
Ca2+ transient amplitude 
Figure 6-7 Example Ca2+  transient trace from a cardiomyocyte perfused with standard buffer before switching to 




6.4.1 Influence of cAMP analogues on isolated cardiomyocyte contractility & 
Ca2+Transient in the absence of Simulated Hypoxia 
6.4.1.1  The response of adult cardiomyocytes 
Cardiomyocytes showed a positive inotropic response when perfused with analogues 
of cAMP. Of these, perfusion with 8-Br generated the greatest magnitude of 
response; a just over two-fold increase in contractility (2.01±0.050, Figure 6-8). 
 
The selective agonists of PKA and Epac, 6-Bnz and CPT, individually also elicited a 
positive inotropic response. 6-Bnz perfusion caused a 63% increase in contractility, 
whilst CPT generated a similar reaction, increasing normalised contractile shortening 




























Adult Cardiomyocyte Contractility Following Perfusion 
with cAMP Analogue
Figure 6-8 Change to Adult Isolated Cardiomyocyte Contractility following perfusion with cAMP analogue or 
cyanide. Change to fractional shortening after 5 minutes perfusion in each experimental arm in adult 
cardiomyocytes; normalised against baseline contractility. Data- mean ±SEM. All data points statistically 




elicited a 40.9% greater contractile response vs. CPT and 37.4% greater response vs. 
6-Bnz.  
 
Similarly, each cAMP analogue showed an induction of a significant increase in the 
magnitude of the calcium transient. This peaked in amplitude after five minutes of 
perfusion; the peak in size was to an almost identical degree with any of the cAMP 
analogues, at just over two- fold; a mean of 2.14 fold for 8-Br, with no significant 
differences to CPT or 6-Bnz (Figure 6-12, Figure 6-13, shown with data for results 
following cyanide perfusion). 
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6.4.1.2 The response of P14 myocytes 
 
Immature cardiomyocytes also showed a positive inotropic response to 8-Br 
perfusion. There was a mean increase of 2.33- fold ± 0.26 after 5 minutes perfusion. 
The effect of the single target agonists was smaller, but still markedly elevated 
compared to control. CPT caused a 1.78±0.081x increase vs baseline, and 6- Bnz 
1.70±0.11x. The response of combined perfusion with 6-Bnz & CPT together was 
comparable to that of 8-Br, at 2.11±0.093x.  
Similar results to the adult were found for response of the Ca2+ transient to drug 
perfusion. Each cAMP analogue showed a significant increase in the magnitude of 
this response. This peaked in amplitude at the five minute sampling point; the peak 
in size similar across the cAMP analogues, at almost 2.5 fold; a mean of 2.48 ± 0.11 





























P14 Cardiomyocyte Contractility Following Perfusion with cAMP 
Analogue
Figure 6-9 Change to P14 Cardiomyocyte Contractility following perfusion with cAMP analogue or cyanide. 
Change to fractional shortening after 5 minutes perfusion in each experimental arm in adult cardiomyocytes; 
normalised against baseline contractility. Data- mean ±SEM. All data points statistically significant by two-tailed 
unpaired T-test at p< 0.05  vs. control perfusion other than cyanide arm; n=6 hearts. 
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for CPT and 6-Bnz (Figure 6-17, Figure 6-18, shown with data for results following 
cyanide perfusion). 
6.4.2 Pre-treatment with cAMP analogues and simulated hypoxia 
6.4.2.1 Adult Cardiomyocytes 
 
As shown in Figure 6-10, perfusion with a sodium- cyanide containing buffer causes 
a steady decrease in contractility; a cell typically being reduced in fractional 
shortening to 21.2% ± 9.0% of the baseline value after 30 minutes perfusion. 
Perfusion with a buffer containing either 10 µM 6-Bnz or CPT as well as the sodium 
cyanide provides a transient amelioration of this effect, but at the end of the 30 
minute perfusion period the contractile function of these cells is indistinguishable 
from those containing cyanide alone.  However, in the experiments in which cells 
were perfused either with 8-Br, or with a combination of 6-Bnz and CPT as well as 
Figure 6-10. Relative fractional shortening of Adult Cardiomyocyte vs time after perfusion with cAMP 
analogue + cyanide 
Prior perfusion with cAMP analogue (as noted) or unmodified buffer (‘cyanide’). Cyanide added to buffer 



























Time Post CN perfusion/ minutes
Relative Fractional Shortening vs. Time after perfusion 
with Cyanide ± cAMP analogue
Control 8Br 6-Bnz CPT
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with cyanide, there was a sustained amelioration of the functional impairment seen 
with cyanide alone. As compared to the pre-perfusion values, perfusion with 8-Br led 
to a normalised contractility value after 30 minutes of 1.08±0.199; this is higher than 
at baseline despite concurrent perfusion with cyanide, such that at the end of the 
experiment those cells perfused with 8-Br and cyanide had a contractility in excess 
of five-fold those perfused with cyanide. A similar degree of rescue from the effects 
of perfusion with cyanide was seen with the addition of the combination of 6-Bnz 
and CPT; resulting in a relative contractility at 30 minutes perfusion of 0.850±0.0018, 
showing a synergistic characteristic resulting from the simultaneous perfusion of 
these two agents.  
The Ca2+ transient data follows a similar pattern to the contractility, with 6-Bnz and 
CPT following a relatively linear pattern of decline during washout and CN perfusion 


































Time Post CN perfusion/ minutes
Normalised Relative Fractional Shortening vs. Time after 
perfusion with Cyanide ± cAMP analogue
Control 8Br 6-Bnz CPT
Figure 6-11 Normalised relative fractional shortening of adult cardiomyocytes vs time after perfusion with cAMP 
analogue + cyanide. Normalised to contractility at the point of addition of cyanide to perfusing buffer. Data shown 




Figure 6-12). However, the results for 8-Br are qualitatively different. Here, 
throughout perfusion with NaCN, the transient amplitude remains greater than the 
baseline value, demonstrating a lasting effect of the drug despite washout and 
simulated hypoxia. 
  
Figure 6-12. Mean peak amplitude of calcium transient in adult cardiomyocytes prior to and following perfusion 
with cAMP analogue and cyanide.Normalised to the initial value of amplitude at the start of control perfusion (T=-
5), and after cyanide added to perfusing buffer at 0 minutes. Control (cyanide) vs buffer containing each cAMP 
analogue. Control= no addition to buffer other than cyanide. Data points represent mean +/- SEM. N=6 hearts.  
The transient results were was then normalised to the maximum value measured 
during perfusion with the cAMP analogue (or baseline for the control). Interestingly, 
even after the drug had been washed out and throughout the perfusion with NaCN, 
the cells perfused with 8-Br have a normalised calcium transient amplitude 
significantly greater than that of the controls well after the drug has been removed 

































CN Perfusion Time/ minutes
Ca2+ Transient Fold Change in Response to Cyanide ± cAMP analogues 
in Adult Cardiomyocytes




The time taken for cells to reach a variety of endpoints (time to arrhythmia, to 
contractile cessation, to cell death, and to hypercontraction) under perfusion with 
each drug was also measured Figure 6-14. For each of these end points, perfusion 
with a cyanide- containing buffer significantly shortened the time that end-point.  
This was also true for 8-Br perfusion for time to arrhythmia and time to 
hypercontraction; however no significant difference to control was seen for time to 
cell death. Perfusion with CPT nor 6-Bnz did not lead to a shortening of the time to 



































CN Perfusion Time/ minutes
Ca2+ Transient Resistance to Cyanide with cAMP analogues in Adult 
Hearts- Normalised to Peak
Control 8Br 6Bnz CPT
Figure 6-13 Normalised amplitude of calcium transient in adult cardiomyocytes following perfusion with cAMP 
analogue and cyanide. 
Normalised to the initial value at time points at the start of cyanide perfusion (T=0) following 5 minutes of 
preceding perfusion with cAMP analogue or control. Underlying data identical to previous figure. Control= no 















































Adult Cardioprotection with cAMP Analogues during Cyanide perfusion
Control Cynanide 8-Br 6Bnz CPT
Figure 6-14 Time taken to reach pathological endpoints for adult cardiomyocytes perfused with cyanide ± a cAMP 
analogue.  Data points represent mean ±SEM. *= p<0.05 vs. control (HEPES buffer perfusion alone). Statistical testing 
by 2-tailed unpaired T-test. N=6 hearts. 5 cardiomyocytes per endpoint per heart studied.  
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6.4.2.2 P14 Cardiomyocytes 
In the P14 group, a similar pattern of decline in contractility following simulated 
hypoxia with NaCN is seen to that in the adult (Figure 6-16 & Figure 6-15). All drug 
intervention groups demonstrate a decline in their contractility. However, by 30 
Figure 6-15 Normalised relative fractional shortening P14 cardiomyocytes vs time after perfusion with cAMP 
analogue + cyanide. Normalised to contractility at the point of addition of cyanide to perfusing buffer. Data shown 

































Time Post CN perfusion/ minutes
Normalised Relative Fractional Shortening vs. Time after 
perfusion with Cyanide ± cAMP analogue; P14




























Time Post CN perfusion/ minutes
Relative Fractional Shortening vs. Time after perfusion with 
Cyanide ± cAMP analogue; P14
Control 8Br 6-Bnz CPT
Figure 6-16 Relative fractional shortening of P14 Cardiomyocyte vs time after perfusion with cAMP analogue + 
cyanide. 
Prior perfusion with cAMP analogue (as noted) or unmodified buffer (‘cyanide’). Cyanide added to buffer after 5 
minutes perfusion (T=0). Data shown as mean ± SE; n=6 hearts. 
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CN Perfusion Time/ minutes
Ca Transient Fold Change in Response to Cyanide cAMP analogues 
in P14 Cardiomyocytes
Control 8Br 6Bnz CPT
Figure 6-18 Mean peak amplitude of calcium transient in P14 cardiomyocytes prior to and following perfusion 
with cAMP analogue and cyanide. 
Normalised to the initial value of amplitude at the start of control perfusion (T=-5), and after cyanide added to 
perfusing buffer at 0 minutes. Control (cyanide) vs buffer containing each cAMP analogue. Control= no addition 
to buffer other than cyanide. Data points represent mean +/- SEM. N=6 hearts.  
Figure 6-17 Normalised amplitude of calcium transient in adult cardiomyocytes following perfusion with cAMP 
analogue and cyanide. 
Normalised to the initial value at time points at the start of cyanide perfusion (T=0) following 5 minutes of 
preceding perfusion with cAMP analogue or control. Underlying data identical to previous figure. Control= no 






































CN Perfusion Time/ minutes
Ca Transient Resistance to Simulated Hypoxia with cAMP 
analogues in P14 Hearts- Normalised to Peak
Control 8Br 6Bnz CPT
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indeed as in the adult it remained improved on the baseline contractility  despite the 
simulated hypoxia. Perfusion with CPT or 6-Bnz did not show this effect, and they 
were not significantly different to control at 30 minutes.  
The data showing the response of the Ca2+ transient in the P14 cardiomyocyte to 
stimulation with cAMP analogues prior to perfusion with cyanide are shown in Figure 
6-17 (raw data) and Figure 6-18 (normalised to peak amplitude just prior to cyanide 
perfusion. As for the equivalent adult data, these show as similar trend as for the 
contractility results; 8-Br, CPT and 6-Bnz all cause at least a 2.1 fold increase in 
systolic Ca2+ levels, which then falls away as perfusion with cyanide begins from t=0 
onwards. Only 8-Br maintains a positive, maintained effect upon the Ca2+ transient 
throughout the period studied, although CPT and 6- Bnz do seem to have an 
intermediate effect between the preservation seen with 8-Br and the reduction to 































Cardioprotection with cAMP Analogues during cyanide 
perfusion; P14
Control Cynanide 8-Br 6Bnz CPT
Figure 6-19 Time taken to reach pathological endpoints for P14 cardiomyocytes perfused with cyanide ± a 
cAMP analogue.  Data points represent mean ±SEM. *= p<0.05 vs. control (HEPES buffer perfusion alone). 






arrythmia and contractile cessation (Figure 6-19), perfusion with NaCN significantly 
shortened the time to observation. (Hypercontracture could not be reliably assessed 
in the P14 group due to the rounded & stellate initial appearances of the 
cardiomyocytes). 8-Br, CPT, and 6-Bnz all improved the time to contractile cessation 
to the point they were comparable to control. However, for time to arrhythmia, there 
was no significant difference to control. Again, only 8-Br produced a protective effect 
against time to cell death (1108s vs 509s); there was no protection seen in the 





6.5 Discussion  
Through this work, I hope to have demonstrated that; 
• Perfusion of both adult and immature cardiomyocytes with PKA & 
Epac agonists is associated with an inotropic effect 
• This effect correlates with changes to the peak Ca2+ transient 
• Perfusion with cyanide is an effective model of hypoxia in the isolated 
cardiomyocyte, showing reductions in Ca2+ transients and contractility 
• There is no great difference in vulnerability between the P14  and 
adult derived cardiomyocytes when exposed to this method of 
metabolic inhibition 
• Epac & PKA agonists ameliorate loss of contractility and calcium 
transients during histotoxic hypoxia in both adult & P14 
cardiomyocytes 
• Synergistic activation of PKA & Epac lengthens the time to cell death 
during cyanide perfusion but may be pro- arrythmogenic 
 
6.5.1 Perfusion of cardiomyocytes with cAMP analogues demonstrates physiological 
response of inotropy 
 
The results of baseline perfusion of isolated cardiomyocytes with any of the cAMP 
analogues used demonstrate that they all trigger an increase in calcium transient 
amplitude, as well as an increase in contractility of the cardiomyocytes originating 
from both P14 and adult rats. These effects are likely mediated through PKA & EPAC 
signalling through the L-type calcium channel (Fujita, Umemura et al. 2016, 
Lezoualc'h, Fazal et al. 2016), and through phospholamban, which collectively 
enhance calcium entry into the cell and aid in the reuptake at the end of systole.  
 
This concurs with other observations of these agents performed in whole heart 
preparations in Chapter 4, and those such as Khaliulin & colleagues (Harmati, Banyasz 
et al. 2011, Khaliulin, Bond et al. 2017), that these agents do act as thought as 
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agonists along the β-AR signalling pathway. These effects were also increased with 
perfusion with 8-Br, versus either 6-Bnz or CPT alone, implying that 6-Bnz and CPT 
acted independently through effector pathways which are both activated during 
perfusion with 8-Br resulting in maximal contractile response.  
 
These will ultimately be acting to increase the increase in calcium- induced calcium 
release during excitation- contraction coupling (Tohse, Seki et al. 2004). There are 
multiple routes by which this might be accomplished, through targets such as 
phospholamban and the ryanodine receptor; these targets are well established for 
signalling through PKA, but less so through EPAC (Oestreich, Malik et al. 2009, 
Pereira, Ruiz-Hurtado et al. 2012).  
 
6.5.2 Simulated hypoxia induces changes in contractility and Ca2+ transients 
Perfusion of the cardiomyocyte suspension with a buffer containing cyanide induces 
a significant reduction in both calcium transient amplitude, and contractility of the 
cells in both the P14 and adult groups. The proposed mechanism of action of cyanide 
in this context is as an inhibitor of aerobic respiration via mitochondrial electron 
transport, specifically by inhibiting cytochrome aa3 in the mitochondrial complex IV 
(Murphy and Steenbergen 2008). Therefore, this is a model of the effects of 
simulated hypoxia on isolated mitochondria, and so a valid way of studying the 
influence of the cAMP analogues on cardiomyocytes subjected to this form of 
hypoxia. This is not synonymous with ischaemia; that would require a perfusate 
deprived of all sources of energy, with not continuous flow to remove metabolic 
byproducts.  
 
6.5.3 EPAC & PKA agonists ameliorate loss of contractility and calcium transients 
during histotoxic hypoxia 
After exposure to cyanide, cardiomyocyte contractility decreases steadily over the 
remaining 30 minutes of the experimental procedure. Figure 6-10 & Figure 6-16 
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demonstrate that all of the cAMP analogues used for these experiments ameliorate 
this effect to a greater or lesser extent. 8-Br provided the most effective protection 
against this functional injury; with 5 minutes prior perfusion, there was no difference 
between the contractile function after 30 minutes exposure to cyanide and the 
baseline contractility which was significant with a p-value <0.001. CPT and 6-Bnz also 
had a protective effect but to a lesser degree; contractility fell to 51 and 49% of 
baseline respectively. The control arm, for comparison, fell to a mean value of 22% 
of baseline contractility. These effects are not due to ongoing direct stimulation by 
the agonists; after 30 minutes of continual perfusion, the drugs will have been 
washed from the system, and so the prior perfusion with the drugs must have 
ongoing effect upon the internal milieu of these cardiomyocytes.  
A similar effect is seen when considering the calcium transient. Perfusion with 8-Br, 
with 6-Bnz, or with CPT leads to a maintained & significant elevation of the calcium 
transient concentration following perfusion with a cyanide- containing buffer. 
However, this effect is most strongly noticed with 8-Br, the effects of the single 
agonists being only a fraction of that seen with 8-Br. 
That 6-Bnz and CPT only provide a fraction of the protection seen with 8-Br, implies 
that (assuming roughly equal efficacy as agonists) they act via independent signalling 
pathways and that the additional effect from 8-Br results from co-incident activation 
of these pathways. That simultaneous administration of 6-Bnz and CPT, as in Figure 
6-8 & Figure 6-9, show a similar combined effect as perfusion with 8-Br alone, implies 
that their mechanisms seem to be synergistic. An end-point for the inotropic action 
of β-AR stimulation has been thought to be through cAMP triggered RyR 
phosphorylation (Bers 2002); it may be that both PKA and EPAC act to effect this 






6.5.4 EPAC & PKA agonists cause a reduction in the likelihood of arrhythmia, as well 
as time to hypercontraction and cell death following cyanide perfusion 
 
The experimental arm least prone to arrhythmogenesis is that with no intervention. 
This is unsurprising, as there is no intervention to predispose towards metabolic, 
electrical or contractile abnormality. 
The onset of arrythmia in cardiomyocytes perfused with cyanide without drug 
treatment was the quickest compared to drug treated myocytes. Cyanide perfusion 
(metabolic inhibition) inhibits ATP production, and this results in loss of SERCA 
function, resulting in elevation and eventual overload in intracellular Ca2+ 
(Venkataraman, Holcomb et al. 2012). This overload will result in arrhythmogenesis, 
explaining why CN perfusion results in this observation. 
Treatment with 8-Br prior to administration of CN had the next shortest time 
followed by those containing CPT. This may be because SERCA is a downstream target 
of EPAC signalling, increasing its activity whilst ATP remains available and thus 
delaying the onset of calcium overload. However, this would need direct 
measurement of SERCA activity in this context to confirm. 
A similar consequence of calcium overload is that of contractile cessation and 
hypercontraction of the cardiomyocyte  (Ruiz-Meana, Garcia-Dorado et al. 1999, 
Marks 2003). This is because of the failure to restore normal levels of intracellular 
calcium by ATP-deprived SERCA following depolarisation and contraction, and so the 
cardiomyocyte fails to relax. In addition, ATP is required to release the actin-myosin 
interaction, so leading to a further cause of hypercontraction. Those cells given 8-Br 
or CPT prior to cyanide perfusion had a significantly longer time to hypercontraction 
and to cessation of contraction. Again this is likely to be due to enhanced SERCA 
activity, via phosphorylation of PLB downstream of cAMP signalling. It is interesting 
to note that 8-Br prolongs this time less than CPT. This may be due to the differing 
affinities and efficacies of the two agents (Rehmann, Schwede et al. 2003), but it is 
also possible that the PKA activity related to 8-Br has other negative regulatory 
activity on this system. 
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Cardiomyocyte death took longest in the control group and was quickest in the group 
perfused with cyanide alone. This effect was almost completely abolished by prior 
perfusion with 8Br, and to a lesser extent by CPT. The mode of death for all of the 
cells studied in these experiments was observed to be apoptotic; a final common 
pathway for apoptotic cell death involves opening of the MPTP and release of 
cytochrome c from the mitochondrion (Suzuki, Yokoyama et al. 2010), prior to the 
activation of the effector caspases. As will be discussed in the experiments on 
mitochondrial isolation, it is possible that 8-Br and CPT are reducing the likelihood of 
pore opening and so prolonging the time until an injured cell commits to apoptosis. 
However, the prior literature is equivocal on the impact of EPAC and PKA signalling 
on apoptosis , with both being reported to have both pro- (Insel, Zhang et al. 2012, 
Okumura, Fujita et al. 2014) and anti- apoptotic effects (Kwak, Park et al. 2008, 
Mangmool, Hemplueksa et al. 2015). It is likely that the context, time- course, and 
duration of the signalling stimulus is critical to determining the outcome. Further 
biochemical studies on effectors of apoptosis in cardiomyocytes briefly exposed to 
these cAMP analogues in the context of this model of injury would be illuminating.  
The next chapter examines the direct role of these signalling pathways on 
mitochondrial permeability transition and is aimed at providing a mechanistic insight 








7 The effects of cAMP/PKA/Epac signalling on MPTP opening  
7.1 Introduction 
In the previous chapters I have shown that both activity at the β- adrenergic receptor 
and at intermediaries downstream confer protection of the whole adult and 
immature Langendorff perfused heart to ischaemia and reperfusion injury; and that 
isolated cardiomyocytes, divorced from whole organ structure and a plethora of 
other cell types in the heart, may also be protected by stimulating this signalling 
pathway. 
Ischaemia and reperfusion injury are mediated by Ca2+ loading and generation of ROS 
which in turn trigger opening of MPTP leading to death by necrosis and apoptosis 
(See Introduction, Role of MPTP in I/R Injury, 1.3.3).  Therefore, prevention of pore 
opening is a strategy aimed at ameliorating the damage to the heart exposed to 
ischaemia and reperfusion injury. The role and even the formation of the MPTP under 
physiological conditions is uncertain, however. Some have argued that under the 
non-pathological state it plays a key role in mitochondrial Ca2+ homeostasis (Ichas 
and Mazat 1998), whereas others have disputed whether the components even form 
a complex without the stimulus for permeability transition (Introduction 1.3.2). 
The opening of the MPTP and swelling of the mitochondria lead to loss of membrane 
potential and electron transport chain uncoupling. Each of these events may be 
studied in order to assess the state of the mitochondria, and from there the 
effectiveness of any potentially protective intervention. There are viable 
experimental approaches to assessing each of these elements. Bernardi et al.  
describe an overview of the experimental approaches to this in Mitochondria and 
Cell Death (Bernardi, Scorrano et al. 1999). The most straightforward and direct 
approach to monitoring MPTP opening was to study spectrophotometrically the 
swelling induced by addition of Ca2+ to a suspension of isolated cardiac mitochondria. 
This approach allowed perfusion of the heart with an agent of choice prior to 
isolation, and then an assessment of the resulting mitochondrial biology independent 
of their host tissue. Therefore, this experimental approach has been utilised to 




The experiments described here had several purposes; 
1) To obtain functionally reliable mitochondria from both adult and immature 
hearts and to establish MPTP opening by elevated Ca2+. 
2) To investigate the effect of cAMP/PKA/Epac signalling pathways on MPTP 
opening under normal physiological conditions and during I/R. 
3) To elucidate the effect of cAMP/PKA/Epac signalling pathways in modulating 
MPTP sensitivity to Ca2+ following I/R. 
 
7.3 Methods 
The procedure for mitochondrial isolation and swelling assays are detailed in 
Materials and Methods, Chapter 2, along with the details of the buffers used. In brief, 
however, hearts were extracted from adult and immature (14 day old) rats by 
concussion, cervical dislocation and then dissection through sternotomy.  These 
hearts were rapidly immersed in cold (4 °C) Krebs- Henseleit buffer, and the superior 
aspect explored to identify the aorta. The heart was then cannulated in the 
Langendorff mode. Exclusion criteria for hearts perfused ex vivo are described in 
Section 4.3.2 and were implemented identically for these experiments.  
The experimental protocols used during heart perfusion are described in Section 
7.3.1. Following these protocols, the hearts were removed from the aortic cannulae 
and placed into chilled buffer. They were then homogenized used a Polytron 
Kinematica probe, and the resulting suspension centrifuged at 2000g to separate the 
cell debris.  
The supernatant from that step was then removed, and centrifuged again at 10,000g 
for two iterations of five minutes, with the supernatant removed and pellet 
resuspended each time. The resulting suspension was considered to be a preparation 
of isolated mitochondria.  
These mitochondria would be of variable concentration due to the differing masses 
of the hearts used initially, and the varying proportion of mitochondria within those 
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hearts. The concentration was then estimated through a Bradford essay, and this 
information used to normalise at 0.2 mg/ml in the mitochondrial swelling buffer.  
The swelling of these mitochondria in response to Ca2+ was then assessed in a 
spectrophotometer (Evolution 201, ThermoScientific, Waltham, United States) at 
520 nm. A baseline recording at 37 °C was made, before the addition of Ca2+ to the 
solution. For the experiments in Sections 7.4.1 and 7.4.2, 3 mM was used as is 
conventional in our group working with non- ischaemic mitochondria to increase the 
sensitivity of the response. For those in 7.4.3, as the mitochondria were obtained in 
ischaemic conditions, the Ca2+ concentration used was 1 mM to ensure the response 
detected was within the sensitive range of the spectrophotometer. The results from 
these two groups is therefore not directly comparable. However, the non-I/R group 
described in 7.4.3 was performed at 1 mM in order to allow a comparison with the 
groups performed in similar conditions. 
The swelling response to this was measured, and the absolute change in absorbance 
and maximal rate of change of absorbance quantified as end points to the assay. 
Exemplar traces for P14 and adult hearts are shown in Figure 7-11 and Figure 7-10. 
7.3.1 Experimental protocols 
Three sets of experiments were performed with these hearts and were all performed 
in both adult and immature organs. In the first, mitochondria were extracted as 
described and assessed for calcium induced swelling from hearts perfused for 30 
minutes with no further intervention. To this suspension of mitochondria was added 
cyclosporin A (CsA; in DMSO as a solvent) 2 minutes prior to assessment of swelling 
(500 nM- a level previously found to completely inhibit pore opening in a similar 
preparation (Griffiths and Halestrap 1991)). This was to establish this technique as 
resulting in a viable population of intact mitochondria; with the hypothesis that if the 
mitochondria were not intact then CsA should not induce any change in their 
behaviour in the swelling assay.  
The second set of experiments investigated the response of mitochondria isolated 
from hearts not exposed to I/R injury to isoprenaline, a non-selective β 
adrenoreceptor agonist, whilst the final set of experiments examined the response 
225 
 
following isoprenaline perfusion and a 30- minute global ischaemic injury followed 
by a 5 minute reperfusion period. At the end of these protocols, the hearts were 
removed from the aortic cannula, and homogenised as described in Chapter 2. These 





Figure 7-1 Experimental protocols for mitochondrial isolation experiments. Groups indicated in left panel. 
Colours indicate phases of experiment; green= standard perfusion with KH buffer; orange= perfusion with KH 
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7.4.1 Characterisation of Isolated Mitochondrial preparation  
7.4.1.1 The effect of CsA on Mitochondrial Swelling in ex vivo perfused hearts 
An initial set of experiments were performed involving hearts taken from adult rats 
and perfused for 40 minutes with KH buffer. For these experiments, 6 hearts were 
used to obtain isolated mitochondria. Each of these preparations was then studied 
for the effect of Ca2+, CsA, and DMSO (used to dissolve CsA) using aliquots of the 
mitochondria.  
Figure 7-2 shows an example family of plots from one of these preparations. At the 
origin, calcium is added which triggers a swelling response, from which the maximal 
rate and amplitude may be quantified and compared.  
Figure 7-2 Exemplar traces of mitochondrial swelling in preparations from adult heart. Y- axis represents 
absorption through mitochondrial preparation vs time on x-axis. Change in absorption vs. time represents 
swelling. Mitochondria pre- treated with or without CsA; the blank group has no further addition. Traces offset to 
common origin. 
Figure 7-3 shows the effects of addition of Ca2+ to the mitochondrial isolation 
preparation from adult hearts. Compared to the change in the untouched baseline 
trace as a control, the addition of Ca2+ to the suspension causes a rapid change in the 
OD reading, interpreted as representing swelling of the mitochondria; an 8.65- fold 
















Calcium Induced Mitochondrial Swelling Ameliorated by CsA
Blank Calcium Calcium + CsA
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When CsA was incubated with the suspension for 2 minutes prior to the addition of 
Ca2+, the amplitude of swelling that resulted was significantly reduced, although it 
remained greater than that of the baseline trace. DMSO is used as a solvent for CsA; 
in order to test that the inhibition of swelling was due to CsA alone rather than an 
action of this solvent, DMSO, which was used as the solvent for both CsA and cAMP 
analogue solutions, was incubated with the mitochondrial suspension before the 
addition of Ca2+. This led to a degree of swelling significantly greater than baseline, 
but not significantly different from that induced by Ca2+ alone. This was done in order 
to demonstrate that subsequent results were not due to the presence of DMSO. 
 
 
Figure 7-3 Absolute Change in absorbance of isolated adult mitochondrial preparation after addition of Calcium 
(1 mM) alone, ±  CsA; additional arm with DMSO without CsA. Change in optical density denotes mitochondrial 
swelling.   *= Significant difference from control swelling; #- significant difference to swelling induced by calcium 
alone. Significance level taken as p<0.05 and performed by Student’s T-test; data expressed as mean; error bars 














































7.4.2 The Effects of Cardiac β-Adrenoreceptor Stimulation on MPTP Opening 
in Adult and Immature Hearts not exposed to I/R Injury 
The next set of experiments examined the ability of exogenous calcium to induce 
swelling in the suspended mitochondria, from hearts perfused with the standard 
buffer (control) or those perfused for 5 minutes with isoprenaline prior to isolation. 
These experiments used 6 hearts per age group per drug treatment; i.e.. 12 adults 
and 12 P14, with 6 in each group given the control treatment or isoprenaline 
perfusion during the Langendorff stage of the experiment.  
Age Group Control Isoprenaline Perfusion 
Adult  6 6 
P14 6 6 
Table 7-1 Numbers of hearts used per age group in experiments comparing pre-ischaemia sensitivity of MPTP with 
or without prior perfusion with isoprenaline.  
For the adult hearts, after pseudo-physiological perfusion i.e. without any ischaemia 
or reperfusion stimulus, the addition of isoprenaline prior to isolation of 
mitochondria produced a significant reduction in the stimulated swelling; this was 
true in considering either absolute amplitude (Figure 7-5) or the maximal rate of 
change of absorbance (Figure 7-4). For absolute change in swelling, the signal from 
the isoprenaline treated mitochondria was 26% less than that from the control 
group; whilst considering rate of change the isoprenaline treated sample showed 
59% of the measurement in the control group. Similar significant observations were 
made in mitochondria derived from P14 hearts (Figure 7-7 & Figure 7-6). Isoprenaline 
produced a 33% reduction in the absolute magnitude of swelling, and a 40% 









































Effect of Isoprenaline on Amplitude of Ca2+-induced 
Mitochondrial Swelling- Adult
*
Figure 7-5 Maximal rate of change in mitochondrial swelling following addition of calcium to adult isolated 
mitochondrial suspension with or without pre-isolation perfusion with isoprenaline measured by absorbance. 
Orange- change in OD during baseline observation; blue- change in OD after calcium addition. *= p<0.05 by 
Student’s T-test; data expressed as mean value; error bars= standard error of the mean. N=6 hearts per group. 
Figure 7-4 Absolute change in mitochondrial swelling following addition of calcium to adult isolated 
mitochondrial suspension with and without pre-isolation perfusion with isoprenaline measured by absorbance.  
Orange- rate of change in OD during baseline observation; blue- rate of change in OD after calcium addition. 



































The corresponding observations in the P14- derived mitochondria are shown in 
Figure 7-7 and Figure 7-6. Here, the levels of baseline swelling are much smaller than 
in the adult at 0.002 vs 0.015 in amplitude, with a similar trend observed for rate of 
swelling. The amplitude of swelling after induction with Ca2+ increases to 0.024 in the 
control. In the isoprenaline treated group, this falls to 0.018, a significant decrease 
of 25%. A similar pattern is observed examining the rate of swelling results; with a 
29% reduction in the maximum rate in the isoprenaline group vs. control.  
All of these observations were statistically significant; so in both adult and P14 
mitochondria, isoprenaline significantly desensitised the pore in a model of 






































Amplitude of Mitochondrial Swelling- P14
*
Figure 7-7  Absolute change in mitochondrial swelling following addition of calcium to P14 isolated 
mitochondrial suspension with and without pre-isolation perfusion with isoprenaline measured by absorbance.  
Orange- rate of change in OD during baseline observation; blue- rate of change in OD after calcium addition. 
*= p<0.05 by Student’s T-test; error bars= standard error of the mean. N=6 hearts per group. 
Figure 7-6 Maximal rate of change in mitochondrial swelling following addition of calcium to adult isolated 
mitochondrial suspension with or without pre-isolation perfusion with isoprenaline measured by absorbance. 
Orange- change in OD during baseline observation; blue- change in OD after calcium addition. *= p<0.05 by 


































7.4.3 The Effect of I/R on MPTP opening 
In adult hearts, whether or not exposed to ischaemia & reperfusion, pore opening 
could be stimulated by the administration of calcium into the mitochondrial 
suspension. However, the degree of swelling stimulated by calcium almost doubles 
in hearts exposed to global ischaemia and reperfusion injury prior to isolation of 
mitochondria. The ability of Ca2+ to stimulate opening of the MPTP was shown in 
Section 7.4.1 with experiments carried out with 3 mM Ca2+ added, but demonstrated 
again in a separate set of experiments at 1 mM for comparability with the 
pharmacological perfusion data. This effect alongside the other experimental results 
for this section in Error! Reference source not found. and Error! Reference source 
not found..  For all of these experiments involving comparative studies with cAMP 
analogues and 1 mM Ca2+ such as these data, the numbers of animals used and 











Isoprenaline 5 5 
8-Br 5 5 
6-Bnz 6 5 
CPT 6 5 







7.4.4 The effect of I/R on MPTP opening with cAMP/PKA/Epac activation  
The next set of experiments examined the pore sensitivity in isolated mitochondria 
from hearts which had been perfused with either isoprenaline or a cAMP analogue 
prior to a global ischaemic injury and reperfusion. There were two controls in these 
experiments; mitochondria from hearts not exposed to I/R, and mitochondria 
exposed to I/R but not perfused with any drugs. In these experiments, as the pore 
was expected to be relatively sensitive to opening stimuli, the concentration of Ca2+ 
used was 1 mM . They are therefore not directly comparable results to Section 7.4.1, 
which used 3 mM Ca2+. As discussed in the methods section, the use of 1 mM Ca2+ is 
common in studies of mitochondria following I/R injury (Abellán, Miró-Casas et al. 
2006, Khaliulin, Parker et al. 2010). 3 mM Ca2+ was used in Section 7.4.1 in order to 
Figure 7-8 Summary of effects on absolute change in mitochondrial swelling by pre-ischaemic pre-isolation 
interventions targeting different stages of the β adrenergic signalling pathway on both immature (P14) and adult 
isolated mitochondrial preparations.Error bars = 1 SEM. *P<0.05, vs IR group in corresponding age group. # P<0.05, 
vs adult age group in corresponding intervention. $ P <0.05 vs isoprenaline in corresponding age group. Significance 
testing by Student’s T-test. N=6 per group. 
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increase the magnitude of response in non- I/R injured mitochondria to produce a 
detectable difference between experimental groups.  
7.4.4.1 Effect of Isoprenaline on I/R induced MPTP opening 
In adult hearts perfused with isoprenaline prior to I/R, there was a significant 
reduction in amplitude of swelling (0.0210 ± 0.0015) compared to those hearts 
receiving no added drug (0.1056 ± 0.0089); this reduction was to below the level of 
the control hearts not receiving an I/R injury (0.0633 ± 0.0109) and was statistically 
significant. 
A similar pattern at lower magnitude was seen in the equivalent experiments on P14 
heart. A significant reduction in amplitude of swelling was seen, falling from a control 
post I/R result of 0.0208 ± 0.0199 to 0.0055 ± 0.0018 in experiments with 
isoprenaline. This was comparable to the non-I/R injured control, although not the 
same supra-normal result, as seen in the adult (0.0049 ± 0.0011). These results are 
also shown in Figure 7-9 Error! Reference source not found.. 
 
 
A similar pattern was observed in the results for rate of swelling, shown in Error! 
Reference source not found.. For the adult hearts, there was a significant reduction 
with isoprenaline compared to I/R treated controls (9.75±2.1 x10-4 OD/s vs 2.5±0.39 
x 10-3 OD/s). This approximates to a roughly 2.5 fold reduction in maximal swelling 
rate, and is comparable to the non-I/R control rate of 7.1±1.4 x 10-4  OD/s. All of these 
differences were statistically significant.  
In the immature group, a very significant reduction was observed (4.9±1.7 x 10-5  
OD/s vs 90.3±18.0 x 10-5 OD/s), which was comparable to the non-I/R control swelling 






7.4.4.1.1 Effect of 8-Br 
Perfusion with 8-Br, the non-selective agonist of both PKA and EPAC reduces MPTP 
sensitivity in adult and immature hearts- Figure 7-9. The total amplitude of swelling 
in adults fell to 0.0505 ± 0.0142 from 0.1056 ± 0.0089 after 8-Br treatment compared 
to I/R injured controls, and was indistinguishable from the uninjured control (0.0633 
± 0.01099).  
In the immature, P14, hearts, there was a clear effect of 8-Br perfusion with the total 
amplitude of swelling falling from 20.8±1.99 to 10.4±1.6 (X1000) OD Units; however, 
this remained greater than the level of the non- I/R control.  
The data for the change in rate of swelling after 8-Br perfusion are shown in Error! 
Reference source not found.. The overall pattern is similar to that for amplitude of 
swelling. In the adult hearts, 8-Br perfusion reduces the maximal rate of swelling from 
2.5±0.4 x 10-3 OD/s to 1.2±0.6 x 10-3 OD/s. This is not quite back to the non- I/R control 
results of 7.1 ±1.4 x 10-4 OD/s. In the immature hearts, the maximal rate falls from 
9.0±1.8 x 10-4 OD/s to 7.7±1.3x 10-5 OD/s , again similar to the non- I/R value of 
5.1±1.4 x 10-5 OD/s. 
 
7.4.4.1.2 Effects of CPT & 6-Bnz 
Finally, the effects of CPT and 6-Bnz on amplitude of swelling change and maximal 
rate of change are also shown in Figure 7-9 and Error! Reference source not found.. 
For the adult group, 6-Bnz and CPT both reduced amplitude of swelling vs the I/R 
control (6-Bnz, -0.04759 ± 0.01507, CPT, -0.03393 ± 0.01344); however neither of 
these effects were significant.  Likewise, for the P14 group, 6-Bnz and CPT caused 
non-significant reductions in the total magnitude of swelling. 
For the changes in maximal rate of swelling, in the P14 hearts, both CPT and 6-Bnz 
produced significant reductions in the rate of swelling vs the I/R control (6- Bnz, -
7.6±1.0 x 10-4 OD/s p< 0.0005, CPT, -8.1±0.9 x 10-4 OD/s, p<0.005) although these 
remained notably greater than the non-I/R control (5.1±1.4 x 10-5 OD/s). In the adult 
hearts, whilst both CPT and 6- Bnz produced observable reductions in swelling rate, 
only 6-Bnz reached significance; 1.2±0.4 x 10-3 OD/s, p = 0.041. 
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7.4.5 Summary of Interventions 
Administration of drugs acting along the β-AR linked signalling pathway prior to 
ischaemia-reperfusion can ameliorate sensitization of permeability transition 
following ischaemia/ reperfusion injury. Figure 7-11 and Figure 7-10 show exemplar 
traces for each drug/ condition in the adult and immature heart demonstrating 
graphically the changes in amplitude of mitochondrial swelling that occur after 
addition of Ca2+. The overall effects of the experiments are summarised in Error! 


































Time After Calcium Addition/ s
P14 Mitochondria Swelling Trace
Control IR Control No IR 8Br CPT 6Bnz Iso
Figure 7-9. Exemplar traces of mitochondrial swelling vs time (s) in isolated mitochondrial preparations from 14 





















Time After Calcium Addition/ s
Adult Mitochondria Swelling Trace
Control IR Control no IR 6Bnz CPT 8Br Iso
Figure 7-10 Exemplar traces of mitochondrial swelling vs time (s) in isolated mitochondrial preparations from 
adult heart, pre- treated with or without IRI and drugs. Traces offset to common origin. 
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In the adult, this effect is most marked with isoprenaline which comes closest to a 
complete rescue from the sensitization from ischaemia/ reperfusion injury; and to a 
lesser extent with the non-selective cAMP analogue 8-Br. The effect is also present 
but to an even smaller degree with either CPT, or 6-Bnz, the selective agonists for 
EPAC and PKA respectively. 
 
When assessing the peak swelling rate of mitochondria after calcium stimulation 
(Error! Reference source not found.) a similar but not identical pattern was 
observed. Swelling could be stimulated without any deliberate injury to the 
mitochondria; from hearts perfused without any ischaemia/ reperfusion injury. 
Those hearts exposed to I/R alone without any further injury swelled with the 
greatest speed, whilst isoprenaline pre-treatment caused maximal reduction in the 
rate of swelling. 8-Br also reduced rate of change to an indistinguishable degree as 
isoprenaline; in this measurement 6- Bnz had a similar effect to 8- Br, whilst CPT 
caused a reduction in the rate of swelling but only to a lesser degree than the other 
agents.  
 
In the experiments on immature, P14 hearts, swelling was observed following 
exposure of mitochondria extracted Langendorff perfused hearts to calcium. In the 
group not exposed to I/R, the amplitude and rate of this swelling was minimal. 
Treatment of these hearts with the 30 minute I/R injury but no other intervention 
produced maximal amplitude and rate of swelling.  Isoprenaline was the most 
effective intervention at rescuing the mitochondria from calcium- induced swelling 
following I/R injury; this treatment reduced swelling down to the level of the hearts 
not exposed to I/R injury. 8-Br produced a similar reduction, but in the rate of 
swelling only. The net amplitude of change was reduced with 8-Br, but not to the 
level of Isoprenaline; it was however significantly different to the reduction in 
amplitude seen with either 6-Bnz or CPT. CPT showed a non-significantly different 
reduction in rate of swelling; however, 6-Bnz showed less of an ability to reduce 
239 
 
swelling rate than 8-Br, although it still produced a degree of amelioration vs. the I/R 
control.  
 
Therefore, considered relative to the adult experiments, the overall pattern was 
maintained, but for each arm, the amplitudes and rates of swelling were reduced in 
magnitude compared to the adult equivalent. The most effective agents were those 
that caused activity of both PKA and EPAC; that is, isoprenaline and 8- Br. The 
individual agonists produced intermediate results; and in the adult, 6-Bnz seemed to 
ameliorate swelling more potently than CPT, although the experiments were not 





















1- Isolated mitochondria from both adult and 14-day swell up in response to 
Ca2+  
2- Mitochondrial swelling can be reversed by CsA confirming MPTP opening  
3- MPTP sensitivity to Ca2+ is lower in 14-day mitochondria compared to adult 
4- I/R increases sensitivity of MPTP to Ca2+ in both age groups which is fully 
reversed in hearts transiently pre-treated with Iso 
5- Pre-treatment with 8-Br induces similar response to Iso whilst pre-treatment 
with CPT & 6Bnz reverse the effect but to a lesser extent compared to 8Br 
 
7.5.1 Isolated mitochondria are intact and their Ca2+-induced swelling can inhibited 
by CsA indicating MPTP opening 
Whilst this method for isolation of mitochondria has been used by several research 
groups with success, it was a new technique in our group. Therefore, in order to 
validate this method, a series of experiments incubating CsA with the mitochondrial 
suspension were performed.  
The demonstration that addition of CsA to the suspension inhibited mitochondrial 
swelling in the presence of calcium, shows that that swelling occurs by induced 
opening of the MPTP. CsA is known to be a potent inhibitor of the pore through 
interaction with cyclophilin D (Elrod, Wong et al. 2010) which is its only known means 
of interaction with the mitochondrial pore, at a dose range similar to that used in this 
experiment (Griffiths and Halestrap 1991). Therefore, the observation that 
incubation of this suspension with CsA is able to ameliorate Ca2+ induced swelling 
implies that the mitochondria isolated in this way are intact with a functional pore 





7.5.2 The Immature Heart’s Mitochondria are Less Susceptible to Ca2+ Induced 
Swelling via the MPTP than the Adult Heart’s 
When the control experiments (those hearts not perfused with any drugs added to 
the buffer without 30 minutes of ischaemia & 5 minutes reperfusion) are considered, 
I have shown that there is a measurable degree of swelling of the mitochondria in 
response to calcium in both adult and immature hearts. This degree of physiological 
sensitivity is demonstrably and significantly greater in the adult heart as compared 
to the immature; so whilst it is possible that this phenomenon may reflect 
unintended injury through the perfusion and isolation process, that different groups 
exhibit this observation to differing degrees implies there is a physiological basis to 
this feature. The proteomic data discussed in Chapter 3 demonstrates a divergence 
in the abundance of many proteins involved in mitochondrial regulation and 
function, including some of the postulated components of the MPTP. It is possible 
that this difference in expression contributes to the observed differences, both in this 
physiological model and in the I/R experiments. Further, the MPTP itself is even more 
poorly characterised in the immature heart in terms of its components and structure 
than in the adult; it may be that differences in these characteristics could account for 
the observed differences.  
The overall physiological role of the MPTP in contexts aside from ischaemia and 
reperfusion injury remains unclear, and further studies on the MPTP in its 
intracellular environment is needed to address this. 
 
7.5.3 Ischaemia & Reperfusion Injury Sensitises the MPTP to Ca2+ in both Immature 
and Adult Hearts 
Both age groups demonstrated a significantly larger swelling response to calcium 
following exposure to I/R injury. The MPTP is well described as being sensitized to 
opening stimuli following ischaemia and reperfusion injury, which is thought to be as 
a consequence of the influence of reactive oxygen species. Therefore, these 
observations are expected in the context of prior work (Suleiman, Halestrap et al. 





7.5.4 The MPTP is less likely to open in the Immature Heart exposed to Injury than 
the Adult Heart 
Although the proportionate change in sensitivity to MPTP opening after I/R is greater 
in the immature control hearts, the absolute magnitude of this swelling response is 
less than a fifth that seen in the adult heart. A similar pattern is seen concerning 
mean rates of swelling. This is strikingly similar to the vulnerability pattern to whole 
heart global ischaemia and reperfusion injury, described as ‘bell-shaped’ or biphasic 
wherein vulnerability is thought to decrease from birth to 2 weeks post-natal age in 
the rat, before rising again to a peak at adulthood (Riva and Hearse 1993, Ostadalova, 
Ostadal et al. 1998). It is therefore appealing to suggest that at least one of the factors 
underpinning this change in vulnerability, is changing behaviour of the MPTP with 
age (Balaska, Halestrap et al. 2005). Why the MPTP should change with age is not 
clear; the structure of this pore is still a matter of debate, and its constituents are still 
not comprehensively clear (Ong, Samangouei et al. 2015). The structural knowledge 
that does exist is from work in adult tissues, and so cannot be assumed to remain 
consistent in the immature heart. It is further possible that mitochondrial 
morphology differs in the immature heart to that of the adult, which may have 
further consequences for the vulnerability to swelling. 
 
7.5.5 The MPTP may be induced to open under physiological conditions and this may 
be ameliorated by Isoprenaline 
The role of the MPTP during physiological conditions is still a matter of debate, and 
so the observation here that firstly opening in uninjured samples can be induced, but 
more so that that opening can be desensitized by isoprenaline was moderately 
surprising and if confirmed is a significant finding. 
The most common view is that of the physiological role for the pore is that of 
‘flickering’ or short opening (Hausenloy, Wynne et al. 2004, Wang, Fang et al. 2008), 
in which brief bursts of opening contribute to maintenance of mitochondrial and 
cytoplasmic Ca2+ levels.  This view is questioned- De Marchi, for instance (De Marchi, 
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Bonora et al. 2014) not finding a role for the MPTP in the maintenance of Ca2+ 
homeostasis in cultured cells.  
The evidence shown here, however, shows that the MPTP in this preparation may be 
induced to open in a suspension of isolated organelles from hearts not exposed to 
any injurious stimulus; at least, presuming that the process of isolation is not in itself 
a similar stimulus to ischaemia and reperfusion of the heart. This would support a 
role for the MPTP changing permeability dynamically in the usual function of the 
heart. This opening of the pore seems to differ between adult and immature hearts; 
the P14 mitochondrial extract being significantly less sensitive to induction of 
permeability transition than the adult. This is similar to the pathophysiological 
changes seen after I/R described in Section 7.5.2. 
Further, these experiments also show that non- I/R induced swelling may be 
significantly ameliorated by isoprenaline in both the adult and immature heart. 
Isoprenaline, whilst not a physiologically occurring substance in the heart is a non- 
selective β adrenoreceptor agonist and therefore pharmacologically functions in 
some respects similarly to adrenaline.  Speculatively then, it might seem reasonable 
that under situations of physiologically increased oxidative stress, such as a sudden 
need to increase ATP production in response to demand, concurrent release of 
adrenaline as part of the physiological sympathetically mediated stress response 
serves to inhibit MPTP opening and reduce damage incurred by this increased ROS 
flux. The MPTP is also thought to be part of the synthetic machinery for ATP; it may 
be that these observed changes in response to adrenergic stimulation help to 
facilitate a response to increase ATP demands. 
7.5.6 Signalling along the β- Adrenergic Receptor linked pathways can desensitize 
the MPTP to opening following I/R injury 
7.5.6.1 Protection at the Receptor Level 
Pre-treatment with isoprenaline reduces the sensitivity of isolated mitochondrial 
swelling to calcium and brings it to the level of the non-injured experiments. 
Isoprenaline is a non-selective agonist at all isoforms of the β- adrenoreceptor 
(Leone, Albanese et al. 2002). The primary mode of action of isoprenaline at these 
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receptors is thought to be by indirect activation of adenylate cyclase, whose action 
is to catalyse the intracellular formation of cAMP (Woo and Xiao 2012). This, 
however, is not the only mode of action of isoprenaline at this receptor; a secondary 
function may be to catalyse the formation of inositol triphosphate as another second 
messaging system (Endoh 1995). It does seem as though isoprenaline therefore 
indirectly modulates pore opening in both age groups studied. Combined with the 
observation that pore opening occurs in physiological conditions, this could mean 
that sympathetic activity has a role in modulating mitochondrial function in normal 
circumstances. This work however, does not show mechanistically how isoprenaline 
may be mediating these effects. I have shown previously (Lewis, Szobi et al. 2018) 
that isoprenaline linked whole-heart cardioprotection is correlated to glycogen 
depletion, and others have shown (Halestrap and Richardson 2015) a link to 
dissociation of hexokinase from the mitochondrion. A study linking these features 
together may well explain the observations of the properties of isoprenaline seen 
here.  
 
7.5.6.2 Protection is Replicated by cAMP Analogues but requires PKA & EPAC synergy 
Prior perfusion of hearts with 8-Br reduces the sensitivity to swelling of both adult 
and immature mitochondria to almost, but not quite, the level seen with 
isoprenaline. This study was not powered or intended to be seen as a non-inferiority 
study between these two compounds, however. It may be that isoprenaline acting at 
the receptor level stimulates other occult pathways of signalling in parallel, or that 
there is a different amplitude of response along the downstream communication 
channels.  
This study has however demonstrated that at a mitochondrial level, a cAMP analogue 
stimulating both PKA and EPAC produces protection against ischaemia and 
reperfusion injury. This effect is not seen in either age group following stimulation 
with either CPT or 6-Bnz alone, where the response is not significantly different to 
that following I/R alone. This may imply that the reduction in sensitivity is due to a 
synergistic effect of the action of PKA and EPAC. It is, however, also possible that the 
protection depends on a mechanism not stimulated by either of these agents but 
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which is by an off-target effect of 8-Br. It would be interesting to examine the effects 
of perfusion with both CPT and 6-Bnz prior to I/R and mitochondrial isolation, to see 
if the effects of 8-Br are replicated. A further possibility would be to use the 
commercially available inhibitors of PKA and EPAC, alongside perfusion with 8-Br, in 




8 Summary, Conclusions, Limitations & Further work 
8.1 Summary of Findings & Overall Discussion 
The results described here have shown physiological and pathological distinctions 
between the adult and developing heart in a number of domains which change as 
the heart matures.  
The proteomic findings, which inform the remainder, have shown that there are 
molecular changes which track with previously known and experimentally observed 
patterns of changes in vulnerability of the developing heart to ischaemia & 
reperfusion injury, including in networks involved in Ca2+ homeostasis, regulation of 
mitochondrial dynamics and function, antioxidant activity, and signalling involving 
cAMP. This confirmed the hypothesis for this work at the outset, that cAMP signalling 
was likely to be of consequence to cardioprotection of the developing heart, and that 
differences observed in the vulnerabilities between adult and developing hearts may 
be accounted for through these changes.  
Interventions which were previously demonstrated to be cardioprotective in the 
adult heart were then also demonstrated in the developing heart. Whilst in the adult, 
consecutive perfusion with isoprenaline and adenosine was previously known to be 
protective, a finding replicated here, in experiments using an equivalent ischaemic 
time the developing heart did not appear to share this effect. This may have been 
because the intrinsic vulnerability of these hearts was quite low, and so a protective 
signal could not be seen against this background. However, when 8-Br, the non-
selective agonist of PKA & Epac, was studied in similar experiments, it protected the 
adult heart to a similar degree as the previous isoprenaline/ adenosine study. Again, 
with a matched ischaemic time of 30 minutes, the developing hearts did not show a 
protective effect of 8-Br. However, an additional group with an ischaemic time of 50 
minutes was added to the P14 age group. This group showed an equivalent 
histological degree of injury to the adult controls exposed to global ischaemia for 30 
minutes. When the 50 minute P14 group was perfused with 8-Br prior to ischaemia, 
a protective effect was then seen to a biologically significant degree. This effect was 
not seen with perfusion with either 6-Bnz or CPT, the PKA and Epac selective agents 
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respectively, suggesting synchronous activity of both intermediaries is necessary for 
the protective effect, perhaps through synergism.  
This group of interventions was then studied at the level of the isolated 
cardiomyocyte using H2O2 and elevated Ca2+ concentrations to simulate the 
environment of a cardiomyocyte during reperfusion. Here, the first group of 
experiments sought to demonstrate the central role of the Mitochondrial 
Permeability Transition Pore in cell death during reperfusion. Incubation of 
cyclosporin A with adult cardiomyocytes significantly ameliorated the rate of cell 
death in the simulated reperfusion conditions. However, at P28 this effect was only 
seen to an intermediate degree, and in the P14 group was entirely absent. This may 
reflect an underlying difference in the regulation or composition of the MPTP in the 
developing heart; however, this group had a very high intrinsic death rate so the 
observation may be due to damage incurred through the process of isolation. When 
these cardiomyocytes were incubated with PKA and Epac agonists, the rate of death 
in simulated reperfusion was ameliorated with simultaneous activation of PKA & 
Epac, although selective activation of either was not sufficient to protect the 
cardiomyocytes against death. Examination of the mechanism of EC coupling in these 
cardiomyocytes perfused with the Epac and PKA agonists  showed that when exposed 
to cyanide in a model of ischaemic injury, the synergistic activity of both caused 
preservation of contractile function and Ca2+ transients in both adult and P14 derived 
cells, as well as a reduction in death rate similar to that seen on exposure to H2O2. 
However, this was associated with an increased propensity to arrhythmia of the 
cardiomyocytes.  
The mitochondrial studies following on from this work then gave some insight into 
the mechanisms of this protection. It demonstrated that in a model of I/R injury, 
mitochondria derived from P14 hearts are intrinsically less likely to undergo 
permeability transition in response to elevated Ca2+ levels. This observation may at 
least in part account for the observed resistance to I/R injury of the developing heart. 
When these hearts underwent perfusion with either isoprenaline alone, or Epac and 
PKA agonists prior to I/R injury and mitochondrial isolation, the isolates from both 
age groups showed a reduced propensity for MPTP opening when stimulated with 
248 
 
Ca2+, thus suggesting a potential end effector for this cardioprotective intervention. 
However, this study did not examine the intermediate steps and so cannot 
definitively demonstrate mechanism. Another interesting observation was that in 
both adult and P14 mitochondria from hearts not exposed to I/R injury, isoprenaline 
could also reduce MPTP Ca2+ induced injury. This hints at a physiological role for the 
MPTP under conditions of high sympathetic flux. 
In general, this work has shown that in both adult, and immature hearts, stimulation 
of both PKA and Epac prior to ischaemia & reperfusion injury is cardioprotective. 
These findings were replicated across whole perfused hearts as well as individual 
cardiomyocytes and so are relatively robust. Further, it has demonstrated that 
immature hearts are more resistant to injury than adult hearts, and that that 
resistance may be due to differences in the MPTP response to oxidative stress.  
Recent work has demonstrated a cardioprotective role for PKA & Epac stimulation 
prior to ischaemia & reperfusion injury (Khaliulin, Bond et al. 2017). However, the 
observation that this protection also extends to developing hearts is a new and 
previously undescribed finding.  
It has been previously shown that stimulation of the cardiac β-adrenoreceptor with 
noradrenaline or isoprenaline, classically thought to act through PKA, triggers 
cardioprotection in a manner much like ischaemic preconditioning (Asimakis, Inners-
McBride et al. 1994, Lochner, Genade et al. 1999). Thus the findings here that 
stimulation with either a PKA or Epac agonist provides a partial protection against 
injury in measures of cardiac function, biochemical injury and cardiomyocyte survival 
is consistent with what is understood (Duquesnes, Derangeon et al. 2010). The 
observation that protection is dependent on the combined activity of both PKA and 
Epac has recently come to be accepted; indeed others have demonstrated through 
the use of the PKA and Epac inhibitors H-89 and ESI-09 (respectively) in combination 
with simultaneous PKA/Epac activity that the cardioprotective effect given by 8-Br 
perfusion is reduced. Others have studied alternative means of activating PKA and 
Epac; Mangmool & colleagues (Mangmool, Hemplueksa et al. 2015) examined 
isolated cardiomyocytes and found an Epac and PKA- dependent cardioprotective 
effect on stimulation of the GLP-1 (Glucagon- like peptide- 1) receptor with the 
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agonist exendin- 4. Interestingly, this study was an early demonstration of the 
cardioprotective effect of synchronous PKA and Epac stimulation in developing 
cardiomyocytes, also. It is therefore thought that Epac activation is a necessary step 
to maximal cardioprotection through targets or mechanisms not shared in common 
with PKA.  
Epac is known to activate phospholipase C amongst its targets (Cazorla, Lucas et al. 
2009), which in turn leads to PKC activation and IP3 linked Ca2+ release. In particular, 
it has recently been shown that Epac activation via the β- adrenoreceptor leads to an 
isoform specific activation of PKCε (Li, Cai et al. 2015). This form of PKC is thought to 
be involved in cardioprotection, and so this is a potential mechanistic explanation for 
the observations in this thesis.  
The observations of protection in the immature heart are novel and not previously 
described elsewhere. The first component of this is the reconfirmation of previous 
observations that the developing heart is less susceptible to I/R injury than the adult; 
Chapter 4 demonstrated that 50 minutes of global ischaemia was required for a 
biochemically and histologically identical injury to that shown after 30 minutes in 
adult rat hearts. Further, Chapter 7 demonstrated a qualitatively similar pattern in 
the opening sensitivities of the MPTP in mitochondria derived from these hearts. This 
is a similar finding to the literature for I/R resistance in immaturity (Ostadalova, 
Ostadal et al. 1998, Ostadal, Ostadalova et al. 2009, Ostadal, Ostadalova et al. 2014), 
which is thought to be due to developmental changes in cardiac energetics and 
mitochondrial function (Modi and Suleiman 2004). This is also matched with clinical 
findings of developmental variation in vulnerability (Imura, Caputo et al. 2001) 
recognised amongst the surgical community.  
The second component to this assertion of protection in the immature heart is the 
demonstration of protection at the levels of whole heart, myocyte, and 
mitochondria. The key observation found is that I/R injury does cause increased 




The mitochondria in the developing heart undergo significant changes during 
ontogeny. There is a significant increase in number and total volume (Anversa, 
Olivetti et al. 1980), as well as in their subcellular localisation. There are significant 
differences in the mitochondrial membrane potential compared to the adult as well; 
newborns exhibit a single population of mitochondria with a relatively high 
membrane potential. A switch occurs at the weaning period- the 14 day post-natal 
stage examined here- where a population with a significantly lower membrane 
potential appears (Ostadal, Ostadalova et al. 2009) which seems to be related to the 
intracellular location. The reasons why this may relate to resistance are not entirely 
clear, but it is attractive due to the linkage between the fall in membrane potential 
with MPTP opening leading to mitochondrial rupture and cell death (Bernardi, 
Scorrano et al. 1999, Bernardi 2013).  
The results of the experiments with MPTP inhibitors on isolated cardiomyocytes were 
also significant. CsA did not provide protection against reperfusion- induced cell 
death in the immature heart as it did in the adult. This is similar to prior reports in 
similar experiments with SfA, another pore inhibitor (Ostadal, Ostadalova et al. 
2009). This then leads the the inference that immature cardiomyocytes may have a 
lower level of mitochondrial cyclophilin D, the MPTP component which acts as the 
receptor for CsA. The reasons for this, or other suppositions about the lack of 
protection, are not clear due to the lack of direct knowledge about the presence, 
density, composition, and function of the MPTP in the immature heart.  
Nevertheless, the observation that the immature MPTP is less sensitive to Ca2+ 
induced opening, and even less so with exogenous signalling through PKA & Epac, 
strongly supports the view that the mitochondria are at the very least a strong 
component of the relative resistance of the developing heart to I/R injury, and that 
this is a modifiable resistance. This suggests an avenue for further investigation into 
the role of the MPTP in the developing heart, and pharmacological avenues for 






8.2.1 Limitations with ex vivo perfusion experiments 
Whilst there are a number of caveats and drawbacks to the use of ex vivo perfusion 
in research, the Langendorff method is well established and these are well 
understood (Bell, Mocanu et al. 2011).  
Within my experimentation using the Langendorff method, a significant degree of 
variability was observed with these experiments, such that relatively large variation 
from experiment to experiment was seen. This limits the size of effect that can be 
confidently identified. There are a number of reasons that might account for this 
variation. Ex vivo organ perfusion is first subject to variability in the organs taken 
from animals. The rats used were all of the same breed and sex, and sourced from 
the same organisation over a limited time period. These measures seem to be as 
much as can be easily done to limit this variation, short of increasing the numbers of 
animals used significantly which expands the scope of the study. 
Langendorff perfusion also requires rapid cannulation of the aorta in order to re-
establish coronary perfusion. This is more straightforward in the larger, adult hearts, 
becoming more technically challenging as the hearts decrease in size. Although all 
the hearts included in these results were cannulated within a defined period of time, 
the neonatal hearts were more likely to be discarded and so although the times to 
perfusion were not recorded beyond meeting or not the threshold, it is probable that 
some would have required multiple attempts at cannulation or a prolonged time to 
perfusion. There is a significant leaning curve and technical difficult to the study of 
small vessels and organs, and so this limited the number of immature hearts that 
could be studied and also presents difficulty in the study of younger hearts. Ideally, 
a 7- day group or even younger would have been included in the experiments 
involving Langendorff perfusion, but this would have increased the failure rate and 
time taken to perform the study.  
There are also multiple points of technical variation during an experiment. The 
introduction of an intraventricular pressure sensitive balloon is a significant source 
of error; the balloon positions itself variably inside the LV cavity, and the diastolic 
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pressure that resulted from its placement was not controlled between experiments. 
Significant changes in developed pressure occurred with stepwise inflation of the 
balloon; this likely reflects changes in the LVEDP. These effects were particularly 
evident in the 14- day group with smallest balloons requiring very small inflation 
volumes. The transducers are also subject to electrical interference which could not 
be eliminated limiting the pressure resolution of the balloon/ transducer system 
which also limited the accuracy of the functional measurements.  
The experimental design of the isoprenaline/ adenosine experiments also did not 
contain a P14 group with an ischaemic injury matched to the size of the adult injury, 
which was included in the later experiments with cAMP analogues. This may account 
for why no protective effect was seen, analogous to the effects seen with the cAMP 
analogue experiments where a time- matched injury did not produce a protective 
effect but a magnitude- matched injury did show that effect.  
8.2.2 Limitations with proteomic experiments 
There are multiple points of inaccuracy that can be considered in the proteomic 
analysis described in Chapter 3. Intrinsic problems of the method, such as the 
problems of false discovery, missing values and external validity, are widely discussed 
in the specialist literature. However, there were limitations specific to the 
experimental approach chosen here.  
The extraction method used was homogenisation with beads in RIPA buffer. Other 
groups have used other extraction methods in the proteomic literature, with use of 
a 4M Urea buffer. However, these buffers have mainly featured in the cancer 
literature with a particular interest in extracellular matrix proteins and seem less 
suitable for analysis of membrane- bound, cytosolic or nuclear proteins than RIPA 
buffer and so we elected to use RIPA buffer whilst being mindful of the potential 
selection bias that this introduces. 
Indeed, as an example of this limitation, the proteomic experiments identified over 
9000 unique proteins across all of the experimental runs and age groups. This would, 
at first glance, appear to offer reasonably comprehensive coverage of the myocardial 
proteome. However, not all of these proteins were found in every group or 
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experiment. Only 47% of proteins were in common to all. This is not likely to be 
because the remainder were not found in a particular group. The analysis of the 
MS/MS data involves assigning a confidence score to each peptide/ protein; 
conventionally those that are not identified with high confidence are discarded. It is 
likely that the majority of proteins missing from each sample were in fact 
represented, but did not appear in the final analysis due to exclusion of lower 
confidence results.  
The use of proteomic TMT-MS/MS techniques for quantification of relative protein 
abundance, especially of individual proteins, is also not as well validated as other 
methods such as Western blotting. This lack of validity would best be remedied by 
using these alternative methods to confirm the results. Also, the use of a 
standardising reference protein in order to normalise these results would be ideal- 
GAPDH is often used for this purpose and would further validate the findings. 
However, this approach is not straightforward in comparative studies of multiple age 
groups. Housekeeping proteins such as GAPDH used for normalisation are known to 
vary across ages; therefore finding a suitable reference protein with an unchanging 
abundance throughout is not trivial; this is problematic in the experimental design 
chosen here to find meaningful comparisons across age groups.  
In addition, these experiments were carried out in male Wistar rats. It is possible that 
there is intersex variation in protein expression at different ages- significant 
differences in comparative vulnerability to I/R between males and females at a given 
developmental stage have previously been noted (Ostadalova, Ostadal et al. 1998). 
The wider validity of these results is also questionable; much of the experience of the 
resistance of the heart to injury comes from the human and clinical experience, and 
indeed the ultimate therapeutic target dependent on this knowledge would be in the 
human. It cannot, however, be assumed that the proteomic changes observed here 




8.2.3 Limitations with Cardiomyocytes Superfusion Experiments 
A clear limitation of this study in approaching the hypothesis on the protective effect 
of CsA was in the methodology used to isolate cardiomyocytes. Consistent with 
earlier findings from this Lab, the rate of spontaneous death of cardiomyocytes 
isolated from immature cardiomyocytes was higher than adults. This could be due to 
the degree of injury sustained by immature cardiomyocytes in the process of 
isolation.  
There are many steps through the process of isolation at which an age- varying injury 
may be introduced. The quality of perfusion was not assessed during isolation; in 
whole- heart studies I have previously assessed functional and biochemical measures 
(creatine kinase release, contractility, estimated coronary vascular resistance) as 
measures of the quality of ex vivo perfusion. Those measures are not available for 
this technique, and so the stringent exclusion criteria I have previously applied for 
Langendorff perfusion could not be applied.  
Another point of variation during isolation is in the process of cardiomyocyte 
digestion the end point is subjective- essentially judged by tactile assessment, and is 
therefore very subject to heterogeneity. As the feel of a very small immature heart 
is clearly different to that of an adult, there is the potential for a systematic bias in 
the degree of digestion to be introduced. Further, a key obstacle in the development 
of attempts to freshly isolate cardiomyocytes was in the control of calcium 
concentration during isolation. This was achieved through the use of chelating agents 
and slow, stepwise reintroduction of Ca2+; however this was an entirely empirical 
process based experimentally on what produced a reasonable yield of viable 
cardiomyocytes. Using the same method for both adults and developing hearts in 
ignorance of the changes in their calcium homeostasis may produce a non-quantified 
independent variable.  
These experiments also used externally applied hydrogen peroxide and calcium as a 
means of simulating reperfusion injury. Whilst hydrogen peroxide is well understood 
to be one of the main ROS species involved in I/R injury, in the intact heart that will 
be produced in the region of the mitochondrion. In this model, it is applied 
exogenously, and so must diffuse across the cell membranes and cytosol to reach the 
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mitochondrion. Thus it is possible that the degree of injury to non-mitochondrial 
structures differs between a whole heart model of I/R injury or indeed the original 
pathophysiological description, and the model I use here in studying isolated 
cardiomyocytes.  
Further, the experiments described here do not directly study the MPTP. It is inferred 
that death is occurring by mitochondrial swelling caused by pore opening and that 
CsA is exerting an action to inhibit death by pore inhibition, but this has not been 
definitively demonstrated by this set of experiments. However, a comparison 
between this method and another more direct way of studying the MPTP, the [3H]2-
deoxyglucose ([3H]2-DG) entrapment technique, shows that they produce similar 
results (Griffiths and Halestrap 1995, Wong, Steenbergen et al. 2012) 
 
8.2.4 Limitations with Contractility and Calcium Transient Experiments  
A significant drawback with this study has been the use of cyanide as a metabolic 
inhibitor. In the context of the wider investigation, the intention is to simulate 
ischaemic conditions. However, cyanide is a complex IV inhibitor, and so functions by 
inhibition of oxygen utilisation; it therefore produces a form of hypoxia. While this is 
similar, an ischaemic insult differs in many ways and it is difficult to speculate if any 
of those differences are relevant to this study. Nonetheless, cyanide is widely used 
in similar preparations by many other groups for this purpose, and in many respects 
produces similar consequences; acidaemia, inhibition of ATP production, and calcium 
overload.  
As for all experiments I have carried out with the cAMP analogues, they should not 
be considered to be perfectly targeted agonists of the intermediaries PKA and EPAC 
(Christensen, Selheim et al. 2003). Others have described significant off-target 
interactions; some of the more significant over the time scales of these experiments 
being phosphodiesterase inhibition (Oestreich, Malik et al. 2009) and activity at the 
A2A adenosine receptor, which may in itself have a cardioprotective role (Murphy 
and Steenbergen 2008, Pereira, Ruiz-Hurtado et al. 2012). Further, the 
concentrations used in these studies have been determined based upon previous 
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work, and used throughout for consistency and comparison. It would be interesting 
to perform dose-response studies to determine to what extent these responses 
described are maintained across a range of concentrations. Time constraints 
prevented the extension of scope to permit this. 
 
8.2.5 Limitations with Mitochondrial Isolation Experiments 
There were several drawbacks to the experimental techniques used in these 
experiments. From a technical perspective, there was no independent marker of the 
quality of Langendorff perfusion. In performing functional Langendorff experiments, 
I would usually measure both intraventricular pressure vs. time and creatine kinase 
activity before and during reperfusion. These are markers of injury, and of functional 
recovery, but can be used independently to identify outlying experiments where 
coronary perfusion is sub-optimal. This was not possible using the chosen 
experimental protocol, and so I cannot be certain that all the included data is from 
hearts that were very well perfused.  
The absolute magnitude of the changes observed in the immature heart groups was 
low vs. the size of the initial absorbance- there is thus a low signal to noise ratio. This 
is reflected in the relatively large values for SEM seen in these results. Alternative 
measures of mitochondrial function may be less susceptible to this problem; for 
example the calcium retention assay performed by other groups (Andrienko, Pasdois 
et al. 2017) may be a more sensitive assay in this context. Also, there is no direct 
measure of the integrity of the mitochondria isolated; it is assumed that they are 
functional, as they exhibit a swelling response to Ca2+, but the proportion of intact vs 
damaged or ruptured mitochondria is not clear; this conceivably could even account 
for the relatively low response of the P14 mitochondria. Direct visualisation by 





8.3 Ongoing & Further Experimental Studies 
Each strand of this work leaves unanswered questions and alternative approaches to 
the problems studied.  
 
The proteomic work provided strands for further investigation described in this 
thesis. However, it produced a very large data set with a scope much larger than the 
networks immediately surrounding cAMP signalling; this dataset could not be 
adequately explored whilst investigating the central hypothesis of this thesis. 
However, there are ancillary signalling networks that play intersecting roles with 
survival after cardiac insults; work investigating these networks and how they 
interact with the cAMP- related effects would provide fuller insights into the 
mechanisms of cardioprotection. Also, the variation in the proteome is not limited to 
relative changes in protein- level expression. A range of post- translational 
modifications take place; most notably regulation by phosphorylation at differing 
sites on proteins; but also a range of more recently recognised modifications. This 
additional layer of modification may well be important in regulation and control of 
the functions of these networks of proteins. 
 
A significant finding from the mitochondrial work also was the demonstration of the 
influence of isoprenaline on MPTP opening without any intentional injury to the 
heart prior to isolation. That the MPTP may have a physiological role which alters in 
response to adrenergic signalling is important. A demonstration of this phenomenon 
in in vivo experiments is necessary in order to persuasively demonstrate that this 
observation is not an artefact of isolation; as it has significant consequences for 
understanding of the dynamic role that the mitochondrion may play in the overall 
function of the cardiomyocyte.  
 
These observations, and those concerning the amelioration of MPTP opening after 
I/R, were at a receptor level only made with isoprenaline. This is a non-selective β-
adrenergic agonist; and so any conclusions made about the function of this drug in 
this context do not discriminate between any of the β- receptor subtypes. Selective  
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β- receptor agonists are in use experimentally, and in everyday clinical practice so 
are readily available, with dobutamine, for instance a well characterised β1 receptor 
agonist already widely used for its inotropic properties.  
  
As these findings are relatively novel, they should also be validated through 
alternative experimental approaches. Similar experimental designs but involving 
measurements of mitochondrial membrane potentials, Ca2+ retention, and validation 
using the [3H]2-DG method would provide replication of these findings using an 
alternative approach, and also some mechanistic insight.  
 
The aim of the whole heart studies was to demonstrate the cardioprotective efficacy 
of the combination of Epac and PKA agonists; this was reaffirmed in the adult and 
demonstrated for the first time in the developing heart. This was shown in the 
context of a global ischaemic injury and subsequent reperfusion; this is used as a 
model for the kind of I/R injury sustained in cardiac surgery, with aortic clamping. 
However, this is a smaller problem than the burden of mortality and morbidity 
caused by regional ischaemia such as that seen with atherosclerotic plaque rupture 
leading to myocardial infarction. Although this is an extremely rare problem in the 
developing heart, for the adult, a demonstration of a viable cardioprotective 
intervention would be extremely important.  
 
Given that in the model of global injury, protection has again been demonstrated, it 
would be useful to attempt to replicate that in an animal model. However, the safety 
and toxicity of the synthetic agents used for the experiments in this thesis has not 
been established; this would have to be shown before examining the effects in 
models of disease. PKA and Epac have widely described, and varying biological effects 
in various tissues (Robichaux-III and Cheng 2018). Therefore the systemic use of these 
agents by, for example, intravenous use is likely to lead to significant non-intended 
physiological effects. More targeted administration, for instance, by direct 
intracoronary injection as part of cardioplegia solutions may avoid some of the off-
target effects; there are well- established large animal models in Bristol which could 
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